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ABSTRACT 
The inter-relationship between depression, medication use and cognitive decline in 
oider persons has potentially important clinical and public health implications, yet 
research findings on the nature of this relationship remain inconclusive. This thesis 
presents a systematic investigation into this topic in a sample of281 medical inpatients 
aged 65 and over, who were followed for up to 12 months after admission. 
In the first three chapters, the concept, population burden and measurement of 
depression and cognitive function in the elderly population are described. The relevant 
Iiterature is reviewed, and the rationale and approaches of this thesis are presented. 
In the fourth chapter (1 st manuscript), the short-term temporal relationship between 
depression and cognitive functioning was explored using an interviewer-rated depression 
severity scale. Based on competing mixed effects models under alternative temporal 
assumptions, the severity of depression symptoms appeared to have a concurrent rather 
than prospective relationship with cognitive functioning. 
In the fifth chapter (2nd manuscript), diagnostic criteria were used to define 
depression. After adjusting for covariates, both major and minor depression were 
significantly predictive of subsequent cognitive decline, and the strength of the 
association appeared to increase with the duration of"exposure". 
In the sixth chapter (3rd manuscript), using a provincial prescription database, the 
effects of medication exposure on cognitive function were evaluated. Antidepressant use 
was not associated with cognitive de cline in general, but interacted with depression 
diagnoses. In exploratory analyses, antidepressant use appeared to be associated with 
improved cognitive function over time in the minor depression group, independent of 
comorbid diseases, current depression symptoms and concomitant medications. Both 
major and minor depression were independently predictive of subsequent cognitive 
decline, especially in those not prescribed antidepressants. 
In summary, this thesis demonstrates that, in this sample of older medical 
inpatients, both major and minor depression are independent risk factors for 12-month 
cognitive decline. The potentially beneficial effects of aIitidepressants for patients with 
minor depression should be investigated. 
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RÉSUMÉ 
La corrélation entre la dépression, l'utilisation de médicaments et le déclin 
cognitif chez les personnes âgées porte des implications de santé publiques et cliniques 
importantes, pourtant les résultats des recherches demeurent non-conclusifs. Cette thèse 
présente une recherche systématique de ce sujet avec un échantillon de 281 patients 
hospitalisés, âgés de 65 ans et plus, qui ont été suivis jusqu'à 12 mois après leur 
hospitalisation. 
Dans les trois premiers chapitres, le concept, l'effet sur la population, la mesure 
de la dépression et de la fonction cognitive chez les personnes âgées sont traités; un 
examen des études appropriées est présenté, ainsi que le raisonnement et la méthodologie 
pour cette thèse. 
Dans le quatrième chapitre (premier manuscrit), le rapport temporel à court terme 
a été exploré en utilisant un système d'évaluation déterminé par les résultats d'entrevues. 
Basé sur des modèles d'effets mélangés en concurrence, sous de diverses prétentions 
temporelles, les symptômes de dépression ont semblé avoir un rapport plus concourant 
que prospectif avec le déclin cognitif. 
Dans le cinquième chapitre (2ème manuscrit), des critères diagnostiques ont été 
employés pour définir la dépression. Après avoir ajusté aux covariantes, la dépression 
majeure et mineure étaient toutes deux prédictives du déclin cognitif qui suivait, et la 
force de l'association a semblé augmenter avec la durée de "l'exposition" aux 
diagnostiqués. 
Dans le sixième chapitre (3ème manuscrit), en utilisant une base de données 
provinciale sur les ordonnances, les effets de l'exposition de médicaments sur la fonction 
cognitive ont été évalués. L'utilisation d'antidépresseurs n'a pas été associée au déclin 
cognitif en général, mais a eu une interaction avec les diagnostiqués de dépression. Des 
analyses exploratoires ont montré que cette utilisation semble être associée à une 
amélioration de la fonction cognitive à long terme chez le groupe atteint de dépression 
mineure, indépendamment des maladies comorbides, aux symptômes courants de 
dépression et aux médicaments concomitants. La dépression majeure et mineure étaient 
toutes deux indépendamment prédictives du déclin cognitif qui suivait; particulièrement 
chez ceux pour qui les antidépresseurs n'étaient pas prescrits. 
En bref, cette thèse démontre que, dans cet échantillon de patients âgés 
hospitalisés, la dépression majeure et mineure sont toutes deux des facteurs de risque 
indépendants du déclin cognitif sur une période de 12 mois. Il faut faire des études sur les 
effets bénéfiques que peuvent avoir les antidépresseurs chez les patients atteints de 
dépression mineure. 
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CHAPTER 1 - INTRODUCTION 
1.1 BURDEN OF DEPRESSION AND COGNITIVE IMPAIRMENT IN 
OLDER POPULATIONS 
Among elderly people depression and cognitive impairment (including dementia) 
represent two major public health problems. Together, they affect more than one quarter 
ofthose aged 65 years and older [1-4], and both have been associated with higher 
mortality [5-7], faster functional decline [8, 9] and increased utilization of health care 
services [10, Il]. The net economic cost for caring of patients with major depression [12] 
and dementia [13] is tremendous. With the rapid expansion of the aged population in 
modem societies, prevention and treatment of depression and cognitive impairment have 
become a major challenge to the health care system. 
Depression and cognitive impairment often coexist clinically: as many as 30% of 
elderly patients with dementia manifest sorne depressive syndromes or meet the 
diagnostic criteria for major or minor depressive disorders [14-17]. More than 50% of 
major depression patients with normal cognition may eventually develop dementia 
several years later [18]. However, epidemiological evidence to date remains inconclusive 
as to whether the correlation between the two conditions reflects a causal relationship, a 
psychological reaction, or a clinical concomitant due to the effect of a third factor that is 
associated with both depression and cognitive impairment-such as cardiovascular disease 
[19, 20] or use of antidepressant or other psychotropic medications [21, 22]. In addition, 
older persons with depression in the community are often !eft untreated [23-26], partially 
due to insufficient evidence regarding the benefits and harms of rigorous antidepressant 
treatments in late-life depression, especially in those with mild or minor depressioil or 
- 1 -
with complex medical conditions [27-31]. Therefore, a clarification of the 
interrelationship between depression, antidepressant and other psychotropic use, and 
cognitive impairment in the elderly population may bear important public health, clinical 
as weIl as etiological implications [32-34]. 
1.2 OBJECTIVES OF THE THESIS 
The main objectives ofthis thesis are two fold: 
1) To examine the temporal relationship between depression (symptoms and 
diagnoses) and cognitive decline in older medical patients and to determine whether 
depression is an independent risk factor or a clinical concomitant of cognitive decline; 
and 
2) To explore the role of antidepressant and other medication use in the 
relationship and to determine whether it is an independent risk factor for cognitive 
decline, an effect modifier, or a mediating factor. 
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CHAPTER 2 - REVIEW OF LITERA TURE 
2.1 DEPRESSION 
2.1.1 Definition and Measurement 
There are two general approaches to the definition of depression: categorical and 
dimensional [1-3]. The categorical approach considers depression as a group of distinct 
entities or independent latent classes, each with its own clinical and biological profile [4, 
5]. For instance, the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
(DSM-IV) [6] has defined two major diagnostic entities of depression: major depression 
and dysthymic disorder. Major depression requires the core symptoms of depressed mood 
or loss of interest or pleasure for two weeks or longer, plus four other symptoms. 
Dysthymic disorder requires a predominantly depressed mood to exist for at least two 
years plus two or more other symptoms. In addition, a minor depression category has also 
been proposed as a research diagnosis for sub-syndromal, sub-threshold, or sub-clinical 
depression and requires the same core symptoms as major depression but only one to 
three other symptoms. However, in clinical and research practice, a minor depression 
diagnosis is often defined loosely, encompassing aIl the mild types of depression 
including dysthymia [7]. A categorical or diagnostic definition is most useful in clinical 
settings, where the main objective of depression detection is to capture depressed patients 
or "cases" that require clinical, especiaIly pharmacological interventions. 
Depression can also be conceptualized as a unitary phenomenon or a continuo us 
spectrum in terms of the population distribution of the depressive symptoms [4, 5, 8], 
which includes most often depressed mood or affect, tearfulness, irritability, suicidaI 
ideas, and somatic complaints (e.g., poor appetite, energy, and libido etc.) [9]. Almost 
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every human being will experience one or more such symptoms during their life time. 
Although the manifestations and consequences of such symptoms may vary dramatically 
from person to person, ranging from Iittle impact on social and psychological functioning 
to extreme disability, there are no clear-cut boundaries between different levels or 
different domains of depressive symptomatology. Therefore, depression may better be 
understood as a constellation of interrelated component symptoms rather than several 
distinct entities. Such a dimensional definition provides an alternative tool to de scribe 
depressive symptomatology and to depict its natural history. It has found wide use in 
non-clinical settings, where the main goal is to assess total population bu rd en of 
depression at ail levels of severity for public health policy making and prevention 
planning, rather than to offer treatment or intervention options to the individuals. 
Although conceptually distinctive, in practice the two approaches often interact in 
many aspects. For instance, both categorically and dimensionally oriented researchers 
tend to define depression using standard depression scales, being either self-report, such 
as the Geriatrie Depression Scale (GDS) [10] and the Center for Epidemiological Studies 
Depression Scale (CES-D) [11], or observer-rated, such as the Hamilton Depression 
Rating Scale (HDRS or HAMD) [12]. Moreover, in the recent de cade there has been an 
increasing trend of integration of the two approaches, especially in the research setting. 
On one hand, population surveys of depression have often used eut-off points on rating 
scales to identify potential "cases"; on the other, emerging criteria for "recurrent brief 
depression" [13], "mixed anxiety-depression" [14] and "minor depression" [3, 6, 9,15] in 
diagnosis-oriented medical nomenclature reflect an adoption of a dimensional alternative 
to approach those otherwise unclassifiable, sub-clinical depressions. Recent studies have 
- 7 -
also suggested that the presence of depressive symptoms or sub-threshold depression 
(i.e., not meeting full diagnostic criteria) were predictive of both a subsequent diagnosis 
of major depression and several adverse outcomes including functional disabilities [10, 
16, 17]. From both public health and etiological perspectives, it seems apparent that 
epidemiological studies would bene fit most from such integration [3, 18, 19]. 
2.1.2 Occurrence 
Major depression has been reported in at least 1 to 3% of the population aged 65 
and over and an additional 8 to 16% have clinically significant depressive symptoms 
[20]. In primary care settings, the prevalence of depressive disorders is about 5 to 17%, 
and that of depressive symptoms about Il to 29% [21]. Studies reporting the incidence 
of new-onset depressive disorders in community-living seniors were sparse, and the 
estimates varied from 5.4% in 6 months [22] to 11.7% in 9 months [23]. However, such 
figures probably reflected an underestimation. According to a questionnaire survey of 
1000 primary care physicians, up to 80% of depressed patients might have failed to be 
recognised [21] and less than 50% ofthose with major or minor depressive disorder 
obtained an accurate diagnosis [24, 25]. 
Depression prevalence appears to decrease with increasing age in the general 
population [26,27], although opposite observations exist [9, 28]. This discrepancy may 
be partially attributable to the difference in the definition of depression across studies. In 
general, studies employing self-rating scales as the sole definition of depression tend to 
report a higher prevalence, whereas those following strict diagnostic criteria often found 
10wer estimates [29]. Thus, although older adults may experience depressive symptoms 
more frequently than younger ones [16, 30], the proportion with "full blown" major 
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depressive disorder among elderly populations tends to be lower [27, 31]. Another 
possible explanation is the selective attrition of the depressed elderly from community-
based samples due to age-related increases in dementia and other morbidities, mortality 
and institutionalization, but this speculation has yet to be confirmed [29]. 
2.1.3 Risk Factors 
Many factors associated with an increased risk of depression in the general 
population apply also to late-life depression, including a family history of depression [20, 
32], a history of other psychiatric disorders, depressive symptoms or anxious-pessimistic 
personalities [33-35], stressfullife events such as recent family loss [20, 32, 36], poor 
physical health or functional status [20, 36, 37] , socio-cultural isolation or lack of social 
support [37-39] , and demographic factors such as lower education or economic status 
[34, 38, 39] and female gender [32, 40]. 
Medical illness and related physical disability increase in frequency among 
seniors and are major risk factors for a depressive episode [41, 42]. Illness severity and 
disability are almost always associated with major depression in studies that measured 
them [33, 39,43]. Older patients with certain medical conditions were reported to be 
particularly vulnerable to major depression, which included especially neurological 
disorders [40, 44], endocrine disorders [45], myocardial infarction and other 
cardiovascular diseases [46], cancer [34, 47], and chronic obstructive lung disease [34, 
43]. 
The relationship between cardiovascular diseases (CVD) and depression seems 
complex. Vascular diseases have been suspected to be a putative cause oflate-life 
depression (so-called: vascular depression) [48,49]; low blood pressure has been 
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associated with an increased risk of depression in a prospective community-based follow-
up study of 1112 initially non-depressed elderly [50]. On the other hand, depression has 
also been associated with the subsequent incidence of several CVD events, including 
hypertension in young adults [51] and myocardial infarction or stroke in older people [52, 
53]. Thus, the causal pathway of CVD and late-life depression remains to be understood. 
2.1.4 Prognosis and Outcome 
A meta-analysis of outcomes of major depression in community-based seniors 
found that at 24 months from study enrollment, 33% of patients were weIl, 33% were 
depressed, and 21% were dead [54], despite the appreciable methodological 
heterogeneity across the studies in outcome measures, length of follow-up, age and 
gender distribution and the diagnostic criteria and antidepressant treatment histories. 
Although less weIl studied, minor depression is associated with persistence of symptoms 
for up to a year [46, 55, 56]. Two other studies suggested that adults with even a few 
depressive symptoms appeared to be at an increased risk for developing major depression 
[16, 17]. A recent longitudinal study of 3434 community-dwelling older adults aged 65 
and over reported that mild depressive symptoms are predictive of becoming and 
remaining disabled several years later [57]. In addition, depression has also been 
associated with greater use of health services, incIuding both specialized psychiatric care 
and other services [58-60] and correspondingly higher health care costs [59,61]. For 
studies of the cognitive outcomes of late-life depression, a detailed review will be 
presented in section 2.3. Relationship between Depression and Cognitive Decline. 
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2.1.5 Treatment and Intervention 
The most common treatment or intervention modalities for late-life depression are 
antidepressant medications and psychotherapy [62-64]. Antidepressant medications 
include tricyclics (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine 
oxidase inhibitors (MAOIs) and other newer agents. Traditionally, antidepressant 
medications are often reserved to treat major depressions, while cognitive and 
interpersonal psychotherapies are often used in the treatment of the mildly depressed 
patients [62]. 
During the recent decades, SSRIs and other new antidepressants gained increased 
popularity and have become the first line antidepressant modality in depressed elderly, 
due mainly to their low side-effect profiles and better tolerability [63]. In a meta-analysis 
of randomized, controlled clinical trials of antidepressant treatment in older persons 
diagnosed with major or unipolar depression, Mittmann and colleagues compared four 
major classes of antidepressants and concluded that the efficacy, safety and tolerability of 
the different classes are comparable [65]. However, in older persons with major 
depression who did tolerate the side-effects of the drugs, the overall response rates to 
TCAs appeared to be higher than that to SSRIs or atypical antidepressant [65, 66]. 
According to the consensus statement update from a NIH expert panel, there was good 
evidence to support the antidepressant efficacy ofboth TCAs and SSRIs in major 
depression and to justify a recommendation of aggressive approaches to detect and treat 
late-life depression [63]. Research evidence for the antidepressant efficacy and benefits 
in the elderly with mi Id depression or with complex medical conditions is sparse [7, 65-
67]. A few randomized clinical trials, including one conducted in a primary care 
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population [67] and several from ambulatory populations, synthesized in a meta-analysis 
[66], reported modest to moderate benefits of SSRIs or heterocyclics in treating 
dysthymia or mild depression. 
Although potentially efficacious and safer treatment modalities are available, a 
number of epidemiological studies have suggested that depressed elderly living in the 
community, either diagnosed [68] or suspected [69], were often left untreated. Newman 
and colleagues collected information on current drug use in 2914 elderly Canadians and 
found that only 9.4% (4.2% for community and 36% for institutionalized populations) of 
those depressed were receiving antidepressants [70]. A population survey by Ganguli and 
colleagues [71] found that only 10% of the community-dwelling elderly with five or 
more depressive symptoms had ever used antidepressants. A similar trend of 
undertreatment exists in studies from primary care populations [39, 54]. 
One ready explanation of the "undertreatment" phenomenon is the lack of 
sufficient evidence for an antidepressant benefit, especially in those with mild or sub-
syndromal depressions or with complex medical conditions [7, 64-67, 72]. Randomized 
clinical trials for potential antidepressant benefits in late-life depression have largely 
excluded such patients [63-67]. Another reason is the concem of the potentiql cognitive 
and other side-effects of antidepressants by patients, their families and physicians, 
especially TCAs, which will be discussed under section 2.3 Medications As a Potential 
Risk Factor For Cognitive Decline. 
2.1.6 Summary 
Depression is common in the elderly population, and has been associated with 
multiple adverse outcomes, increased health care utilization and costs. Conceptually 
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depression can be defined as a dimensional continuum (by severity of symptoms) or as 
distinct entities (by diagnostic criteria), with each serving a different perspective; but in 
practice the two approaches often converge. Great variations across studies exist in the 
prevalence and incidence estimates and the identified risk factors, which may be 
attributed to the differences in study populations (clinical versus community), definitions 
of depression (symptoms versus diagnoses), and study designs (cross-sectional versus 
prospective). Many socio-demographic and clinical factors may increase the risk of 
developing depression in older people, ofwhich CVD may deserve specific attention for 
this thesis, because it might confound the relationship between depression and cognitive 
decline. The lack of sufficient evidence for the benefits of antidepressant treatment for 
late-life depression, especially for older persons with mi Id depression or with complex 
medical conditions, may have contributed to the under-treatment phenomenon, and calls 
for rigorous epidemiological investigation and randomized clinical trials. 
2.2 COGNITIVE IMP AIRMENT AND COGNITIVE DECLINE 
2.2.1 Definition and Measurement 
Cognitive function can be conceptualized as a constellation of the brain's power 
to acquire, process, integrate, store and retrieve information. It is generally believed that 
human cognitive function reaches its peak in early adulthood and appears to decline later 
in life [73], although the limits of normal aging of the human brain and its impact on 
cognitive function has not yet been established [73-75]. Quantitatively, cognitive 
function can be measured by performance on memory, language, praxis, abstraction, and 
execution tasks. Examples included conventional intellectual tests, such as the Wechsler 
Adult Intellectual Scale and its revised versions (W AIS, W AIS-R) and the Nation Adult 
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Reading Test (NART) [76]. A score within two standard deviations of the population 
norm at the same age can be viewed as a rough guide for normal cognition. However, 
such conventional intelligence tests are not suitable for clinical or epidemiological 
purposes due to their insensitivity to low cognition, lengthy format and complex 
administrative procedure. In the latter settings, most frequently employed cognitive tests 
are brief ones, such as the Short Portable Mental Status Questionnaire (SPMSQ) [77], the 
Mini Mental State Examination (MMSE) [78] and its modified versions (e.g., 3MS) [79]. 
A score below sorne clinically validated cut-point, such as 24 points (out of 30) on the 
MMSE, is usually considered as indicative of cognitive impairment [78, 80]. A major 
advantage of such brief cognitive tests is their ease of use: they involve no complicated 
tasks, can be administered in less than 10 minutes, and thus, are suitable for frail or 
physically handicapped elderly. 
From a longitudinal perspective, cognitive impairment can be approached in 
terms of deterioration in cognitive performance, or cognitive decline from the previous 
level. A common measure for cognitive decline is the so-called annual rate of change 
(ARC), i.e., the change score on a given test over a one year period [81]. An advantage 
of the ARC is that it may reveal a downward trend when the overallievei of the 
individual's cognition may still be within the normal population range [82]. However, 
difficulties often arise in comparing change scores across studies due to variations in 
study methodology and the lack of consensus with regard how to distinguish normal, age-
related decrements from pathological declines [75, 83]. In addition, appropriate 
statistical methods to simultaneously deal with both between- and within-subject 
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variation have fallen behind the advances in the research setting with longitudinal, 
repeated measure cohort design until very recently [84]. 
In clinical settings, specific diagnostic entities have been developed to capture 
patients who manifest predominantly cognitive impairments and who se cognitive 
impairments are severe enough to interfere with his or her physical or social functioning. 
For instance, DSM-IV [6] defines three main categories of cognitive disorders: delirium, 
dementia and amnesic disorders. Dementia is defined as a presentation of multiple 
chronic cognitive deficits that include memory impairment, with Alzheimer' s disease 
being the most predominant and common type. Delirium typically presents with acute 
and transient cognitive changes coupled with a reduced level of consciousness, often with 
identifiable extraneous cause; whereas amnesic disorder involves only memory 
impairment without other significant cognitive impairments. 
The definition and classification of non-dementing cognitive impairments, other 
than those described above, have posed major challenges to both researchers and 
clinicians. DSM-IV [6] proposed an "age-related cognitive decline" to den ote low 
measurable cognitive performance within normallimits of a person's age, to replace its 
non-specific precursor-"mild cognitive impairment" in DSM-III-R [86], and the 
International Classification of Disease lOth Edition (lCD-l 0) [87]. Another collective 
term, "cognitive impairment, no dementia", was subsequently proposed by the working 
committee of the Lancet conference on dementias (1996) to encompass not only delirium 
and mental retardation, but also other cognitive impairments due to depression and 
chronic alcohol and drug use, etc [88]. Similarly, both "circumscribed memory 
impairment" [88] and "age-related memory impairment" [89,90] refer to isolated 
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amnesic impairments but attribute them to different causes. Despite the terminological 
confusion, the importance of such non-dementing cognitive impairments is that they may 
signal an early phase of an underlying progressive neurodegenerative disease, during 
which the intervention modalities may prevent or hait disease progression [91]. Towards 
this end, it has been proposed that the currently predominant "dementia epidemiology" 
should be complemented by an "epidemiology of cognitive impairment" [92, 93]. 
2.2.2 Occurrence 
The prevalence estimates of cognitive impairment in community-dwelling elderly 
vary greatly depending on the measurement, definition, and detection methods as weIl as 
the age composition of study populations. For dementia and moderate to severe cognitive 
impairment, a few review articles [94-96] provided prevalence estimates. The overall 
prevalence of dementia, variously defined, ranged from 2% [97] to 7.8% [98]. Of aIl the 
dementing disorders, Alzheimer' s disease had the highest prevalence rates ranging from 
1.4% [99] to 11.2% [100]. In the Canadian population aged 65 and over, the prevalence 
of Alzheimer's disease was estimated to be 5.1 %, followed by vascular dementia (1.5%) 
[101]. The prevalence of Alzheimer's disease seems to increase with age, at 
approximately two to five fold every five years after 60, reaching over 20% in those aged 
85 and over [95, 101]. The incidence of Alzheimer's disease and dementia parallels this 
age-trend but at lower magnitudes [96, 102]. 
Delirium, given its acuteness in onset and relation to extraneous pathologies, is 
often detected in hospital rather than the community setting. Its prevalence at hospital 
admission ranged from 5% to 22% and incidence during hospitalization from 17% to 
52% [103, 104]. 
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Prevalence estimates for mi Id cognitive impairment, variably defined, ranged from 
12.9 to 17.0 % [105,106]. Epidemiologic studies ofspecific conditions, such as 
"cognitive impairment, no dementia" etc, are sparse. A recent study that employed 
improved diagnostic criteria reported prevalence estimates of 16.8% for "cognitive 
impairment, no de menti a" and 5.3% for "circumscribed memory impairment" (or "age-
related memory impairment") [88]. 
Longitudinal studies measuring cognitive decline in community-dwelling elderly 
varied greatly in the instruments used and the 1ength of follow-up, which makes resulting 
estimates difficult to compare. A few of these using the MMSE may be worth noting 
given the popularity of the MMSE in both clinical and research settings and its relevance 
to this thesis. Jacqmin-Gadda and colleagues [107] followed 2537 elderly people aged 65 
years and older with annual MMSE assessments for five years and observed a small but 
statistically significant mean ARC of 0.02 to 0.57 declining points. In another 
longitudinal study of community-dwelling population, the change scores over a mean 
interval of 11.5 years for those aged 60 years and above (n=260) were 2.6 and 3.2, 
respectively [108], corresponding to an ARC of 0.22-0.28. For the most common type of 
primary dementia-Alzheimer' s disease, our group conducted a meta-analysis of 37 
longitudinal studies and obtained a pooled ARC estimate of 3.3 (95% CI: 2.9-3.7) during 
the first one or two years following the disease diagnosis [109]. 
2.2.3 Risk Factors 
Studies of cognitive impairment, cognitive decline and dementia have generated 
an extended 1ist of potential risk factors. In the case of Alzheimer' s disease and other 
dementias, the se have included genetic factors (e.g., ApoE 4 genotype [110], loci on 
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chromosomes 14, 19 and 21) [111], environmental factors (e.g., drinking water 
aluminum) [112], and demographic factors (e.g., male gender, older age, and less 
education) [102, 107, 108]. 
Medical conditions constitute a major group of such factors, which have included 
depression [113,114,115], other psychiatric disorders (e.g., alcohol abuse) [102], 
neurological conditions (e.g., epilepsy, head trauma, etc) [102], diabetes [116], and 
cardiovascular diseases (CVD) [117, 118]. Among physical diseases, CVD seems 
particularly important, because it has been implicated directly or indirectly in etiologies 
of different types of dementia [117, 118]. Evidence for the role of depression as a 
potentially important risk factor is the topic of this thesis and will be reviewed separately 
in section 2.4. 
Another potentially important risk factor is the medications used to treat 
depression or alleviate its accompanying symptoms, such as insomnia and restlessness, 
etc. Given its specific relevance to this thesis, the clinical pharmacological and 
epidemiological evidence for drug-induced cognitive impairment in the elderly 
population will be reviewed separately in the next section. 
2.2.4 Summary 
The concept of cognitive impairment can be approached dimensionally or 
categorically. While the categorical approach considers various forms of "cognitive 
impairment" having distinct characteristics, the dimensional definition perce ives them as 
coming from a single population continuum. In practice, the categorical approach finds 
wide use in clinical setting, where standardized diagnostic criteria are employed to 
identify significant cases of cognitive impairments or cognitive disorders that may 
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require pharmacological or other therapeutic interventions. The dimensional approach is 
often adopted to measure the severity of cognitive impairments and to assess the total 
population burden due to such cognitive impairments in community-based 
epidemiological studies. No matter which definition one follows, cognitive impairment in 
older persons represents a common, devastating and costly public health problem, to 
which amenable intervention modalities have yet to be discovered. A possible alternative 
to intervention, though, is to identify potential risk factors for cognitive impairment weil 
before it develops into the full blown, non-reversible phase, upon which effective 
treatment modalities may be devised to pre vent or hait the progression of the underlying 
disease process. Depression and psychotropic medications are among such potentially 
important and modifiable risk factors that require further investigation. 
2.3 MEDICATIONS AS A POTENTIAL RISK FACTOR FOR COGNITIVE 
DECLINE 
2.3.1 Drug-induced Cognitive Impairment in Older Populations 
Drug-induced cognitive impairment has long been recognized as an important and 
challenging problem in the elderly [119, 120], and seems to be increasing during the past 
decades with the increased consumption of drugs in that population [119, 121]. Such 
impairment can manifest as limited deficits in cognitive performance or apparent clinical 
syndromes, such as acute confusional state or delirium. Many authors believe that drug 
intoxication is a leading or common cause of acute cognitive impairment [103, 122]. The 
depressed elderly have been reported to have a significantly higher risk Qf developing 
adverse drug events than non-depressed older pers ons [123]. 
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ln clinical pharmacologicalliterature, drugs that have been reported to cause 
cognitive impairment include hypnotics and sedatives, especially benzodiazepines [119, 
120], antidepressants, especially tricyclics [120,124-126], antipsychotics [119,120], and 
other agents with centrally active depressant effect [119, 120]. Although the 
pharmacological mechanisms of drug-induced cognitive impairment are probably multi-
faceted, the anticholinergic effects ofa medication are particularly relevant [119,120, 
122, 124-126]. Considerable evidence suggests that failure of cholinergic transmission 
plays a key role in several memory disorders including Alzheimer's disease [127]. A 
decreased synthesis of cerebral acetylcholine and epinephrine has been postulated to 
account for the impaired cognitive and attentional function, and slowing of the 
electroencephalographic background activity commonly seen in delirium [127-129]. 
Induction of experimental delirium by administration of anticholinergic drugs has been 
observed in humans and could be reversed by a cholinergic agonist [129]. Elderly 
patients may be more vulnerable to anticholinergic intoxication due to an aging-related 
reduction in cholinergic brain receptors and altered pharmacokinetics [127]. Consistent 
with clinical observations and animal experiments, a few large-scale epidemiological 
studies have found independent associations between poorer cognitive performance and 
exposure to antidepressants [115, 132], benzodiazepines [115,132, 133, 134] and 
antipsychotic medications [115, 132, 127], ofwhich manyagents have pote nt or 
detectable ACH effects in vivo [119, 124-126, 130, 135]. In my Master Thesis, 1 used a 
clinician-rated anticholinergic score as an index for total anticholinergic burden of 
medication exposure and found it to be independently and specifically predictive of the 
severity of delirium symptoms in older medical patients [109]. 
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2.3.2 Antidepressants and Cognitive Impairment 
Traditional antidepressants, especially TCAs, are a group of medications 
possessing a high potential to compromise cognition [124-126, 137, 13 8]. In addition to 
the evidence from animal experiments and clinical observations, treatment of depression 
in older persons with TCAs has been associated with decreased cognitive functioning in 
sorne [115, 120, 124-126, 132-134], but not other studies [139-143]. A few 
comprehensive literature reviews covering both randomized clinical trials and 
observational studies that measured cognitive function have provided valuable 
information for the cognitive profiles of antidepressant medications in older persons 
[124-126,136]. In general, these reviews conclude that TCA agents, especially tertiary 
amine amitriptyline and doxepin and secondary amine nortriptyline, tend to have the 
most detrimental cognitive effects, especially on attention and concentration. 
Antidepressant agents with high anticholinergic properties, such as nortriptyline, 
maprotiline and amitriptyline, may particularly cause short-term recall memory. In 
addition, cognitive impairment induced by nortriptyline during treatment appears to be 
dose-dependent on its plasma concentrations and may la st as long as treatment continues. 
Data regarding the effects of SSRIs or MAOI on cognitive performance in the elderly 
mostly indicated no detrimental effect. 
A systematic review published in 1999 covering a broad range of drug-induced 
cognitive disorders in the elderly arrived at a similar conclusion, based on thirteen studies 
including eight reports of double blind, randomized clinical trials [137]. Specifically, the 
review concluded that there was moderate to strong evidence for an increased risk of 
cognitive impairment linked to TCAs (especially amitriptyline) and trazodone and for a 
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minimum risk linked to SSRIs and reversible MAOIs [137]. The outcome measures 
included global (e.g., the MMSE) or specific (e.g., short recall memory) cognitive tests. 
Of the three clinical trials that used the MMSE, an overall mean increase of2.0 to 2.6 
points over four weeks was observed for those treated with an SSRI . However, the 
studies included highly heterogeneous populations in terms of baseline cognitive 
function, had a short follow-up period (up to eight weeks) and did not measure the 
cognitive function as a primary outcome. For instance, three out of the eight clinical trials 
were conducted in patients with both depression and cognitive impairment or de menti a, 
and another two did not specify the baseline cognitive function of the study population. 
A more recent meta-analysis published in 2006 of 32 randomized comparative 
trials (selected from 163 studies) of antidepressants for depressed elderly reported that 
the TCAs and SSRIs had comparable efficacy, yet classical TCAs tend to have a higher 
profile ofside effects [138]. Unfortunately, the authors grouped the side-effects by organ 
system (e.g., broad "neuropsychiatric" rather than specific "cognitive") and reported the 
results in percentage and number of persons experiencing the side-effects. Great 
heterogeneity across the trials was observed in terms of study quality scores, except the 
age of the study population and the types of studies. In addition, the duration of trials was 
short (up to 24 weeks) and no information on comorbidity profiles of the study 
populations or concomitant medication use was given [138]. 
A number of studies with specific measure of cognitive function showed that 
treatment with newer antidepressants, especially SSRIs, may even improve the cognitive 
function of depressed patients [141-143]. In a placebo-controlled clinical study, Siegfried 
and colleagues. found that the elderly depressed patients treated with antidepressant 
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nomifensin, in comparison to controls, showed significant improvement in both 
depression symptom rating and several cognitive domains [142]. Another study pooled 
data from two randomized clinical trials of 444 elderly pers ons with major depression 
following a double-blind treatment. After controlling for an anticholinergic se verity score 
based on peripheral side-effects ofmedications (dry mouth and constipation)and number 
of concomitant medications and other covariates, improvement in depression symptoms 
was found to be significantly associated with improvement in cognitive tests in patients 
treated with either SSRIs (sertraline and fluoxetine) or TCAs (nortriptyline) [143]. 
Interestingly, although nortriptyline is highly "anticholinergic", patients with sorne 
cognitive impairment at baseline seemed to show improvement in cognitive tests after a 
3-month treatment with this drug. This preliminary observation suggests that the net 
cognitive effect of antidepressants may depend on the relative strengths of, or a trade-off 
between their "antidepressant" efficacy (presumably due to serotonergic augmentation) 
and anticholinergic toxicity. 
2.3.3 Benzodiazepines and Other Psychotropic Medications 
Studies of benzodiazepines and other psychotropic medications have been 
inconsistent; while most found these medications to be predictive of lower cognitive 
functioning [115,133,134,139, 144], others did not observe such a relationship [145] or 
conversely, found a protective effect [146]. However, given their inherent hypnotic and 
sedative properties in suppressing arousal, vigilance and muscular tone, it is 
understandable that use of benzodiazepines and other psychotropic medications with 
durable effect, such as long-acting benzodiazepines [115, 147], would generally depress, 
rather than augment, cognitive performance and other functions that requires attention 
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and concentration. In addition, studies also revealed that many psychotropic medications, 
including benzodiazepines, also have detectable anticholinergic activities in vivo [130], 
which would subject their users, especially the older ones, to an increased risk of 
cognitive impairment. 
The implication ofbenzodiazepines in late-life depression lies also in their 
pervasive use in this population. In a study of 153 older medical inpatients with 
diagnosed depression, Koenig and colleagues [68] observed that 25.5% received 
benzodiazepines only, in comparison with 40.5% who received antidepressants at sorne 
time during their hospital stay or the follow-up period. A similar trend of overuse of 
benzodiazepines and underuse of antidepressant has been associated with persistence or 
relapse of depression in a 3-year follow-up study of 106 elderly patients with either 
psychiatric or neurotic depression [148]. 
2.3.4 Summary 
Pharmacologically, both the TCAs and benzodiazepines commonly prescribed to 
depressed elderly are capable of causing cognitive impairment, potentially through an 
anticholinergic mechanism. Exposure to such medications may put older persons at 
increased risk for cognitive impairment due to an age-related increase in the sensitivity to 
anticholinergic intoxication. The new generation of antidepressants, such as SSRIs, tends 
to have lower anticholinergic profiles, and hence, fewer or no cognitive side-effects. 
Moreover, preliminary evidence from randomized clinical trials and observational studies 
suggest that they may even improve rather than compromise cognitive function in older 
persons with major depression. However, randomized clinical trials typically focused on 
the therapeutic efficacy rather than cognitive side-effects of the antidepressants, had short 
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follow-up, overrepresented healthy elderly, and did not allow for evaluating confounding 
by concomitant medication. In addition, potential cognitive benefits have not yet been 
established in older persons with minor depression or with complicated medical 
conditions. The underuse of antidepressants, despite the availability of safer modalities, 
and over-use of benzodiazepines, despite their potential to cause cognitive impairment, in 
depressed elderly living in the communities might reflect in part the consequence of such 
a knowledge gap and caUs for rigorous epidemiological investigation. 
2.4 RELATIONSHIP BETWEEN DEPRESSION AND COGNITIVE DECLINE 
2.4.1 Background 
Early studies of the depression-cognitive impairment relationship were often 
conducted in clinical samples with diagnosed depression or dementia. Since the onset of 
dementia and depression is often insidious and their clinical manifestations may 
significantly mimic each other, it is often difficult to ascertain their temporal sequence or 
establish a causal pathway. In addition, patients who seek medical attention are often 
prevalent cases or "survivors" of the disease who have already passed the pre- or sub-
clinical stage, during which etiological agents (or causal risk factors) are most likely to 
be detected. Thus, the ability of the clinical studies to delineate the causal relationship of 
depression and cognitive impairment is limited. 
The earliest epidemiological finding from community samples advocating for an 
association between depression and dementia may be owing to Jorm and colleagues 
[149]. In a pooled analysis of6 case-control studies conducted between 1984 and 1991, 
the authors found a significant association between late-onset depression and diagnosis of 
Alzheimer's disease with either greater (relative risk (RR): 2.1 95%CI: 1.1-3.8) or less 
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(RR: 4.5, 95%CI: 1.2-16.0) than 10 years of previous history of depression. In addition, 
they also observed a non-significant effect of antidepressant use (RR=1.2, 95%CI: 0.25-
2.78) from 2 studies that had such data. However, the strength ofthese findings was 
weakened by the lack of adjustment for potential confounding, the retrospective nature of 
depression ascertainment, and the methodological heterogeneity across the pooled 
studies. 
2.4.2 Current State of Epidemiological Knowledge - A Critical Literature Review 
To identify relevant research in the epidemiologicalliterature addressing the 
relationship between depression and cognitive decline in the elderly, 1 searched the 
MEDLINE database, 1975 to February 2006, for original prospective studies of the 
relationship conducted in persons aged 45 years or older, using three groups of keywords: 
1) depression or depressive symptoms or depressive disorders; 2) cognitive impairment 
or decline or dementia; and 3) epidemiological or cohort or longitudinal or prospective or 
follow-up studies or research methodology (e.g., confounding factors). 1 also reviewed 
the bibliographies of identified papers to locate more relevant studies. Finally, 1 identified 
14 studies that met the following criteria: prospective design; study population consisting 
of elderly people age 60 year or older with ascertainable size; measured both depression 
and cognition, with cognition as a study outcome; and adjusted for at least one additional 
risk factor. In the next sections, 1 will provide a systematic review of these studies and 
try to identify potential methodological issues that may help improve the quality of my 
thesis. 
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2.4.2.1 Overview of study designs 
The major study design and methodological features of the 14 reviewed studies 
are summarized in Table 1 (150-163). In brief, aIl the studies used a prospective cohort 
design and followed up a defined groupes) of community-dwelling elderly, with the 
sample sizes at baseline ranging from 500 [162] to 7511 [151]. The durations offoIlow-
up varied from one to twelve years and the number of assessments (or foIlow-up waves) 
from two to four, with the minimum time lag of one to two years between depression and 
cognitive assessments. Depression was often measured using a self-rated depression 
scale, mostly the Geriatrie Depression Scale (GDS) or Center for Epidemiological 
Studies Depression Scale (CES-D) or their modified versions, or further defined 
dichotomously by a eut-off point on these scale. The most common instruments used to 
measure cognitive functioni,ng were the Mini Mental State Examination (MMSE) and 
Short Portable Mental Status Questionnaire (SPMSQ). The outcome measures included 
cognitive decline, as defined by ARC or a change score on the cognitive test between two 
foIlow-up waves [151,153,156-158, 160, 162, 163], or by crossing a eut-point on a 
cognitive test of presumed clinical significance [151-154, 156], or a diagnosis of 
de menti a or Alzheimer' s disease according to the Diagnostic and Statistical Manual of 
Mental Disorders, the 3rd revised (DSM-IIIR) or the 4th Edition (DSM-IV) [150, 154, 
155, 157]. AlI the studies employed one or more multivariate modeling techniques to 
control for confounding from potential risk factors. Therefore, the resultant effect 
estimates represented the association between the depression measures and subsequent 
cognitive outcomes, independent of the adjusted covariates. 
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2.4.2.2 Main findings 
Of the 14 studies reviewed, several [150-152, 154, 156-159], but not aIl [153, 
155, 160-163] found a statistically significant association between depression and 
subsequent cognitive outcomes. However, in sorne studies the observed association 
seemed to vary across other risk factors. For example, it was found to be significant only 
in the subgroup with sorne cognitive impairment at baseline [152], or with greater than 
eight years of education [154], or in male gender only [161]. In addition, the 
interpretations of the association or the temporal sequence of depression and cognitive 
decline varied across studies. While sorne suggested that depression increased the risk of 
future cognitive decline or development of de menti a [151,156-159], others interpreted it 
as a prodromal syndrome or early manifestation of dementia [150, 152, 154, 155, 163], 
still other considered it as a consequence of a third factor or common etiology [150, 152, 
161], or merely a clinical concomitant of cognitive impairment [161]. Therefore, it 
remains inconclusive as to whether depression is an independent risk factor, a clinical 
concomitant, or a consequence of cognitive impairment. 
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Table 1. Recent prospective cohort studies of the depression-cognitive impairment association in elderly population 
Author Studï Population 
. 
Follow- Depression Cognitive Outcome Main Covariates Adjusted Adjusted Effect 
Iyear 
N, F% &Age CI/DEM up yrs Measuret Ilndex Measure Main Index Drug Usel Others IMethod for of Depression* % Iwaves Treat. adjustment 
8assuk N: 2030/2812; 12.4 3-12/4 CES-DI 1. SPMSQ 1) Decline to NIA age, functional OR: 1.7 (1.0-2.8) 
'98152 F%: 62.8 (SPMSQ score~16 (15.4%); [category: 9- a lower disability, CVD profile, for 3-y FU; 2.4 
Age: ~65 0-6) 2. Dysphoria 10,7-8,0- category; alcohol usel (1.3-4.3) for 6-y 
(10.2%). 6]. 2) Last polytomous logistic & FU! 13=-0.44 
scores. multiple linear (p=0.01) 
regression. 
Chen '99155§ N: 803/954; 11.5/9.6 1-812-3 CES-D-ml DEP DSM-IIIRI Incident AD NIA age, sex, education RR: 1.3 (0.6-2.9) 
(full cohort) F%: 60.0 byDEP cluster (6.5%) NINCDS- orDEM ICox proportional on DEM; 1.3 
Age: 73.7 group ADRDA(& hazard model (0.5-3.2) on AlzD 
MMSE etc) outcome. 
(subcohort) 751 non-DEP NIA 2.2/2 (above)1 incident same as same, but NIA (above)+ subjective OR: 5.2 
(39 developed DEP at wave 3 above treated as memory loss 1 Logistic (1.8-15.1) for 
DEM/AD later). "exposure" regression DEM,6.5 
(2.2-19.1) for 
AlzD. 
Cervilla N: 374/1083 18.5 9-12/2 Self-CARE-D: 1) MMSE Log NIA baseline cognition, 13=0.004 
'00161 F%: 66.1; raw score; 2) ~6 transformed age, sex, education, (p=0.92); 
Age: 70.2 (11.2%) vs <6. (& raw) score smoking etc Ifactorial 
MANOVA 
Devanand N: 478/852; 47.0 1-51> 2 HRSD/1. DEP DSM-IIIRI Incident NIA age, sex, language, RR: 2.1 
'96150 F%: 69.4 ~2 mood (37.4%); 2. NINCDS- DEM orAlzD memory & functionsl (1.2-3.6)/13=1.1 
Age: ~60 deficit Scores. ADRDA Cox PH model (1.0-1.1) for total 
tests) score. 
_. lq-
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Table 1 Cont'd 
Dufouil '96 N: 1600/2726 18.5 3/2 CES-DI 1). ~17 for MMSE 1) Decline> NIA age, sex, marital OR: 0.8 
(cohort) 153 F%: 60.0; M, ~23 for F; 5 points; 2) status, IADL Imultiple (0.3-2.1). 
Age: 72.8 (13.7%) ;2). Change logistic llinear 
Change score score. regression 
Ganguli N: 595/1265 0.0 1216 CESDm/1) MMSEI ARC AD use at age, sex, education ~=0.003 (NS) in 
'06163 F%: 60.8; (>0 on Score>5 (10.1%); other baseline incipent dementia & dementia-free 
Age: 74.6 CDRS) 2) Transient vs cognitive recruitment group, & 0.02 
persistent DEP tests statuslrandom effects (NS) in eventual-
model dementia grouQ. 
Geerlings N1 :1911/3137; 0.0 3.2/2 GMSSI DEP score DSM-IV Incident AlzD NIA age, sex, memory OR: 5.3 F%: 62.3 3-6 (9.7%) (CAMDEX, complaints, psychiatrie (1.9-15.0) 
'00154 Age: 73.1 MMSE) historyl Logistic (cohort 1) (65-80) regression 
(cohort 2) N2: 1894/2399; 0.0 3.112 CES-D 11. Score MMSE Decline ~3 NIA (from above) +baseline OR: 1.8 (0.9-3.6) 
F%: 52.9 ~16 (11.6%); 2. points MMSE, 1~=1.1 (1.0-1.1) 
Age: 68.5 Total score. psychiatrie history. for total score. 
(55-84) 
Henderson N: 709/1045 NIA 3/2 CES-D score MMSE (& Change NIA age, sexlconditional No actual data 
'9i 6D Plo: 51.5; other score linear regression given, only cited 
Age: 76.5 mental asNS. 
tests) 
Paterniti N: 1003/1389 0.0 4/3 CES-D/DEP MMSE 1) Change Psychotro- age, sex, education, 1) ~=-0.54 
'oi 56 F%: 57.2; group by ~17 for M score; 2) pic use alcohol/tabaco use, & (p=0.002); 2) OR: 
Age: 65.0 and ~23 for F Decline ~3 chronic disases/linear 1.6 (0.95-2.55); 
points; 3) & logistic regression 3) OR: 3.2 (1.2-
Score <25 8.4) 
Saches- N: 3094/4162; 46.0 3/2 CES-DI scores SPMSQ # errors NIA age, gender, race, ~= 0.04 (p=0.01) 
Ericsson F%: 65.0 (SPMSQ economic status, 
'04159 Age: 76.6 errors baseline cognition and 
>1 ) physical functionl 
multiple regression. 
-30-
Vinkers 
'04162§ 
Wilson 
'Oi 57 
N: 298/500 
F%: 63.0; 
Age: 85.0 
N: 651/821 
F%: 67.5; 
Age: 75.4 
N: 2783/4392 
17.0 4/4 GDS-151 scores 
«24 on 
MMSE) 
NIA 7/5.5 CES-D 10-iteml 
scores 
NIA 5.313 CES-D 10-iteml 
'\ 
Table 1 Cont'd 
MMSEI ARC NIA sex, educationl Mixed (3=-0.01 (p=0.79) 
other regression model 
mental tests 
clinical Incident NIA age, sex, education, 1) HR: 1.19 (1.1-
diagnosisl AlzDI ARC memory complain, 1.3); 2) (3=-0.009 
19 cognitive on a global apoE, comorbiditiesl (p=0.004) 
tests score Cox PH & random 
effects models 
MMSE/4 ARC on a NIA age, sex, race & (3=-0.03 unit Wilson 
'04158 F%: 62.1; scores (15% >3) other brief composite z education (plus chronic (p=0.OO2) 
Age: 73.9 cognitive score across 
tests the 4 tests 
Yaffe '99151 N: 5781/7511 NIA 41 2 GDS-s/1. # MMSE-m 1) Change AD use in 
F%: 100.0; symptoms; 2. (Trails B, score; 2) past 30 
Age: 72.8 scores>6 (3.6%), Digit Decline ~ 3 days 
3-5, (vs 0-2) symbol) points 
Notes: 
* If both cross-sectional and longitudinal data were available, only the longitudinal ones were presented; 
N: Denotes # subjects at the end of follow-up versus # subjects at baseline. 
F%: Denotes proportion of female among the study population; 
illnesses etc)1 random 
effects models 
age, health, physical 
function, alcohol use 
etcl ANOVA & logistic 
regression 
Age: Denotes mean or median (range) age in year of the study population or reference group at baseline, except otherwise indicated. 
t. Refers to those used as a predictor in the multivariate analyses, which were assessed at baseline only in ail the studies; 
OR: 2.1(1.4-3.1) 
for GDS-s >6; 1.6 
(1.2-2.1) for 
GDS-s 3-5 
:t:. Refer to effect estimates for depression associated with the Main Index for Cognitive Outcome adjusting for the selected covariates, with 95% 
confidence interval or p value (as specified) in parentheses. 
§. The subcohort analyses on depression as an outcome in these two studies were not presented. 
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Table 1 Cont'd 
Abbreviations: 
AlzD, Alzheimer's disease; CI, Cognitive impairment; DEM, Dementia; DEP, Depression or depressed or depressive; FU, follow-up; 
NINCDS/ADRDA, Nationallnstitute of Neurological and Communicative Disorders and Strokel Alzheimer's Disease and Related Disorders Association. 
M, male; F, Female; NIA, not available or not applicable; NS, p>O.05 or not significant according to the paper; 
AD, antidepressants; PH, Proportional hazard model; CVD, Cardiovascular diseases; 
CAMDEX, The Cambridge Examination for Mental Disorders of the Elderly (Roth 1988); CORS: Clinical Dementia Rating Scale; 
CES-D(-m), Center for Epidemiological Studies Depression Scale (-modified) (Radloff 1977); 
DSM-III(R), The Diagnostic and Statistical Manual of Mental Disorders, 3rd Edi (Revised) (American Psychiatrie Association 1987); 
GMSS(-dep), GMSS(-org), Geriatrie Mental State Schedule (-depression or -organic score) (Copeland 1976); 
GDS(-s), Geriatrie Depression Scale (-short form) (Yesavage 1983); HORS, Hamilton Depression Rating Scale (Hamilton 1967) 
MMSE(-m), Mini-Mental Status Examination (-modified) (Foistein 1975); SPMSQ, Short Portable Mental Status Questionnaire (Pfeiffer 1975); 
ARC, Annual Rate of Change in the test scores; OR, Odds ratio; RR, Risk ratio or rare ratio; 13, Beta coefficient; 
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2.4.2.3 Methodological implications 
There are several common methodological issues in these studies that may have 
important implications for this thesis. 
2.4.2.3.1 Lack of specificity of the depression measure 
In ail the reviewed studies with only one exception [150], the depression 
symptoms in the association analyses were defined using self-rated, rather than clinical 
assessment-based, depression scales [152,155,156,160,151,162]. A cut-offscore (e.g., 
> 16 on CES-D) was often used to determine the presence or absence of depression. 
However, the "self-report" depression symptoms tend to have an inadequate criterion 
validity to identify clinically significant depression and great intra-individual variation 
[164, 165]. In fact, a four to ten fold overestimation of true depressive disorder (false 
positive) by CES-D against clinical standard diagnostic criteria for major depression has 
been observed [29, 166]. Therefore, studies relying solely on self-report scale to define 
depression symptoms may, on one hand, lead to a spurious association when clinical 
confounders such as physical illness or stress reaction are not adequately accounted for; 
on the other, their findings may be difficult to translate into clinical practice with regards 
to whether and to what extent these "depressed" elderly are comparable to clinically 
significant cases of depressive disorders, who may bene fit from antidepressant 
intervention. 
2.4.2.3.2 Ignorance of the natural course of depression symptomatology 
Depression, either by symptomatic or diagnostic definition, is an episodic and 
recurrent condition, often with complete remission at intervals [6]. A typical major 
depressive episode usually lasts three to six months [6]. Without a consideration ofthe 
- 33 -
biologically plausible "pathogenic" effect period of depression pathology and account for 
its dynamic course, a prospective study that simply associates a depression score at 
baseline to a distant cognitive outcome observed several years later may lead to a 
spurious association, which cou Id result from an unmeasured intervening event, such as 
the side-effect of recent antidepressant treatment or an acute psychological stress, or fail 
to detect an existing causal association that may have diminished before the time when 
the outcome was assessed. 
Almost all the reviewed studies have assessed depression and cognitive outcome 
at least one year, mostly two to three years apart. In addition, though sorne studies 
assessed depression on more than one occasions during the follow-up [150, 152, 155, 
162, 163], no one had examined it as a dynamic, time-varying exposure when examining 
its prospective association with the cognitive outcome. Therefore, it is questionable that 
an observed cognitive decline or incident dementia could be attributed to the causal effect 
of the remote depression symptoms. As Dufouil suspected [153], the lack ofa 
prospective association in sorne studies [153, 160-163] could simply be explained as the 
failure of the over-protracted follow-up intervals to capture the true depression effects, 
which may have diminished before the delayed outcome assessment, rather than a proof 
of no causality. Another drawback of such prolonged follow-up studies is that they do not 
allow for examining the specific short-term clinical concomitants that may confound the 
relationship in a close temporal context, such as an acute physical illness or a recent 
stressfullife event. 
- 34 -
2.4.2.3.3 Lack of consideration of potential effect of medication use 
Substantive knowledge exists that both antidepressants, such as TCAs, and other 
psychotropic medications frequently prescribed to depressed elderly, such as 
benzodiazepines, may potentially compromise cognition [119, 124, 126]. In addition, the 
agents, dosage and frequency of antidepressant administered often varies over time in 
response to the variation of depression symptoms or other factors, which may affect both 
depression pathology and cognitive functioning ofthe patients. Therefore, it is important 
to disentangle the cognitive effects of depression pathology from those attributed to the 
concomitant antidepressant or other psychotropic medications. 
Among the reviewed studies, only three reported an adjustment for antidepressant 
[151,163] or psychotropic use [155] as a covariate. However, the medication use was 
merely ascertained at baseline and represented by a dichotomous indicator, exposed 
versus not exposed. Due to ignorance of the dose, duration and changes of medication 
regiment over time, the use of a single baseline measure to represent current medication 
exposure may introduce serious misclassification bias in observational studies [167]. 
Furthermore, collapsing different levels of exposure into a dichotomous exposure status 
may result in a significant loss of precision and efficiency in the effect estimation [168]. 
Both concems may be particularly implicable in the studies of late-life depression, given 
the dynamic nature of the depression symptoms and the complexity of medication 
regimen of older persons with depression. 
2.4.2.3.4 Other methodological implications: 
Two other potential limitations from several studies may also be worth 
mentioning: 
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1). Omission ofpotentially important clinical confounders. For instance, 
cardiovascular diseases (CVD) have been consistently associated with both depression 
[48, 49] and dementia [117, 118] in literature, but was only adjusted for in one study 
[152]. Another study measured, but did not control for, baseline blood pressure [151]. 
2). Inclusion of a large proportion (10% or greater) of cognitively impaired 
subjects in the study population without adequate statistical adjustment [150, 152]. 
Elderly people with mi Id cognitive impairment may be more likely to report depression 
symptoms due to awareness of their declining cognitive function. They are also at higher 
risk of developing dementia subsequently than those cognitively normal elderly. Thus, 
the se studies may be subject to great ambiguity as to whether depression was an 
independent or causal risk factor of cognitive decline or dementia, or merely a prodrome 
of or early reaction to the underlying dementia process that was already in operation. 
2.4.3 Summary 
While large-scale, population-based prospective epidemiological studies have 
added to our knowledge about the depression-cognitive impairment relationship in the 
elderly, the research findings remain inconclusive with regard to the nature of the 
relationship, i.e., whether depression is an independent risk factor, a clinical concomitant, 
or a consequence of cognitive decline. However, there remain several unanswered 
questions on this relationship. First, several methodologicallimitations, namely, the lack 
of specificity of the depression measure, lack of consideration of the dynamic course and 
biologically plausible short-term prospective effects of depression pathology, and 
omission of potential effect of antidepressant use or cardiovascular diseases, may have 
hampered the ability of CUITent epidemiological studies to delineate the temporality and 
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causality of the relationship. New epidemiological studies attempting to solve the 
ongoing controversies with improved methodology are warranted. 
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CHAPTER 3 - OVERVIEW OF STUDY DESIGN AND DATA SOURCE 
3.1 STUDY DESIGN: APPROACHES AND RATIONALES 
This thesis is concemed with the relationship between depression and changes in 
cognitive function. As described in section 2.2, several terrns have been used in the 
literatures to describe levels of and changes in cognitive function in older populations. 
To keep terminological consistency with the literature while maintaining the conceptual 
clarity and unique feature ofthis thesis, 1 will use the terms "function" or "functioning" 
to qualitatively describe the cognitive outcome, cognitive "change" to describe the 
quantitative increases and decreases over time in cognitive functioning, and cognitive 
"decline" to refer specifically to a decrease over time in cognitive functioning. While in 
the literature the latter terrn often implies a long-terrn, and sometimes irreversible, 
cognitive deterioration, this thesis will treat it as a short-terrn and dynamic phenomenon, 
without a persistency or pathological implication. 
Based on my literature review, this thesis is intended to further address the 
following unsolved research questions in a cohort of elderly medical inpatients who were 
followed for up to twelve months: 
1). Is depression in older persons an independent risk factor, a clinical 
concomitant, or a consequence of cognitive decline? 
2). Are antidepressants or other psychotropic medications associated with 
cognitive decline, independent of depression and other risk factors, or do they modify or 
mediate the relationship between depression and cognitive decline? 
Ta avoid the methodologicallimitations ofprevious cohort studies, namely, the 
non-specific depression measures, long follow-up interval, lack of consideration of the 
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dynamic nature of depression symptoms, and omission of potentially important clinical 
confounders, such as medication use and cardiovascular diseases, this thesis adopted a 
prospective, repeated measures, cohort design, with the following innovative features: 
1). Both the "exposures" (i.e., depression and medication use) and the outcome 
(i.e., cognitive decline) were measured at multiple time points during follow-up. A 
longitudinal analysis using a mixed effects linear regression model was conducted to test 
the hypotheses, which allowed for a simultaneous control for both baseline (or patient-
specific) and time-varying risk factors and addressing the dynamics of depression 
symptomatology over time. In addition, the study power and efficiency were increased 
due to utilizing additional data from repeated measures on the same patients [1, 2]. 
2). The primary exposure, depression, was defined using both an interviewer-
assessed symptom scale and the structured clinical diagnostic criteria, which enhanced 
the clinical interpretability and applicability of the study, and stimulated deeper insights 
into the properties of the dimensional (Le., symptomatic) and categorical (i.e., diagnostic) 
approaches to the concept of depression. 
3). The medication regimens of the cohort members during the follow-up period 
were obtained from a comprehensive administrative prescription database, linked with 
clinical research data, which minimized potential measurement errors in medication 
exposure due to sole reliance on baseline assessment, self-report or hospital records, and 
maximized the capacity of the study to control for confounding by indication, a major 
threat to the validity ofpharmacoepidiological studies [3,4]. 
4). The follow-up interval between repeated assessments ofthree to six months 
was shorter than any previous cohort study in the subject field and approximated the 
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natural course of major depressive disorder more closely. The alternative exposure time 
windows and measures of medication exposure were devised in light of both substantive 
pharmacological knowledge, and a biologically plausible cholinergic deficiency 
hypothesis for dementia etiology. 
3.2 DATA SOURCE 
This thesis used the data collected in two previous studies conducted in two 
university affiliated, acute care hospitals in Montreal, Canada, St. Mary's Hospital and 
Jewish General Hospital. The two studies included a randomized controlled trial (RCT) 
of the treatment of major depression and a prospective obseryational cohort study of 12-
month outcomes of depression in older medical inpatients [5, 6]. Both studies were 
funded by the Canadian Institutes of Health Research. The study protocol was approved 
by the research ethics committees ofboth hospitals (see Appendices II and III for letters 
of approval). 
The objective of the RCT was to determine the impact of systematic detection, 
treatment, and follow-up on the course and outcome of elderly medical inpatients with 
major depression. Eligible patients aged 65 years and older who were admitted from the 
emergency room to the medical services were screened by the study nurse using the 
SPMSQ; those who scored four or less (indicating at most mild cognitive impairment) 
were assessed using the Diagnostic Interview Schedule (DIS) [7]. Patients diagnosed 
with major depression (DSM-IV criteria) [8], and who consented to participate, were 
enrolled in the study (n=244), and randomly allocated to intervention or control groups. 
The intervention group received special care by a geriatric psychiatrist and study nurse. 
Patients in the control group received usual hospital care. All patients were assessed at 
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baseline, then three, six, twleve, and 24 weeks later. Primary outcomes included repeated 
measures of the HDRS and the Medical Outcomes Study Short Form (SF-36). Secondary 
outcomes included cognition, physical function, side effects of medication, and number 
of depressive episodes, mortality, suicide and suicide attempts and use ofhealth services. 
The prospective observational cohort study used identical data collection methods 
and instruments (including follow-up at three, six, and twelve months after enrolment) 
among three cohorts of cognitively intact medical inpatients aged 65 and over: a major 
depression cohort and a minor depression cohort, in whom these diagnoses were made 
during the first few days ofhospitalization; and a control cohort without a depressive 
disorder. It followed the same set of general exclusion criteria as the RCT: a) admissions 
to intensive care unit or to cardiac monitoring unit (unless transferred to a medical ward 
within 72 hours of admission); b) admissions to palliative care (unable to be followed for 
at least 6 weeks); c) do not speak or understand English or French (or unable to 
communicate), and d) do not live on the island of Montreal (who would be difficult to 
follow-up). However, patients with major depression who were excluded from the RCT 
because of severe depression or psychosis were included. 
The two studies shared common methods and measures, including cognitive 
screening using the SPMSQ, two approaches to assessing depression (symptomatic and 
diagnostic), the MMSE to assess cognition, and measures of covariates (e.g., severity of 
illness, comorbidity, physical function, and quality of life). The research assistants 
conducting baseline and follow-up assessments were kept blind to study cohort. The 
interview instruments were limited to confine each interview to one ho ur, for the sake of 
minimizing the burden on patients and "testing effects". 
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Information about medication prescriptions of the study participants during the 
follow-up period was obtained though linkage of their hospital medical records with the 
provincial prescription claims databases (the Regie de l'assurance maladie du Québec, 
RAMQ) [9]. RAMQ provided the product name, dose and duration of each filled 
prescription from the 6 months prior to the index hospitalization up to the end of the 12-
month follow-up period for aIl the enrolled patients. 
Enrollment for the two studies began in September, 1999 and concluded in 
October, 2002. The follow-up covered one year after enrolment. In total, 1,686 eligible 
patients were screened for depression, ofwhom 530 consented to participate and were 
enrolled into the study. The main reasons for exclusion included: too sick, severe 
cognitive impairment, admission to intensive care, already discharged, transferred to long 
term care, not proficient in either English or French language, and residing outside of 
Montreal island. Of the 530 enrollees, 22 died and 94 withdrew before the base li ne 
interview, leaving 414 for baseline and follow-up interviews. 
For this thesis, the study sample included 281 participants with at least two valid 
outcome measures (i.e., MMSE scores, see section 4.2 for details) during the twelve 
month follow-up period, including participants from the observational study and the 
ReT, and from both study hospitals. The main reason for this selection was to 
accommodate the repeated measure mixed model analysis. Patient with only one measure 
did not contribute data to assessing longitudinal variation, and hence, essentially 
irrelevant for the analyses. Similarly, participants from the ReT were included to 
increase study power, especially for evaluating the effect of major depression. This 
inclusion was also justified by the lack of any effect, clinical or statistical, of the 
- 57 -
experimental intervention on cognitive status in the trial [5]. The 281 selected patients 
represented 67.9% of the baseline cohort (N0=414.). The sample consisted of 185 
(65.8%) women and 96 men (34.2%), with a mean age of79.1(SD: 7.2). 121 were 
diagnosed as with major depression, 51 with minor depression and 109 with no 
depression. There were no statisticaIly significant differences (aIl p> 0.07) between those 
included (N=281) and excluded (N=133) with respect to age, sex, living condition, ADL 
scores, study group, hospital sites, diagnosis of depression and cognitive impairment at 
screening. However, patients who were excluded were more severely iIl (p<O.Ol), had 
more comorbid conditions (p<0.01), higher HDRS (p=0.05) and lower MMSE scores 
(p=0.03). 
3.3 SPECIFIC AIMS AND HYPOTHESES 
Three inter-related specifie research aims are pursued in the three manuscripts that 
comprise this thesis: 
1). To explore the temporal relationship between depression symptoms and 
cognitive functioning, independent of other risk factors, with a specifie focus on testing 
whether depression symptoms as measured by an interviewer-assessed scale are an 
independent predictor of subsequent cognitive decline, versus a clinical concomitant; 
2). To examine the temporal relationship between depression diagnoses and 
cognitive decline, independent of other risk factors as weIl as the severity of depression 
symptoms; and to determine whether the short-term trajectories of cognitive functioning 
of the cohort differed among persons with major, minor or no depression; 
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3). To examine the role of antidepressant and other psychotropic exposure in the 
relationship between depression and cognitive decline, and to determine wh ether it was 
an independent risk factor, an effect modifier, or a mediating factor. 
My main hypotheses were as follow: 
1). If depression is indeed an biologically val id risk factor for cognitive decline, 
then such an association would be more likely to be detected during the active clinical 
phase of the depression pathology than during its residual or remission period. 
2). The diagnoses of depression should have better predictive power for 
subsequent cognitive decline than the severity of depression symptoms, since the former 
are more likely to identify clinically significant, and potentially more biologically 
homogeneous depression syndrome than latter. 
3). In general, exposure to antidepressants (especially TCAs) and other . 
psychotropic medications (in particular benzodiazepines) should be associated with a 
decreased cognitive function. However, since depressive pathology itself may lead to 
cognitive decline and such a detrimental effect may be potentially reversed or alleviated 
by effective antidepressant treatment, the "net" cognitive effect of the medications would 
depend on a trade-off between the antidepressant "efficacy" of the medications and the 
severity of depression pathology. 
A final and exploratory hypothesis was that the detrimental effects of medication 
use on cognitive function would mainly be driven by the total anticholinergic burden 
across ail the concurrent medications, consistent with the cholinergic deficit hypothesis 
for dementia etiology. 
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3.4 STUDY MEASUREMENTS 
3.4.1 Measure of Depression 
Severity of depressive symptoms was measured using the 21-item version of the 
HDRS [10] at enrolment and at each follow-up by a research assistant. The HDRS is the 
most widely used interviewer-rated scale for monitoring depressive symptoms and signs 
in intervention studies of depression patients. Items are rated from 0 to 3, with higher 
scores indicating more pathology. A total score of 13 or more is usually considered as 
indicative of clinical depression. 
The depression diagnoses were made through a structured psychiatric evaluation 
using the depression section of DIS at baseline and then three, six and twelve months 
latl!r during follow-up by a research assistant. Patients were classified as major, minor, or 
no depression according to DSM-IV criteria using an "inclusive" approach, which counts 
CUITent symptoms with a duration of at least two weeks towards a diagnosis, regardless of 
the:ir origin of physical illness or primary affective disorders [11]. This approach appears 
to be most reliable for assessing depression in medically ill older persons, especially from 
a longitudinal perspective [11]. 
The inter-rater reliability was checked periodically, with a kappa coefficient being 
0.78 (95% CI 0.52 to 1.00) for a diagnosis of major depression vs. minor or no 
de pression and 0.61 (95% CI: 0.35 to 0.87) for a diagnosis of either major or minor 
depression vs. no depression (n=28). The intra-class correlation coefficient for HDRS 
scores was 0.93 (95% CI: 0.86 to 0.97, n=26). 
The content ofHDRS and DIS, and the diagnostic criteria for depression from 
DSM-IV are presented in Appendices IV and V. 
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3.4,,2 Measures of Medication Exposure 
3.4 .. 2.1 Major medication classes 
Using the prescription records from RAMQ, three major classes of psychotropic 
medications were defined, based on their documented cognitive effects in literatures and 
specific relevance to depressed older persons: 
1). Antidepressants included tricyclics (TCA: amitriptyline, desipramine, 
dmœpine, imipramine, nortriptyline, trimipramine and clomipramine), selective serotonin 
reuptake inhibitors (SSRIs: fluoxetine, sertraline, fluvoxamine, paroxetine and 
citalopram), and other agents, which included tetracyclics (maprotiline), monoamine 
oxidase inhibitors (tranylcypromine) and atypical antidepressants (trazodone, 
nefazodone, venlafaxine and bupropion). 
2). Benzodiazepines were divided into long-acting agents, which included 
clonazepam, clobazam, chlordiazepoxide, diazepam, flurazepam and nitrazepam, and 
short-acting agents, which included oxazepam, lorazepam, triazolam, temazepam, 
bromazepam and alprazolam, based on a half-life of above or below 24 hours [12]. 
3). Other psychotropics included non-benzodiazepine sedatives, anxiolytics, 
neuloleptics, lithium, anticonvulsant and antiparkinson drugs. These medications were 
co llapsed together because of their potential to cause cognitive impairrnent [13, 14] yet 
low exposure frequencies in the study population. 
A sample of prescription records from RAMQ is presented in Appendix IV. 
3.4.2.2 The clinician-rated anticholinergic (ACH) score 
To allow for causal inference in light of the cholinergic deficit hypothesis for 
dementia etiology, 1 also used a clinician-rated ACH score, originally developed in my 
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MSc Thesis, as a measure of total anticholinergic burden across medications without 
regard to their therapeutic class [15]. The ACH score is an ordinal scale, with scores 
ranging from 0 for no ACH effect to 3 for strongest ACH effect. It was found to be 
predictive of severity of delirium symptom in a cohort ofhospitalized older medical 
pat lents [15]. Since its publication, the ACH score has been used in several clinical and 
pharmacological studies [16, 17] and was judged to have adequate criterion validity 
against a serum ACH activities assay and to be one of the most feasible tools for routine 
clinical use [17]. Although not validated against chronic cognitive decline, preliminary 
results from an external older community-dwelling population suggest that the 
cumulative ACH score of multiple medications is independently and specifically 
predictive of poor performance on Hopkins verbal recall over two years [18]. For this 
PhD thesis, the original ACH drug list was updated following the original protocol and 
procedure, as briefly described below. 
First, a complete list of the prescription records retrieved from RAMQ database 
for this study population was reviewed. Medications that matched with one of the 340 
generic medications evaluated in the original ACH list were assigned the available score 
(n==204) by myself and verified by a senior geriatric psychiatrist (MC) and a senior 
clinical pharmacologist (RC). For medications without an available ACH score, their 
pharmacological properties were judged based on the therapeutic classification by 
American Hospital Formulary Service (AHFS) system [19]. Medications under a class 
that was believed to have no anticholinergic effect as a whole were assigned a zero score 
(n:=174), which include antibiotics, hematologic drugs, diagnostic agents, expectorants 
and cough preparations, ophthalmic/otic/nasal preparations, antiperspirants, dietary 
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supplements, and vitamins. For the remaining medications whose anticholinergic 
properties can not be determined (n=62), an inde pendent rating by the two clinicians (MC 
and RC) was conducted and the median value of the two ratings was adopted as final 
ACH score, following the original protocol. 
A list of psychotropic medications evaluated in this thesis, along with their 
therapeutic classification and assigned ACH scores is provided in Appendix VII. 
3.4.2.3 Exposure time window 
In traditional pharmaco-epidemiological studies, an exposure time window refers 
to the number of exposed days assignecl to each prescription [20], during which the 
number of outcome events (numerators) and total exposure time (denominator) are 
computed. It is essential that the time window should not simply coyer the duration of the 
drug intakes (so-called a "legend" time window), as estimated from the filled 
pn:scriptions, but should also take into consideration the potential induction and residual 
period of the pathogenic effects of the drugs [20,21]. 
In this thesis, two alternative exposure time windows were defined based on both 
data availability and biologically plausible pathogenic mechanisms of the medications of 
interest. A long time window was defined as the 3-month period prior to each follow-up 
MMSE assessment, in an attempt to capture the cumulative effects of the medication 
exposure over time; whereas a short time window was defined as the one-day period 
immediately preceding each MMSE assessment, intended to capture potential acute 
effects of the medication exposure. Although the choice of a 3-month duration for the 
long time window was somehow arbitrary, constrained by the actual follow-up intervals 
of three or six months, it also reflects the reality that a course of successful antidepressant 
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treatment usually takes two to three consecutive months [22, 23], and that a maximum 
tim~ window of 90 days was often tested in pharmacoepidemiological studies of adverse 
drug events [20]. On the other hand, the short-time window of one day represents the 
typical mode of acute cognitive impairnlent, such as delirium, and other transient adverse 
drug events due to intoxication of ACH and other psychotropic medications, which 
typically arises in minutes or hours [22, 24, 25]. A comparison of the two alternative time 
windows would allow for a greater insight into the biological plausibility of an observed 
association between chronic medication exposure and cognitive decline. 
3.4.2.4 Variables to represent medication exposure 
For both the long- and short- exposure time windows, the total exposure to each 
medication class, as defined above, was quantified by the total exposed drug-days (EDO), 
which was a sum of the total dispensed days across prescriptions within each class. 
Similarly, a total ACH burden was defined as the sum ofproducts of the assigned ACH 
score and number of days dispensed for each individual medication across ail the 
pn::scriptions. To account for potential residual effects of the medications after the intake 
of their last doses and the possibility that a patient may have skipped a few doses and 
th\:::n resumed beyond the prescribed duration, due to incomplete compliance or other 
reasons [26], a 7-day block was added to each prescription. This addition wou Id increase 
th\:: tolerance of the short-time window to the afore-mentioned potential measurement 
errors, thought its impact on the long time window should be trivial. 
The duration-based measures d,~scribed above assumed that the patients were 
actually taking the medication as prescribed, and that the effects of the medication 
exposure were proportional to the exposure duration. In case such assumptions do not 
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hold (e.g., a patient may not fully comply with the prescription), a simpler measure by 
number of medications or a sum of their ACH scores, without considering duration, was 
also computed. The duration-based measures also imply that the cognitive effects of the 
medications occur immediately following their intake, without any delay. While this 
assumption seems plausible for benzodiazepines or anticholinergics, it may not be so for 
antidepressants. The therapeutic effects of both TCAs and SSRIs usually take two to four 
we,~ks to appear after taking these drugs at recommended therapeutic dosage [22, 23]. To 
avoid bias on estimated cognitive effect for antidepressant use due to potential minimum 
induction period, the total EDDs for antidepressants were redefined by excluding ail such 
prescriptions during the most recent two or four weeks prior to each follow-up 
assessment from the long time windows. 
A case scenario demonstrating the above-strategy for definition and quantification 
of medication exposure is provided in Appendix VIII. 
3.4 .. 2.5 Measure of cognitive function 
The study outcome, cognitive decline, was .measured using the Mini-Mental State 
Examination (MMSE) [27] by a trained research assistant at baseline and then at 3, 6, and 
12 months. The MMSE is the most widely used brief cognitive instrument for screening 
cognitive impairment or monitoring its progression [28, 29], with scores ranging from 30 
(no impairment) to 0 (maximum impairment). It asses ses global cognitive function 
encompassing several different domains, such as orientation, attention, short-term 
memory, and visual construction and execution of complex command, with great 
emphasis on verbal and language ability. Studies of its psychometric properties show 
moderate to high levels of short-term tl~st-retest reliability, construct and criterion 
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validity, and adequate responsiveness to cognitive change over time [28,29]. In practice, 
a sc:ore of 23 or less is usually accepted as an' index for cognitive impairment. 
The majority (N=214, 76.2%) of the patients completed their baseline MMSE 
assessments during hospital stay, while aIl the foIlow-up assessments were conducted in 
patients' homes after discharge from hospital. A dummy variable was used in the analysis 
to adjust for the place of the assessment (see next section). To reduce the burden for these 
eld,;:rly patients and to allow adequate time for other assessments, a time limit was set for 
each MM SE item. A prorated total scon;: of 0 to 30 was generated based on the completed 
items, ignoring the responses beyond the set time limit. The inter-rater reliability of the 
MMSE was assessed in a convenience sample of patients at intervals throughout the 
study period, using independent simultaneous ratings by two or more raters, including the 
study psychiatrist (MC). The intraclass correlation coefficient was 1.00 (n=20). 
3.4.2.6 Measures of covariates 
Data on covariates were collected at enrolment from either patient interviews or 
patients' hospital charts, and included the following variables: 
Sociodemographic characteristics: Variables included age, sex, education, marital status 
(married vs. other) and living condition prior to admission (home vs. other), and the 
data were obtained from interview with patients. 
Baseline cognitive function: Subclinical or minimum cognitive impairment or low 
mental function has been associatedl with future development of dementia [30, 31], 
and may also interfere with the depression assessment of patients. Although the study 
protocols screened out patients with five or more errors on the 10-item SPMSQ [32], 
residual confounding may occur since this cutoff had only an 82% negative predictive 
- 66-
value for moderate to severe dementia [33]. Therefore, the SPMSQ scores obtained 
by a research assistant at screening were used as a covariate in the multivariate 
regression model. 
Ph'/sical function: The pre-morbid level of ADL and IADL function was assessed at 
baseline by the research assistant using the OARS ADL scale [34]. Both ADL and 
IADL subscales consist of seven items, each on a 3-point scale, with a total score 
ranging from 0 (completely dependent) to 14 (completely independent). The ADL 
component assesses basic or physical activities of daily living, while the IADL 
component evaluates complex physical activities involving judgment, reasoning, 
decision-making, and action planning and execution. The OARS instrument has been 
validated in both English and French version, with the Spearman correlation 
coefficient with clinical assessment of disability being around 0.80 [34, 36]. 
History of alcohol abuse: A history of alcohol abuse was obtained by the research 
assistant using an informant questionnaire, CAGE (Cut down, Annoyed, Guilty, Eye-
opener), and represented dichotomously as either with or without such a history. The 
CAGE is a 4-item questionnaire to detect people at risk of alcohol problems [37,38], 
and has been validated in older adults with appreciable sensitivity (86-88%) and 
specificity (78-88%) [39,40]. 
Physical illness and comorbidities: To maximize the ability of the thesis to control for 
confounding by physical illnesses and comorbid conditions, two global measures of 
comorbid physical conditions were defined, which included a nurse rated clinical 
severity of current illnesses, scored 1 (not ill) to 9 (moribund) [41], and the Charlson 
comorbidity index (CCI) [42] based on hospital chart- a well-validated, composite 
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measure of number and severity of co-morbid conditions from medical diagnoses 
present at or before enrollment. In addition, given the implication of cardiovascular 
diseases (CVD) in both dementia and depression etiologies [43,44], we defined a 
binary (high vs low) indicator for risk of CVD, based on a diagnosis of stroke, 
diabetes, or myocardial infarction during the previous two years or a measured sitting 
blood pressure of at least 160/95 mm Hg from the hospital chart. 
History of depression: Studies have suggested that older persons diagnosed with major 
depression who had a remote history of depressive episode may differ from those 
without such a history in terms of the clinical characteristics and prognoses [45]. To 
control for potential confounding due to etiological heterogeneity of the "inclusive" 
diagnostic criteria, we collected data on history of previous depression episode 
(remote, recent, versus neither) during the past two years and history of 
antidepressant treatment in the past year from patients' self-report and hospital 
records as potential markers for primary affective disorders. 
Other covariates: These included a time-dependent measure for follow-up time and two 
baseline variables denoting the source of the study population, i.e., hospital (A versus 
B) and study group (RCT Intervention, RCT -Control, versus Not RCT). While the 
two parent studies and the two participating hospitals followed the same study 
protocol and used the same study measurements, adjustment for baseline 
heterogeneity of the study population would help reduce potential residual 
confounding due to unmeasured factors related to hospital sites and/or RCT. 
In addition, a dummy indicator for the place of the baseline MMSE 
assessment, in hospital (N=124) versus at home (N=67), was used in sensitivity 
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analyses of the antidepressant effects. Because the RAMQ does not cover 
prescriptions dispensed in hospital, the medication use of the 214 participants whose 
baseline interviews were conducted during the index hospitalization period was 
approximated using the RAMQ records during the prior 3 months. As suggested by a 
recent study, older persons tend to have lower cognitive scores during hospitalization 
than at home, due to the physical and psychological impact of the hospitalization 
rather than real cognitive impairment [46]. An adjustment of antidepressant effects 
for place of baseline interview allowed for simultaneously addressing the imprecise 
measure ofbaseline medications and potential "place" effects ofbaseline MMSE 
assessment. 
3.5. PRINCIPLES OF STATISTICAL ANALYSES 
3.5.1 General approaches 
Descriptive statistics, including means, standard deviations for quantitative 
variables and proportions for categorical variables, were used to describe the 
characteristics of the study population. Within-patient means of the quantitative time-
dependent variables, including the HDRS scores, EDDs for different medication classes, 
total ACH burdens and corresponding measures by number of medications, were 
calculated by averaging all the repeated measures. Pearson product-moment and 
Spearman's intraclass correlation coefficients were used to examine the crude 
associations among exposures, covariates and outcomes, and to check for potential 
collinear variables. A weighted-kappa was used to evaluate the consistency of depression 
diagnoses between baseline and each follow up time. Graphical approaches were used to 
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plot the longitudinal variations in depression symptoms and cognitive functioning over 
time and to facilitate assessing model fit. 
A generallinear regression model was employed to examine the association 
between baseline depression measure and MMSE decline at the end of the follow-up 
period, following the conventional wisdom of cohort analysis. It was also employed as a 
mean to screen and select covariate for mixed model analyses (see Chapter 5 for details). 
3.5.2 The Mixed Effects Linear Regression Model 
A mixed effects linear regression model was used as the primary approach to 
hypotheses testing [46, 47] and to adjust for confounding, with the difference in the 
MMSE scores between baseline and three, six and twelve months as a time-dependent 
outcome. Because the follow-up intervals (or spaces) in this study were unequal (i.e., 
three or six months) and the number of measurements varied across subjects (ranging 
from 2 to 4), the only covariance structures capable of handling this level of complexity 
art! compound symmetry (CS) and spatial power (SP(pow)) [46]. However, CS naively 
assumes that the between-measurement correlations remain the same regardless of their 
spacing or time-Iag, which seems unreasonable for longitudinal data. On the contrary, 
SP(pow) assumes the correlations de cline in a rate to the power of the time-Iag between 
two measurements as they move far apart. Therefore, 1 chose SP(pow) as the default 
covariance structure in the mixed model analyses throughout the thesis. 
Similarly, because the number of subjects (N=281) was much larger than the 
number ofmeasurements per subject (4), and the main objective ofthis study was to 
estimate mean difference between depression groups, 1 chose a fixed-effects mixed model 
with the seriai correlation as a main source of random variation, rather than specify extra 
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random effects for between-subject variations. A practical reason for this decision was 
tha1: random effects model facility in current SAS environment does not enable 
correlations within subject to change over time (with random-intercept only) or require a 
much larger sample size to ensure model estimatability and valid inference due to fitting 
too many parameters (with both random intercept and slopes) [46,47]. 
The temporal relationship between depression and cognitive decline were tested 
by manipulating the timing of depression measures in relative to the MMSE assessments. 
The! precedence of medication exposure to the cognitive functioning was established by 
confining the medication data to the defined exposure time window preceding each 
MMSE assessment during the follow-up. Interactions between depression or medication 
exposure and follow-up time or other biologically plausible effect modifiers were tested 
routinely. If a statistically significant interaction were detected, different models for each 
level of the modifiers would be fitted to achieve more accurate effect estimates for the 
primary exposure. 
Sensitivity analyses were performed to verify the primary analyses under 
alte!mative assumptions for exposure time windows or residual effect period, by different 
representations of the total medication exposure without considering duration of use, and 
by adjusting for an additional covariate denoting the place ofbaseline interview (in 
ho:;pital versus at home). For details ofthese analytic procedures towards specific 
research aim, readers are referred to each manuscript under Chapters four to six. 
All the statistical analyses were conducted using SAS software version 9.1 [48]. 
Goodness of fit was assessed using the Akaike's Information Criterion (AIC) [49] and 
compared among nested models using the likelihood ratio chi-square tests based on the -2 
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restricted Log Likelihood statistics [46]. The hypotheses were tested at a two-sided 
significance level of a =0.05. 
3.5.3 Sam pie Size and Power Consideration 
The sample size required for this study was estimated a priori on the primary 
outcome, MMSE scores using the approach developed for multiple linear regressions 
[50]. Assuming a R2 of 10% for the covariates only and the target or minimum 
me:aningful semipartial R2 of 5% for the exposure (i.e., depression symptoms, diagnoses 
and medication use), a total of 21 0 subjects, or 70 in each depression group, would be 
required to achieve a 80% power of detecting a significant effect of the exposure at 
a=:0.05. Then, taking into account both potentialloss based on an expected overall 
attrition rate of 35% during the follow-up, and apotential gain due to repeated measures 
per patient (by a factor of one minus correlation coefficient between the repeated 
m(:asures [1], the target sample size required to ensure the adequate power was estimated 
to be likely close to the crude estimate of 21 0, or 70 per group; this power prediction has 
been ultimately confirmed to be adequate by the significant effects for both depression 
and sorne medication exposure, as reported under each manuscript. 
3.6 SUMMARY 
In summary, this thesis adopted a prospective cohort design with a repeated 
mt::asures analysis to achieve three specific yet closely linked research aims: the temporal 
relationship between depression symptoms and cognitive decline, the temporal 
relationship between depression diagnoses and cognitive decline, and finally, the role of 
antidepressant and psychotropic medication use in this relationship. The list of covariates 
covered a large array of potential confounders and/or effect modifiers based on their 
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established or postulated importance in the subject area, sorne of which were specifically 
devised to facilitate the designed hypothesis testing for the thesis, su ch as CVD risk and 
history of depression. 
With the abundant data from two parent studies, this thesis was able to make 
several methodological innovations, namely, use ofboth dimensional (i.e., symptomatic) 
and categorical (i.e., diagnostic) approaches to defining depression, examination of 
depression as a dynamic and time-varying exposure, integration of clinical and 
administrative data to ascertain and quantify medication exposure over time and to 
control for confounding by indication. Finally, this thesis focused specifically on the 
clinically relevant, and biologically plausible short-term temporal relationship between 
depression and cognitive decline while taking into account potential effects from 
concurrent antidepressant exposure, which has rarely been examined in the 
epidemiological context. 
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CHAPTER 4 - THE TEMPORAL RELATIONSHIP BETWEEN DEPRESSION 
SYMPTOMS AND COGNITIVE FUNCTIONING IN OLDER MEDICAL 
PATIENTS (Manuscript 1) 
4.1 PREFACE TO MANUSCRIPT 1 
ln this manuscript, 1 started my systematic investigation with a specific focus on 
the potential temporal effects of depression symptoms on cognitive decline. As an 
attempt to overcome the potential methodologicallimitations identified from the 
literature review, 1 adopted several innovative study design and analytic approaches. 
First, 1 used a well-validated, clinical assessment-based, rather than self-report, 
instrument to measure depression symptoms. Second, 1 examined the effects of 
depression symptoms as a dynamic or changeable, rather than a constant or enduring, 
exposure, using an appropriate longitudinal analytic technique - linear mixed effects 
model. And finally, 1 targeted the investigation on disentangling two specific competing 
hYJotheses, i.e., whether depression symptoms are a short-term predictor, or a clinical 
concomitant of cognitive decline due to other risk factors, while leaving the third one, 
i.e, cognitive decline be a consequence of or psychological reaction to cognitive decline, 
out of the scene by applying both "population restriction" at study entry and "statistical 
ad.lustment" in analyses on baseline cognitive function. 
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4.2.1 ABSTRACT 
Background. Epidemiological studies remain inconclusive on whether old age 
depression is an independent risk factor, a prodrome, or a clinical concomitant of 
cognitive impairment. The objective ofthis study, using repeated measures over a 12-
mcnth period, was to examine the short-term temporal relationship between depressive 
syrnptoms and cognitive impairment. 
Mc!thods. 281 medical inpatients aged 65 and over were foIlowed up with the Hamilton 
Depression Rating Scale (HDRS) and Mini Mental State Exam (MMSE) at enrolment 
and 3, 6, and 12 months later. A repeated measures mixed linear regression model was 
ust:d to evaluate the association between HDRS scores and MMSE changes over time and 
to test competing hypothesis about their temporal sequence. 
Rfsults. After adjusting for age, cardiovascular risk, illness severity, baseline physical 
and cognitive function and other covariates, a one-point increase in HDRS score 
(baseline mean±sd: 14A±7A) was associated with a lower MMSE score (-0.03, 95% CI: 
-0.07-0.00) at the same time points, but not with the MMSE at subsequent time points (aIl 
p values above 0040). There were no statisticaIly significant interactions detected between 
follow-up time and HDRS scores measured at baseline or during foIlow-up. These results 
w~:re confirmed in alternative models using dynamic measures of both HDRS and MMSE 
changes over each successive foIlow-up interval. 
Conclusions. These findings suggest that the short-term relationship between depression 
sy mptoms and cognitive functioning may be concurrent or temporary, rather than 
prospective or protracted, consistent with the clinical concomitant hypothesis. 
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4.2.2 INTRODUCTION 
While the coexistence of depression symptoms and cognitive impairment in older 
persons has long been recognized clinically [1], the temporal relationship between the 
two conditions was not examined from an epidemiological perspective until relatively 
recently [2]. However, early epidemiological studies [3] were often retrospective or 
cre ss-sectional in nature, and hence, inadequate to address the temporality of the 
relationship. In the past ten years, a number of large-scale, community-based, cohort 
studies have been undertaken to address the temporal relationship prospectively [4-14]. 
At least four hypotheses have been postulated to explain the relationship. First, 
latl~-life depression may be an independent risk factor of cognitive decline [12, 13], 
perhaps via the "glucocorticoid cascade" pathway [15], in which the progression of 
depression pathology may ultimately lead to hippocampus damage and dementia. 
Se::ond, depression and cognitive decline may result from risk factors common to both 
diwrders, such as vascular diseases [16, 17]. Third, the relationship may be confounded 
by short-term situational factors (e.g., acute medical illness or disability) - the clinical 
concomitant hypothesis [3, 4, 6, Il, 16]. Fourth, depression may be an early 
manifestation or prodrome of dementia (7-10,14). 
Almost all the prospective studies conducted so far have assessed depression and cognitive 
outcomes at least one year, mostly two to three years, apart. In addition, most studies 
evaluated depression symptoms at baseline only as a constant or enduring predictor of 
cognitive decline [5, 9-13]. Studies with measures repeated at relatively frequent 
in:ervals (months rather than years) can help to elucidate the relationship by examining 
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wh ether the association is cross-sectional (consistent with the clinical concomitant 
hypothesis) or prospective (consistent with the prodrome hypothesis). 
The objective of the current study was to examine the potential short-term 
temporal relationship between depression symptoms and cognitive decline, with a 
sp{:cific focus on depression symptoms as a dynamic, time-varying exposure. We used 
data from a cohort of older medical inpatients that was assessed for both depression 
symptoms and cognitive function at three, six and twelve months later, with no or little 
cognitive impairment at study entry. 
4.2:.3 METHODS 
Participants 
The participants for this study were selected from the study samples of a randomized 
controlled trial (RCT) of a geriatric psychiatric care service for major depression and an 
observational cohort study of 12-month outcomes of depression in older medical 
inpatients, conducted at two university-affiliated acute care hospitals in Montreal, 
Célnada. The enrollment process of the original study has been described elsewhere [18]. 
In brief, 5,283 patients over age 65 admitted from the emergency room to the medical 
services were screened by a research clinician using the Short Portable Mental Status 
Questionnaire (SPMSQ) [19]. Ofthem 3597 were excluded due to severe cognitive 
impairment (n=612, 11.2%) or other reasons (too sick, entered intensive or long term 
care, language barriers, or residing outside of Montreal island). The remaining 1,686 
p~ltients who scored four or less (indicative of no or mild cognitive impairment) were 
then screened for depression using the depressive disorders section of the Diagnostic 
Interview Schedule (DIS) [20]. Among them 530 (31.4%) consented to participate in the 
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study. The study protocol was approved by the research ethics committees ofboth 
hospitals. Of the 530 enrollees, 22 died and 94 withdrew before the baseline interview, 
leaving 414 (78.1 %) for baseline and follow-up interviews. For this longitudinal analysis, 
we selected 281 participants with at least 2 MMSE scores, representing 67.9% of the 
ba!:eline cohort of 414. There were no statistically significant differences (all p> 0.07) 
belween those included (N=281) and excluded (N=133) with respect to age, sex, living 
condition, AOL scores, study group, hospital sites, diagnosis of depression and cognitive 
impairment at screening. However, patients who were excluded were more severely ill 
(p<O.OI), had more comorbid conditions (p<O.OI), higher HORS (p=O.05) and lower 
MMSE scores (p=0.03). 
Measurements 
Se verity of depressive symptoms was measured using the 21-item version ofthe HORS 
[21], the most widely used interviewer-rated scale for monitoring depressive symptoms 
and signs in intervention studies of depression. Items were rated from 0-4, with a higher 
score indicating more pathology. Cognitive functioning was measured using the MMSE 
[n] at the same 4 time points. The MM SE is the most widely used brief cognitive 
in:itrument for screening cognitive impairment or monitoring its progression [23, 24], 
with a score range from 30 (no impairment) to 0 (maximum impairment). Studies of its 
psychometric properties show moderate to high levels of short-term test-retest reliability, 
ccnstruct and criterion validity, and adequate responsiveness to cognitive change over 
time [23,24]. The inter-rater reliabilities of the HORS and MMSE were assessed in a 
convenience sample of patients at intervals throughout the study period, using 
independent simultaneous ratings by two or more raters, including the study psychiatrist 
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(MC). The intraclass correlation coefficients are 1.00 for both the HDRS (n=28) and 
MMSE (n=17). 
Since cardiovascular diseases (CVD) have been associated with both dementia 
and depression [4, 5, 25], we defined a binary indicator (high vs low) for CVD risk. 
Patients were classified as "high" risk for CVD if they had a diagnosis of stroke, 
dia betes, or myocardial infarction during the previous two years or a measured sitting 
blood pressure of at least 160/95 mm Hg from the hospital chart. Independence in 
ac1ivities of daily living (ADL) was assessed at baseline by the research assistant with the 
Olier Americans Resources and Services (OARS) ADL scale [26], with a score range 
frem 0 (completely dependent) to 14 (completely independent). History of alcohol abuse 
WLS obtained by the research assistant using the 4-item informant questionnaire- Cut 
down, Annoyed, Guilty, Eye-opener (CAGE, rated from 0 for no alcohol use to 4 for 
heavy alcohol use) [27]. Age, sex, education, living condition prior to the admission, 
Charlson comorbidity index (CCI), a composite measure by number and severity of 
comorbid conditions [28], and a nurse rated illness severity (scored from 0 for not ill to 9 
for moribound) [29] were obtained either from interview or hospital charts abstraction. 
Statistical analyses 
The characteristics of the study population at baseline and the distribution ofHDRS 
ard MMSE scores over time were described using means and standard deviations or 
frequencies and proportions, as appropriate. 
We used a mixed effects linear regression model approach to examine the temporal 
relationship between depression symptoms and cognitive functioning over time, in which 
the HDRS and MMSE scores were both updated every three or six months during follow-
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up. The mixed model allows for both fixed (time-invariant) covariates, whose values do 
not change over time (such as sex), and time-dependent covariates, who se values can be 
updated during the foUow-up (such as HDRS scores) [30]. We adopted the Spatial Power 
covariance structure of errors to account for potential inter-correlations among the 
repeated measures on the same patient, which assumes the correlations between any two 
measures to de crea se as their distance increases, while aUows for the unequal follow-up 
intervals and number of assessments across subjects [31]. 
We tested two sets of operational mixed models under competing hypotheses, 
termed as "concurrent" and "prospective", respectively, by different representations of 
HDRS and MMSE scores. In the "concurrent model", the HDRS was associated with the 
M\1SE changes at the same foUow-up time points, without a c1ear-cut temporal or causal 
implication. Whereas in the "prospective" model, the HDRS at each foUow-up was used 
to predict the MMSE changes at the next foUow-up after a three or six month time lag, 
which aUowed us to evaluate the depression symptoms as a potential causal risk factor of 
cognitive dec1ine without temporal ambiguity. On the other hand, the last available 
HDRS score of a patient had to be discarded, which reduced the statistical power to sorne 
degree. We also fit a generallinear regression model with baseline HDRS score as a 
predictor, and the difference between baseline and last available MMSE score as an 
outcome. 
Covariates were adjusted in a hierarchical fashion. First, decided a priori, we 
inc1uded age, education, CVD risk, ADL function, hospital sites, study group (RCT-
intervention, RCT-control, Non-RCT), and follow-up time in aU the models, regardless of 
their statistical significance, given their established importance in confounding the 
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relationship between depression and cognitive decline in the literature or due to the study 
de~;ign. Second, we tested effects of other covariates, inc\uding sex, living arrangement, 
illness severity, CCI, and CAGE score, individually and simultaneously, but did not 
retlÏn them in the final models due to lack of statistical significance. In addition, we 
sequentially adjusted for the baseline MMSE score, attempting to control for potential 
cOllfounding by unmeasured factors or events that might have operated on the subjects' 
cognition before the start of the follow-up, and the baseline HDRS score, in case the 
longitudinal effects of depression symptoms might be pre-determined by their initial 
leyel. Finally, we tested the interaction between baseline HDRS scores and follow-up 
time in the final models. If a statistically significant interaction was detected, separate 
models would be estimated for each following-up interval. Depression group was 
exc\uded from the multivariate regression models because of the substantial conceptual 
overlap between this variable and HDRS score, and the significant correlation between 
th,! two variables (Spearman's p=0.58, p<O.OOI). 
All the statistical analyses were conducted using SAS software version 9.1 [31]. 
Goodness of fit of nested models was compared using the Akaike's Information Criterion 
(AIC) [32]. The hypotheses were tested at a two-sided significance level of a =0.05. 
4.2.4 RESUL TS 
Claracteristics of the study population 
The characteristics of the study population at baseline are presented in Table 1. A 
total of 61 % of the sample were depressed at baseline. The study sample had a mean 
MMSE score of25.8 (SD=3.5) with 26.0% below 24. The mean MMSE scores (25.6 vs 
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26.3, p=0.12) and mean numbers of SPMSQ errors (1.6 vs 1.6, p=0.82) were similar 
between the depressed and non-depressed patients 
The distribution the HDRS and MMSE scores across time is summarized in Table 
2. There was a trend of negative (Pearson product-moment) correlations between the two 
measures at baseline (r=-O.1 0, p=0.08) and three months (r= -0.12, p=0.07). 
Table 3 presents the results of a series of mixed regression models. Of the three 
"concurrent" models, model 2 had a minimum value of AIC, and thus, can be considered 
as providing best fit to the data. It suggested that for patients with comparable cognitive 
function at baseline, a one point increment in the HDRS score was associated with a 
dedine of -0.03 MMSE point (95% CI: -0.07 to 0.00, p=0.05) when measul'ed at the 
same foIlow-up time points, after adjusting for other covariates. This estimate did not 
change materially when the baseline MMSE was not adjusted for (-0.04,95% CI: -0.07 
to -0.02, p<O.O 1, model 1), or wh en additional covariate, the baseline HDRS was 
aqjusted (-0.04, 95% CI: -0.08 to -0.0 1, p=0.02, model 3). On the contrary, none of the 
three "prospective" models (models 4-6) yielded a statistically significant association 
between depression symptoms and subsequent cognitive declines (aIl p values above 
0.40). In either concurrent or prospective models, no statistically significant interaction 
between depressive symptoms and folIow-up time was detected (aIl p values above 0.25, 
data not shown). 
In additional mixed model analyses in which both HDRS and MMSE were 
represented by their score changes between two adjacent foIlow-ups, the associations 
bttween the two measures were statistically significantly only in concurrent models (aIl p 
values below 0.05), not in the prospective models (aIl p values above 0.75). Similarly, 
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the multiple linear regression models, in which the'time lag between the measures of the 
depression symptoms and the MMSE changes was extended up to twelve months, failed 
to detect an independent association (ail p values above 0.35, data not shown). To ensure 
that our exclusion of the secondary covariates did not introduce bias, we included sex, 
liv lng arrangement, illness se verity , Charlson comobidity index and CAGE score 
altogether in the final models and found no material changes in the effect estimates for 
the HDRS scores in both concurrent and prospective models (data not shown). 
4.2,.5 DISCUSSION 
In this cohort of 281 older medical inpatients followed up to twelve months, we 
sy:;tematically evaluated two sets of statistical models under alternative hypotheses about 
th{: temporal sequence between depression symptoms and cognitive decline. After 
co ntro lIing for the effects of a number of potential confounding factors and initial level of 
cognitive function, we observed that depression symptoms were independently associated 
with worse cognitive functioning cross-sectionally, at the same follow-up time points. 
However, such an association disappeared when the exposure and outcome were 
se parated temporally by a three to six month time lag, a period corresponding to a typical 
major depressive episode [33~. These results were confirmed in the alternative mixed 
effects models using dynamic measures of depression symptoms and cognitive 
functioning and in the generallinear model evaluating the relationship with a maximum 
follow-up interval oftwelve months. Taken together, our study suggests that depressive 
s)' mptoms are a clinical concomitant, rather than a predictor or prodrome of cognitive 
d{:cline. 
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Our observation of a concurrent association is consistent with several previous 
cohort studies in older community-dwelling populations. Dufouil and colleagues [4] 
followed 1600 elderly persons 65 years and older in France and found the MMSE scores 
at 3-year follow-up were only cross-sectionally associated with CES-D scores measured 
at the same time point, not at baseline. Similarly, Henderson et al [5], Chen et al [8], 
Cervila et al [11], and Vinkers et al [14] all failed to find an independent prospective 
aswciation between depression and subsequent cognitive decline or onset of dementia. 
However, the follow-up intervals in these studies were much longer than this one, 
ranging from one to twelve years. 
Several reasons may underlie a cross-sectional or concurrent relationship. First, it 
may be determined or mediated by a shared short-term risk factor such as acute medical 
illlless or, functional disability [3,16,17], a recent stressfullife event (e.g., bereavement), 
and use of antidepressant medications [34]. We plan to evaluate these factors in future 
analyses ofthis cohort. Altematively, a cross-sectional relationship may be an artifact, 
due to poorer performance on cognitive tests like the MMSE among depressed people, 
especially on the items that demand strong attention, motivation or psychomotor speed 
[35]. 
Our study has several strengths. First, we focused specifically on the short-term 
effects of depression symptoms as a dynamic, time-varying exposure, using a clinically 
plausible effect period for depression symptoms [33] and an appropriate longitudinal 
modeling approach. Second, we carefully se1ected and rigorously controlled important 
confounders based on both substantive knowledge and statistical efficiency, including 
cHrdiovascular diseases, functional disability and illness severity. Third, we avoided a 
- 90 -
"reverse causality" bias by excluding patients with moderate or severe cognitive 
·impairment at study entry and adjusting for baseline cognitive function in the analyses. 
Finally, we enhanced the study validity by blind exposure and outcome assessments and 
adopting an objective, interviewer-rated (i.e., HDRS) depression scale. 
On the other hand, several study limitations should be noted. First, the MMSE has 
been criticized for insensitivity to small cognitive changes and ceiling or floor effects 
[2~',24]. Second, the HDRS has been criticized for its inclusion of somatic symptoms . 
These measurement issues may have biased our results towards the null. A third 
limitation is the relatively high rate of exclusion and cohort attrition, perhaps not 
surprising in medically ill older people. Given that the excluded patients tended to be 
more severely ill than those in the study sample, our findings may not be generalizable to 
the most severely ill older persons or to those outside hospital settings. 
To conclude, we have documented the existence of a concurrent or temporary, 
rather than a prospective or protracted, association between depression symptoms and 
cognitive decline in this cohort of oIder medical patients, independent of other potentially 
important risk factors. These results do not support the hypothesis that depression 
symptoms in older people are an independent short-term risk factor for cognitive decline 
or a prodrome of dementia. Rather, they suggest that the two conditions occur 
ccncomitantly. Future studies should account for extraneous factors that may account for 
this association, such as recent life events and medication use, and improve the 
measurements for both depression and cognition. 
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Table 1. Characteristics* ofthe study population at baseIine 
Gender Female 185 ( 65.84 ) 
Male 96 ( 34.16 ) 
A!~e (n, mean ± SD) 281 79.11 ± 7.15 
Education <6years 31 ( Il.03 ) 
6-12 years 105 ( 37.37 ) 
> 12 years 132 ( 46.98 ) 
unknown 13 ( 4.63 ) 
Lilving arrangement 
Home 236 ( 83.99 ) 
Other 45 ( 16.01 ) 
Risk for cardiovascular disease 
Law 254 ( 90.39 ) 
High 27 ( 9.61 ) 
Hospital A 228 ( 81.14 ) 
B 53 ( 18.86 ) 
Study group ReT-control 35 ( 12.46 ) 
ReT-intervention 43 ( 15.30 ) 
Not ReT 203 ( 72.24 ) 
Depression group 
Depressed 172 ( 61.21 ) 
Not depressed 109 ( 38.79 ) 
HDRS score (n, mean ± SD) 281 14.71 ± 7.38 
S:PMSQ errors (n, me an ± SD) 281 1.62 ± 1.32 
MMSE score (n, me an ± SD) 281 25.84 ± 3.49 
ADL score (n, mean ± SD) 281 12.02 ± 2.19 
IIIness severity (n, mean ± SD) 270 3.83 ± 1.01 
Charlson Comorbidity Index (n, mean ± SD) 279 1.43 ± 1.52 
CAGE score (n, mean ± SD) 252 0.21 ± 0.30 
* Values represent N and (%), except otherwise indicated. 
Abbreviations: RCT, Randomized clinical trial; HDRS, Hamilton Depression Rating Scale; 
SPMSQ, Short Portable Mental Status Questionnaire; MMSE, Mini-Mental State Examination; 
ADL, Activities of daily living; CAGE, Cut down, Annoyed, Guilty, Eye- opener. 
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Table 2. Distribution of repeated measures HDRS and MM SE scores during follow-up 
F,[)llow-up HDRS score MMSE score 
Time N Mean ± SD N Mean ± SD 
3 mo 228 12.69 ± 7.24 223 26.09 ± 3.22 
{mo 245 12.00 ± 6.60 243 26.58 ± 3.34 
12 mo 207 12.63 ± 6.73 211 26.07 ± 3.54 
A bbreviations: HORS, Hamilton Depression Rating Scale; MM SE, Mini-Mental State 
Examination. 
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Table 3. Mixed Iinear regression models evaluating the effects of depression symptoms on MMSE changes* over time. 
... _ ............ ----_ .. 
~ __ I'10 ....... n.n'" 1\1101'101 
",-",v •• "," Il Prosnective Model 
. , , 
Covariatest 
, 
Modell Model2 , Model3 Model4 Model5 Model6 , , 
, , 
heta 1 heta 
, 
95% CI i heta 95% CI 95% CI ~ beta 95% CI heta 95% CI heta 95% CI 
1 
, 
. , 
HDRS scores , , , , 
during follow-up+ -0.04 -0.07 - -0.02 : -0.03 -0.07 - 0.00 ~ -0.04 -0.08 - -0.01 0.00 -0.01 - 0.08 0.00 -0.04 - 0.03 : -0.02 -0.06 - 0.02 
: , 
. : , Baseline MMSE , , , 
-0.46 -0.54--0.37: -0.45 -0.54--0.37 scores - - - -0.47 -0.55 - -0.39 ~ -0.46 -0.54 - -0.38 - - -
. , 
1 
, 
Baseline HDRS , , , 
scores - - - i - - - ~ 0.03 -0.01-0.08 - - - - - - : 0.03 -0.02-0.08 
: , : Akaike's information , , 3974.40 2833.60 , 2837.20 3016.10 2922.90 , 2927.10 
criterion § , , , , 
---
- - ._-
* Defined hy the score differences hetween haseline and 3, 6, and 12 months, respectively, with negative values indicating decline; 
t Ail the models also adjusted for follow-up time. In addition, models 2, 3, 5 and 6 adjusted age, education, risk for cardiovascular disease, 
activities of daily living, hospital site and study group. 
t Measured at time t for concurrent models and at time (- 1 for prospective models; 
§ Lower value indicates hetter fit. 
Abhreviations: HDRS, Hamilton Depression Rating Scale; MMSE, Mini-Mental State Examination. 
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4.3 POSTSCRIPT TO MANUSCRIPT 1 
Several salient issues arise from the exploratory investigation in the 1 st manuscript, 
Fint, contrary to my expectation, the clinical assessment-based depression symptoms 
fail ed to detect a prospective association, suggesting the lack of predictive validity or 
power for future cognitive decline may not be a shortcoming unique to the self-report 
method, but possibly inherent to the dimensional approach per se. Second, while the 
sharp contra st between the concurrent and prospective models seems to have provided 
unambiguous evidence in favor of the former, its marginal p value of 0.05 may be 
thought of as no more than a chance finding by the conventional frequentist wisdom. 
After extensive discussion with my thesis committee, 1 tried to address these issues in the 
ne(t manuscript with following methodological improvements: 
1) Two additional covariates, history of previous depression episode during the 
la~t two years and history of antidepressant treatment during the last year, were added to 
the list of covariates. These two factors have been suggested in the literature to be the 
main clinical characteristics that may distinguish major from minor depression in older 
persons [Koenig 1997], and presumably, primary from secondary depressive syndromes. 
Adjustment for these proxy "etiological" markers would help account for heterogeneity 
of current depression diagnoses under the "inclusive" approach that does not distinguish 
the origin or etiology of the depression symptoms [Koenig 1997b]. 
2) A transformed HDRS score was created by subtracting the mean of each 
diagnostic group at baseline from the observed HDRS score at each follow-up as a time-
dependent covariate. The transformation (or standardization) of the original HDRS score 
to the group-mean by baseline depression diagnoses would statistically remove the 
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potential collinearity between the two measures in the multivariable models due to their 
substantive overlap (Spearman's p=0.58, p<O.OOI). This time-dependent HDRS score 
serves three specific purposes. First, it directly extends the tirst manuscript by verifying its 
findlng of the concurrent association. Second, it helps disentangle the potential 
"diagnosis" effect of depression from its symptomatic variation over time, while allowing 
a comparison between the two conceptual approaches to depression, i.e., dimensional (or 
symptomatic) versus categorical (or diagnostic). Third, it partially addresses the potential 
confounding by unmeasured situational factors, such as a recent life event or an acute 
illm:ss, which may directly precipitate or perpetuate the depression symptoms during the 
follow-up and whereby affect the cognitive performance on the MMSE. 
A final comment 1 want to make was regarding the effects of gender and education 
on the relationship between depression symptoms and cognitive impairment. A few 
pn:vious studies observed an independent association between the two conditions only in 
those "highly educated" elderly [Geerlings 2000] or in older men [Cervilla 2000, Fuhrer 
2003] or women [Fuhrer 1992]. A common determinant or shared etiology that underlies 
both depression symptoms and cognitive impairments in men, such as functional 
disability [Cervilla 2000, Fuhrer 1992, 2003] or cerebral vascular pathology [Cervilla 
2000, Fuhrer 2003], has been postulated tp explain the relationship. In this manuscript, 1 
te~:ted, but did not find statistically significant interactions between depression symptoms 
and gender (p=0.89, 0.21) or education (p=0.85, 0.96) under either concurrent or 
pr)spective models, though lower educational attainment did appear to be an independent 
ri~k factor of cognitive impairment (p=O.OI). Therefore, whether the effect modification 
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by gender or education observed in previous studies is a generalizable or sample-specific 
phenomenon remains to be clarified. 
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CHAPTER 5 - 12-MONTH COGNITIVE OUTCOMES OF MAJOR AND 
M1NOR DEPRESSION IN OLDER MEDICAL PATIENTS (MANUSCRIPT 2) 
5.1. PREFACE TO MANUSCRIPT 2 
ln this second manuscript, 1 address the second study aim, the temporal 
relationship between the diagnostic entities of depression and cognitive decline. Based 
on the results and experience from the first manuscript, 1 included two additional 
cO'lariates (history of depression and history of antidepressant treatment) as proxy 
markers for primary affective disorders to account for potential etiological heterogeneity 
of the "inclusive" diagnostic criteria, adopted a more thorough covariate selection and 
ad.lustment procedure to enhance scientific parsimony for hypothesis testing, and used a 
transformed, time-dependent measure of HDRS scores to address potential confounding 
due to unmeasured situational confounders and the specificity of the effect of depression 
diagnoses. In particular, 1 evaluate the operational mixed models under alternative 
as:;umptions for the temporal precedence of the depression diagnoses to cognitive 
decline. 
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5.2.1 ABSTRACT 
Context: Epidemiologic studies relating late-life depression to cognitive decline have 
focused on the role of its symptoms. Little is known about the cognitive outcome of the 
diagnostic groups of late-life depression, especially over a short follow-up period. 
Objective: To examine the short-term temporal relationship between depression 
diagnoses and cognitive decline in older medical patients. 
De:,ign: Prospective cohort study with repeated assessments of depression diagnoses and 
cognitive functioning at baseline, three, six and twelve months, using a mixed effects 
linear regression model. 
Se1ting: The medical services of two acute care hospitals in Montreal, Canada. 
Participants: 281 medical patients aged 65 and over without apparent cognitive 
impairment at baseline. 
Muin outcome measure: Cognitive change scores over time on the Mini-Mental State 
Ex,lmination (MMSE). 
Results: Depression diagnoses at baseline were associated with subsequent MMSE 
changes. Relative to no depression, the estimated excess decline points were -0.8 (95% 
Confidence Intervals: -1.5--0.1) for major and -1.0 (-1.8--0.3) for minor depression over 
a median follow-up interval of 6 months, independent of age, sex, education, 
comorbidities, physical function, risk for cardiovascular disease, history of depression 
and antidepressant treatment, baseline cognitive function, and concurrent changes in 
depression symptoms. A generallinear model adjusting for the same set of covariates 
yielded an average excess decline of -0.9 (-.8--0.03) for major and -1.5 (-2.5--0.5) for 
mi l'lor depression over 12 months. 
C(]nclusions: Both major and minor depression are independently predictive of 
subsequent cognitive decline in this cohort of older medical patients, and the strength of 
aswciation appears to increase over time. 
Keywords: Minor Depression, Major depression, Cognitive decline, Aged, Longitudinal 
study. 
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5.2.2 INTRODUCTION 
Depression and dementia together affect more than one quarter ofthose aged 65 years 
and older, 1,2 and both have been associated with higher mortality,3, 4 faster functional 
dedine5 and increased health care costs.6, 7 Therefore, research efforts devoted to 
delineating the relationship between the two conditions are of great clinical and public 
health importance. 
Severallarge-scale, community-based epidemiological studies have been 
undertaken to address the temporal relationship between depression and cognitive 
deeline,8-20 with conflicting results. In sorne studies, depression appeared to be an 
independent risk factor of cognitive decline or dementia,lO, 16-18 while in others, it either 
followed the onset of de menti a Il, 12, 19,20 or the relationship was cross-sectional only. 8, 15 
Still others found no independent association between the two conditions.9, 13, 14 
The published studies conducted on this topic have three limitations. First, they 
have focused on self-reported depression symptoms,8-20 rather than depressive syndromes 
or diagnoses. Self-report depression symptom scales often lack adequate positive 
predictive validity for identifyil'1:g clinical significant depression,21-23 which made the 
study results difficult to translate into clinical practice. Second, due to lack of clinical 
as:,essments, the community-based epidemiological studies had limited ability to control 
confounding by comorbid physical diseases, which often manifest depression-like 
symptoms and interfere with patients' cognitive performance. Third, most studies 
as ;;essed depression at baseline only and attempted to link su ch a single measure to a 
cognitive outcome observed several years later. This study design does not permit an 
examination of the dynamic temporal relationship between the two conditions over a 
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short period oftime, which may be c1inically relevant given that a typical major 
depressive episode usually lasts three to six months?4 
In this study, we aimed to examine the short-term temporal relationship between 
depressive diagnoses and cognitive decline in a cohort of older medically ill patients who 
were assessed longitudinally for both depression and cognitive function at baseline, three, 
six and 12 months. In initial analyses of these data, we found that the severity of 
depression symptoms was associated with cognitive functioning only cross-sectionally.25 
In the CUITent study, we extend the previous finding by testing two major competing 
hypotheses (i.e., depression diagnoses are an independent predictor versus a clinical 
cotlcomitant of cognitive dec1ine), and determining whether the 12-month trajectories of 
cognitive decline differ among those with major, minor, or no depression. 
5.2.3 METHODS 
P~lLrticipants: The participants in this study were selected from the study population of a 
randomized controlled trial (RCT) of a geriatric psychiatric care service for major 
de pression and an observational cohort study of 12-month outcomes of depression in 
older medical inpatients, conducted at two university-affiliated acute care hospitals in 
Montreal, Canada. The recruitment criteria and interview procedures have been described 
ehewhere.26,27 In brief, eligible patients aged 65 years and over admitted from the 
emergency room to the medical services were screened by a research c1inician using the 
Short Portable Mental Status Questionnaire (SPMSQ).28 Those scored four or less 
(indicative of no or mild cognitive impairment) were assessed using the depressive 
disorders section of the Diagnostic Interview Schedule (DIS, DSM-IV criteriai9 and the 
Hamilton Depression Rating Scale (HDRS).3o AlI those with a diagnosis of CUITent major 
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or minor depression and a random sample of non-depressed patients were invited to 
participate in the longitudinal component of the study. As soon as possible after 
recruitment, patients were interviewed by one of two trained research assistants 
(psychologists). The study protocol was approved by the research ethics committees of 
both hospitals. 
In total, 1,686 eligible patients were screened for depression, of whom 530 
consented to participate and enrolled into the study. The main reasons for exclusion 
included: too sick, severe cognitive impairment, admission to intensive care, already 
discharged, transferred to long term care, not praficient in either English or French 
language, and residing outside of Montreal island (who would be difficult to follow up). 
Of the 530 enrollees, 22 died and 94 withdrew before the baseline interview, leaving 414 
for baseline and follow-up interviews. For this longitudinal analysis, we selected 281 
paJticipants with at least two MMSE scores during the follow-up period, representing 
67,9% of the baseline cohort. 
Measurements: 
Depression diagnoses and symptoms: A structured psychiatric evaluation was 
adninistered using the depressive disorders section of the DIS by a trained research 
as~;istant at baseline and each subsequent interview. Depression symptoms were assessed 
us,ng the 2I-item version of the HDRS, the most widely used interviewer-rated scale for 
monitoring depressive symptoms in intervention studies, with a higher score indicating 
more pathology. Patients were classified as major, minor, or no depression according to 
DSM-IV criteria using an "inclusive" approach, which counted current symptoms with a 
duration of at least two weeks towards a diagnosis, regardless of their origin of physical 
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illness or primary affective disorders.31 This approach appears to be most reliable for 
assessing depression in medically ill older persons, especially from a longitudinal 
perspective.31 The inter-rater reliability was checked periodically, with a kappa 
cm{ficient being 0.78 (95% CI 0.52-1.00) for a diagnosis of major depression vs minor 
or 10 depression and 0.61 (95% CI: 0.35-0.87) for a diagnosis of either major or minor 
vs no depression (n=28). The intra-class correlation coefficient for HDRS scores was 
0.S3 (95% CI: 0.86-0.97, n=26). 
Cognitive decline: The Mini-Mental State Examination (MMSE)32 was administered by a 
trained research assistant at baseline and subsequently at thee, six and twelve months. 
The MM SE is the most widely used brief cognitive instrument for screening cognitive 
impairrnent or monitoring its progression,33, 34 with scores ranging from 30 (no 
impairrnent) to 0 (maximum impairrnent). Studies of its psychometrie properties 
demonstrated moderate to high levels of short-terrn test-retest reliability, construct and 
criterion validity, and adequate responsiveness to cognitive change over time.33, 34 The 
in1er-rater reliability of the MMSE was assessed in a convenience sample of patients at 
intervals throughout the study period, using independent simultaneous ratings by two or 
more raters, including the study psychiatrist (MC). The intraclass correlation coefficient 
was 1.00 (n=20). 
Covariates: Data on covariates were collected at enrolment from either patient interviews 
or hospital charts. The demographic-behavioral factors included age, sex, education, 
living condition prior to admission, and history of alcohol abuse (using the 4-item CAGE 
(Cut down, Annoyed, Guilty, Eye-opener) questionnaire).35 Premorbid physical function 
was assessed with the Older Americans Resources and Services (OARS) Center 
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Instrumene6 for basic and instrumental activities of daily living (AOL and IAOL), with 
scores ranging from 0 (completely dependent) to 14 (complete independent). 
We used two global measures of comorbid physical conditions: a nurse rated 
clitlical severity of current illnesses, scored i (not ill) to 9 (moribund),37 and the Chari son 
comorbidity index (CCI),38 a well-validated, composite measure ofnumber and severity 
of co-morbid conditions from medical diagnoses present at or before enrolment. In 
addition, given the etiological implication of cardiovascular diseases (CVO) in both 
dementia and depression,39, 40 we defined a binary (high vs low) indicator for risk of 
CVD, based on a history of diagnosed stroke, diabetes, or myocardial infarction during 
the previous two years or a measured sitting blood pressure of at least 160/95 mm Hg 
from the hospital chart. Furthermore from interviews with patients or review of their 
hospital charts, we collected data on history ofprevious depression episode (remote, 
reœnt, versus neither) and history of antidepressant treatment in the past year as potential 
makers for primary affective disorders. Other covariates were related to study design or 
participants selection, including hospital (A versus B), study group (RCT Intervention, 
ReT-Control, versus Not RCT), SPMSQ errors at screening and follow-up intervals. 
Statistical analysis 
The baseline characteristics and longitudinal profile of cognitive functions of the study 
population were summarized by descriptive statistics and compared across depression 
diagnoses using one-way ANOV A or chi-square tests, as appropriate. The consistency of 
the depression diagnoses over time was evaluated using weighted Kappa. 
A mixed effects linear regression model for longitudinal data was adopted as the 
primary approach to hypothesis testing. This allowed us to include both fixed-in-time and 
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time-varying covariates, and to account for potential inter-dependence of repeated 
measures on the same patient over time.41 , 42 The depression diagnoses were repr~sented 
by two dummy indicators, major and minor depression, with no depression as a 
reference. The cognitive decline was defined by the difference in the MMSE scores 
be':ween each follow-up (at three, six and twelve months) and baseline. Given the 
unequal follow-up intervals and number of MMSE assessments across subjects, we chose 
tht: Spatial Power covariance structure to account for the potential interdependence 
among the repeated MMSE measures on the same patients.42 
We evaluated two sets of alternative mixed models under competing temporal 
hypotheses, termed "prospective" and "concurrent", respectively. In the "prospective" 
models, the depression diagnoses were represented in two alternative ways. First (model 
A~, the baseline depression diagnoses were used as a fixed-in-time predictor of 
subsequent MMSE changes at three, six and twelve months. Second (model B), the time-
dependent depression diagnoses updated at each follow-up were used to predict the 
MMSE change at the next follow-up. In the "concurrent" mode l, we examined the cross-
sectional relationships between the depression diagnoses and the MMSE change during 
follow-up at the same time points. 
We sequentially adjusted the effects of depression diagnoses for potentially 
important covariates in the mixed effect models. First, study design variables (age, 
SPMSQ errors, hospital, study group and follow-up duration) were forced into ail the 
models. Next, we included sex, education, ADL function, living arrangement, risk for 
c2Tdiovascular disease, previous history of depression and antidepressant treatment. 
These covariates were pre-selected from a larger array of seventeen candidates through a 
- 110 -
for ward selection procedure based on their unique contributions to the model fit,43 in an 
attl!mpt to enhance the statistical efficiency of the formaI hypothesis testing using the 
mt.:.ltivariable mixed models. As a way to account for the potential impact of pre-
determinants of participants' cognitive function before they entered the study, we added 
thé baseline MMSE score into aIl the models. To investigate if the relationship changes 
OVI!r time or varies across biologically plausible effect modifiers, we tested in the final 
models the interactions of the baseline depression diagnoses with foIlow-up intervals, 
CVD risk, illness severity, history of depression and history of antidepressant treatment. 
To assess the specificity of the potential cognitive effects of depression diagnosis 
be)'ond the severity of depression symptoms, we adjusted the final models for a 
transformed HDRS score as a time-varying covariate. This transformed score was created 
by subtracting the mean of each diagnostic group at baseline from the observed HDRS 
score at each follow-up, which statistically removed the inter-correlations between 
HDRS scores and depression diagnoses (Spearman's p =0.58, p<O.OOl), and hereby, 
allowed us to evaluate both in the same multivariable models without loss of efficiency 
due to their potential collinearity. 
To assess the potential bias due to inappropriate (mixed effects) model 
specification and to facilitate comparison with other studies, we conducted a 
conventional multiple linear regression model analysis using the difference between the 
baseline and last available MMSE scores as an outcome and the baseline depression 
diagnoses as a predictor, adjusting for the same set of covariates. Although ignoring the 
100gitudinai dynamic of the relationship, this general linear model extended the 
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prospective mixed models to a maximum folIow-up interval of twelve months, and as 
such, allowed us to examine the potential "duration" effect of the depression diagnoses. 
AlI the statistical analyses were conducted using SAS software version 9.1.42 
Gcodness of fit was assessed using the Akaike's Information Criterion (AIC), and the 
ne~;ted models were further compared using likelihood ratio chi-square tests (LRT) based 
on the models' -2 restricted Log Likelihood statistic.43, 44 The hypotheses were tested at a 
tWJ-sided significance level of a =0.05. 
5.2:.4 RESUL TS 
The baseline characteristics of the three depression diagnostic groups are summarized in 
Table 1. The three depression diagnostic groups differed in HDRS, ADL and IADL 
scores, history of depression and history of antidepressant treatments (P<0.05-0.00 1). Of 
th{: seventeen candidate covariates, CAGE score, Charlson Comorbidity Index and IADL 
score were eliminated later on in the model selection process due to inadequate 
cO:1tribution to the model's R squared (data not shown). There was no significant 
diiferences (aIl p values above 0.07) between the 281 participants and those excluded 
(N=133) with respect to age, sex, living condition, ADL scores, study group, hospital 
sit~s, diagnosis of depression and cognitive impairment at screening. However, the 
excluded patients were more severely il1 (p<0.01), had more comorbid conditions 
(p<0.01), higher HDRS (p=0.05) and lower MMSE scores (p=0.03). 
The longitudinal profiles of cognitive function by baseline depression diagnosis are 
prl!sented in Table 2. The three diagnostic groups differed in the MMSE scores at aIl the 
foJow-up times (p<0.05 to 0.01), except at baseline (P=0.14). Patients with minor 
de pression had lower MMSE scores than those with no depression at aIl the three foIlow-
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up:; (p<0.05 to 0.01), and than those with major depression at six and twelve months 
(p<0.05); whereas major depression only had a trend toward lower MMSE scores than no 
depression at 3 month (p=0.05). 
The depression diagnoses at each follow-up had a fair to moderate agreement with 
th{: baseline (weighted Kappa: 0.27 to 0.42), though significant variations existed at three 
(p==0.03) and six (p=0.02) months. Based on updated diagnoses during the follow-up, the 
M\1SE scores among the three depression groups differed at six (p<0.05) and twelve 
(P'=0.06) months, with minor depression having lower MMSE scores than no depression 
at six (p<0.05) and twelve (p=0.03) months and than major depression at six month 
(p<0.05). 
Table 3 summarizes the results of the mixed models. In prospective models A, 
bcth major and minor depression at baseline were associated with subsequent MMSE 
decline (p<0.05 to 0.01), after sequentially adjusting for study design variables (model 
Al), selected covariates (model A2), as weil as the time-dependent, transformed HDRS 
scores (model A3). There were no significant associations (all p values above 0.30) 
detected from prospective models B or concurrent models. Among each set of 
hierarchical models (i.e., A to C), models 3 appeared to provide the best fit to the data 
b~lsed on both AICs and LRT X2 tests (ail p<O.Ol), and hence, were chosen as our final 
models. 
Of the three final models, only prospective model A3 yielded a statistically 
significant association, with an excess MMSE decline of -0.8 (95% CI: -1.5- -0.1) for 
major and -1.0 (95% CI: -1.8- -0.3) for minor depression, relative to participants with no 
depression and with the same baseline MMSE scores. The difference between major and 
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millor depression was not significant (p=0.52). The depression diagnoses did not interact 
(aH p values above 0.07) with follow-up intervals or other potential effect modifiers, 
indicating their effects to remain stable over time or across subgroups with different 
characteristics. In all the three final models, the effects of HDRS scores were not 
significant (-0.01 to -0.03, p=0.07 to 0.36). Beyond our expectation, a history of 
an:idepressant treatment was independently associated with higher MM SE scores in both 
prospective models A3 (0.7, p=0.03) and B3 (0.7, p=0.04), and concurrent model 3 (0.7, 
p=0.04). 
The general linear regression model using baseline depression diagnoses as a 
pn!dictor and the last available MMSE change score as an outcome, adjusting for the 
same set of covariates as the final mixed models, yielded an average excess decline point 
of -0.9 (95% CI: -1.8- -0.03, p=0.04) for major and 1.5 (95% CI: -2.5- -0.5, p<O.Ol) for 
m: nor depression. Across the three prospective models, i.e., this general linear model and 
m xed effects models A3 and B3, the strength of observed association appeared to 
in::rease with the median follow-up intervals. The predicted MMSE decline points were -
0.:2 over three months (p=0.38, mixed model B3), -1.0 over 6 months (p<O.O 1, mixed 
m:lde1 A3) and -1.5 over 12 months (p=0.01, general1inear model) for minor depression, 
ar.d correspondingly, -0.1 (p=0.62), -0.8 (p=0.02) and -0.9 (p=0.06) for major depression. 
5.2.5 DISCUSSION 
In this cohort of 281 older medical inpatients followed-up for twelve months, we 
observed an independent association between depression diagnosis at hospital admission 
and subsequent cognitive decline, with an average excess decline of -0.8 (95% CI: -1.5 -
-C.l) per 6 months for major and -1.0 (95% CI: -1.8 - -0.3) for min or depression, 
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re~pectively, relative to participants with no depression but with the same age, gender, 
comorbidity, risk for CVD, ADL function, histories of depression and antidepressant 
treatment, and MMSE score at baseline. Concurrent severity of depression symptoms 
neither had an independent association with cognitive decline after adjusting for 
de pression diagnosis, nor affected their effect estimates materially. To our knowledge, 
this is the first prospective epidemiological study that has reported an independent short-
term temporal relationship between specific diagnoses of depression and subsequent 
cognitive decline in the older, medically ill population. 
Several plausible mechanisms have been postulated to explain the apparent 
relationship between depression and dementia,45,46 su ch as an early reaction or 
manifestation of underlying dementia, a shared etiology or a causal biochemical pathway. 
Since we excluded participants with more than mild cognitive impairment at study entry 
and adjusted for baseline cognitive function in multivariable models, the observed 
association would be unlikely a reflection of an underlying dementia process. Similarly, a 
shared etiology can not readily explain our findings, at least not the cerebral-
cardiovascular diseases or functional disability, because we have explicitly adjusted for 
these two most common extraneous determinants of the association. While we can not 
entirely rule out the possibility that sorne situational risk factors, such as recent stressful 
life events or side-effects of a course of antidepressant treatment, may play a 
precipitating or mediating role,45, 47 our adjustment for concurrent variation of depression 
symptoms, a reasonable proxy for such short-term confounders, made this explanation 
less likely. Altematively, the prospective association may represent the phenotype of a 
tr Je causal relationship between depression and dementia pathologies via sorne biological 
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mechanisms. According to the glucocorticoid cascade hypothesis, repeated and 
prolonged stress, a common risk factor for depression, may over-activate and eventually 
exhaust the hypothalamic-pituitary-axis and lead to permanent brain damage and 
co:5nitive impairment.45,46 Recent advancement in neurobiology has also suggested that 
tht: serotonergic neurotransmitting system, whose deficiency has been implicated in the 
etiology of major depression, may play an important role in modulating cognitive 
behavior through interactions with cholinergic system,48 a target ofneurodegenerative 
di~;ease such as dementia. If such causal mechanisms do exist, it should not be surprising 
that an "exposure" to the clinically significant depression syndromes should be closely 
and quantitatively associated with subsequent cognitive decline weil before its 
development into a full-blown dementia at distance.45 
The strengths ofthis study are severa!. First, we focused specifically on the 
dnically significant diagnostic entities of depression, rather than the severity of 
de pression symptoms. Second, we confined our delineation of the dynamic temporal 
relationship within a clinically relevant, short follow-up interva!. Finally, we carefully 
selected and rigorously controlled for potential confounders in light of substantive 
knowledge and statistical efficiency. 
This study has sorne important limitations. First, the MMSE has been criticized for 
insensitivity to small cognitive changes and ceiling or floor effects,32, 33 especially over a 
relatively short period of follow-up. Second, the rates of excluded subjects and cohort 
attrition were relatively high, which may limit the generalizability ofthis study to more 
st:verely ill patients, Third, the results may not be generalized to elderly populations 
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ou1.side of hospital settings. Finally, our measure of antidepressant treatment was crude 
and needs to be investigated further using comprehensive data. 
The clinical implications of our findings are two fold. First, these findings may 
stœngthen the rationale for treating clinically significant depression in older, medically 
ill patients, who may benefit not only from relief from disabling depression but 
potentially from a risk reduction for cognitive deterioration. Our preliminary finding that 
a history of recent antidepressant treatment was independently associated with better 
MMSE performance further enforces this position. Second, the gradient increase in the 
strength of the observed prospective association with the duration of "exposure" to 
de pression diagnoses implies that an early antidepressant intervention may be potentially 
more cost-efficient than later intervention in terms of reducing risk of cognitive decline. 
To conclude, we have documented that both major and minor depression are 
prl;!dictive of cognitive decline over a course as short as twelve months, independent of 
other potentially important risk factors. Future epidemiological studies and clinical trials 
di:ectly examining the effectiveness and feasibility of antidepressant treatment in 
m~dically ill older patients with major or minor depression are warranted. 
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Table 1. Cha racteristics of the Study Population at Baseline 
Depression Diagnoses P 
Characteris1 ics Major Minor No Value* 
(N=121~ ~N=51) (N=109) 
Demographic:-behavioral factors 
Age (in year), mean ± SD 78.7 ± 7.1 78.4 ± 6.9 79.9 ± 7.3 0.333 
Gender, n (%): Female 75 ( 62.0 ) 33 ( 64.7 ) 77 ( 70.6 ) 0.378 
Male 46 ( 38.0 ) 18 ( 35.3 ) 32 ( 29.4 ) 
Education, n (%)t: <6 years 13 ( 11.2 ) 9 ( 18.4 ) 9 ( 8.6 ) 0.446 
6-12 years 43 ( 37.1 ) 18 ( 36.7 ) 45 ( 42.9 ) 
> 12 years 60 ( 51.7 ) 22 ( 44.9 ) 51 ( 48.6 ) 
Living arrangement, n (%): Home 101 ( 83.5 ) 43 ( 84.3 ) 92 ( 84.4 ) 0.979 
Other 20 ( 16.5 ) 8 ( 15.7 ) 17 ( 15.6 ) 
CAGE score, mean ± SD 0.3 ± 0.8 0.1 ± 0.3 0.2 ± 0.8 0.373 
Psychological-functional factors 
HDRS score, mean ± SD 19.9 ± 5.8 13.5 ± 5.3 9.5 ± 5.7 <0.001 
SPMSQ errors, mean ± SD 1.6 ± 1.2 1.6 ± 1.4 1.6 ± 1.4 0.960 
ADL score, mean ± SD 11.5 ± 12.0 12.1 ± 11.7 12.5 ± 12.5 0.003 
IADL score, mean ± SD 10.0 ± 2.9 10.5 ± 3.1 11.0± 3.1 0.025 
Clinical factors 
Charlson Comorbidity Index, mean ± SD 1.4 ± 1.6 1.3 ± 1.4 1.4 ± 1.5 0.791 
Nurse-ratl~d illness seve rit y, mean ± SD 3.9 ± 1.0 3.9 ± 1.0 3.7 ± 1.1 0.380 
Risk for cardiovascular High 12 ( 9.9 ) 3 5.9 12( 11.0) 0.584 
disease (CVD), n (%): Low 109 ( 90.1 ) 48 ( 94.1 ) 97 ( 89.0 ) 
History of depression, n Remote 16 (13.2) 8 ( 15.7 ) 5 ( 4.6 ) <0.001 
(%)t: Recent 34 ( 28.1 ) 6 ( 11.8 ) 6 ( 5.5 ) 
Neither 71 ( 58.7 ) 37 ( 72.5 ) 98 ( 89.9 ) 
History of antidepressant Present 54 ( 45.0 ) 16 ( 31.4 ) 23 ( 21.1 ) <0.001 
treatment, n (%)t: Absent 66 ( 55.0 ) 35 ( 68.6 ) 86 ( 78.9 ) 
_ 12.3-
Characteristics of study population at baseline (cont'd) 
Source of pa iicipants 
Hospital, ri (%): A 91 ( 75.2 ) 43 ( 84.3 ) 94 ( 86.2 ) 0.083 
B 30 ( 24.8 ) 8 ( 15.7 ) 15 ( 13.8 ) 
Study group, n (%): 
ReT-intervention 33 ( 27.3 ) 6 ( 11.8 ) 4 ( 3.7 ) <0.001 
ReT-control 26 ( 21.5 ) 8 ( 15.7 ) 1 ( 0.9 ) 
Not ReT 62 ( 51.2 ) 37 ( 72.5 ) 104 ( 95.4 ) 
* Oerived from X2 (df=2) for categorical and one-way ANOVA (df=2) for continuous variables. 
t The percentages may not sum up to 100 due to exclusion of a few missing observations. 
Abbreviations: CAGE, Cut down, Annoyed, Guilty, Eye-opener; SPMSQ, Short Portable Mental 
Status Quesl:ionnaire; AOL, Activities of Oaily Living; IAOL, Instrumental AOL; RCT, Randomized 
Clinical Trial. 
~ 
Table 2. Longitudinal profiles of MMSE scores by depression diagnoses at baseline 
Depression Diagnoses 
Time Major Minor No P value* 
N mean SO N mean SO N mean SO 
Baseline 121 25.8 ± 3.2 59 25.1 ± 3.3 109 26.2 ± 3.9 0.137 
3mo 102 25.9 ± 3.1 40 25.0 ± 3.3 81 26.8 ± 3.2 0.008 t 
6mo 102 26.5 ± 2.9 43 25.3 ± 4.1 98 27.2 ± 3.3 0.010 :j: 
12mo 88 26.2 ± 3.5 37 24.7 ± 4.1 86 26.6 ± 3.2 0.022 § 
* Oerived froll one-way ANOVA (df=2) testing overall differences among the depression diagnoses 
at each follow-up time point, with pairwise subgroup comparisons (df=1) when appropriate. 
t Major vs no depression, p=0.053; minor vs no depression, p=0.002; 
:j: Minor vs no depression, p=0.002; major vs minor depression, p=0.047; 
§ Minor vs no depression: p=0.006; major vs minor depression, p=0.033. 
Abbreviation: MMSE, Mini-Mental State Examination. 
-1 2 5-
) 
Table 3. Association between depression diagnoses and MMSE changes* estimated using mixed effects models 
Model Prospective Model A Prospective Model B Concurrent Model 
0.,- D __ ..... :_40_~ f"""_.a. .r ncoi 1"'. n .. _1 •• _ r::_. nr:.OI 1". n ...... 1 ........ r::_. nc:.ol f". n ...... 1 ........ l'\IV. 1 IÇU'''''VI 1 "';:",11 ;;J.,J lU '-'. 1 VGlIU';::; L,,:n. o;.Jv/u vi 1 VQlue L,.;n .• vv lU VI 1 VQIUv 
Major depression -0.68 -1.34 - -0.02 0.044 -0.19 -0.65 -0.28 0.427 0.16 -0.28 -0.61 0.467 
1+ 
Minor depression -1.21 -1.96--0.46 0.002 -0.16 -0.67-0.35 0.532 -0.22 -0.72 -0.27 0.376 
Major depression -0.77 -1.43--0.11 0.023 -0.17 -0.65-0.30 0.468 0.19 -0.26 -0.64 0.402 
2§ 
Minor depression -1.20 -1.94 - -0.46 0.002 -0.14 -0.65-0.37 0.592 -0.26 -0.76 - 0.23 0.297 
Major depression -0.79 -1.45 - -0.14 0.018 -0.12 -0.58-0.35 0.622 0.30 -0.19 -0.79 0.225 
311 
Minor depression -1.04 -1.77 --0.30 0.006 -0.22 -0.72- 0.28 0.384 -0.19 -0.69 -0.32 0.467 
* Defined by the differences in the MMSE scores between each follow-up and baseline, with negative values indicating decline. 
t Refers to the two dummy indicators for depression diagnoses, as measured at baseline (prospective model A), or the preceding 
(prospective model B) or the same (concurrent model) follow-up time points as the MMSE, with no depression as a reference. 
+ Adjusted for age, hospital, study group, SPMSQ errors, baseline MMSE score and follow-up interval. 
§ Adjusted for ail the covariates in model1, plus: sex, education, ADL score, iIIness severity, living arrangement, CVD risk, history 
of depression and history of antidepressant treatment. 
Il Adjusted for ail the covariates in model 2, plus a transformed HDRS scores during follow-up. 
11 Effect estimate, denoting expected differences in MMSE changes between major or minor depression and no depression group. 
Abbreviations: MMSE, Mini-Mental State Examination; SPMSQ, Short Portable Mental Status Questionnaire; ADL, Activities of Daily 
Living; CVD, Cardiovascular diseases. 
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5.3 POSTSCRIPT TO MANUSCRIPT 2 
ln this section, 1 provide additional details for the statistical analyses and further 
dis<:uss sorne statistically insignificant yet potentially clinically meaningful results, which 
were omitted in the manuscript due to the joumal's word limit. 
5.3.1 The Covariate Selection Procedure 
The screening process followed a step-wise, forward selection procedure 
[Hücking RR 1976]. First, 1 evaluated the bivariate associations between each covariate 
and both depression diagnoses and MMSE scores at baseline using chi-square or t tests, 
and among the covariates using Spearman's rank-order correlation. Covariates with a p 
value above 0.3 for bivariate associations with the outcome and exposure, and a 
cocelation coefficient above 0.5, indicative of a moderate to strong relationship [Looney 
20('2], were eliminated from further consideration. Next, 1 sequentially evaluated each 
covariate using a generallinear regression model, with the difference between the 
baseline and last available MMSE scores as an outcome, adjusting for the baseline 
depression diagnoses and five default covariates related to study design or sampling: age, 
hospital, study group, number of SPMSQ errors and follow-up time. Then, one at a time, 
each candidate covariate was entered the baseline model and its contribution to the model 
fit was examined based on the adjusted R squared [Cohen 2003], without regard to the p 
value. The covariate whose inclusion led to the largest adjusted R squared for each model 
wa:; retained to update the baseline mode!. This process was continued iteratively until no 
co\ariate increased the model's R squared by 5%. Finally, three out of the seventeen 
coyariates: CAGE score, Chari son Comorbidity Index and IADL score, were eliminated. 
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5.3.2 Examine the Appropriateness of the Mixed Model 
To assess the validity of the final mixed effects models, 1 performed a series of 
residual analyses using graphical approach [L itte Il 1996, Verbeke 2000]. Three 
population-averaged residual plots for the final prospective model A, one by predicted 
values and the other two by baseline depression diagnoses and transformed HDRS score, 
respectively, are shown in Figures A-I.I to A-I.3. There was no systematic trend of 
de'liation from normality, homoscedasticity and linearity assumptions or extreme 
oudiers, suggesting the fixed effects for the model were selected properly. 
5.3.3 Comments on the Difference between Major and Minor Depression 
While not statistically significant, the better cognitive outcome of major than 
minor depression patients may be worth discussion. Consistent with previous studies 
[Koenig 1997, McCusker 2005, Tannock 1995], 1 found that more people with major 
de Jression had a previous history of depression episodes and antidepressant treatment 
than those with minor depression, though there was no significant difference in physical 
co morbidities. 
However, unexpectedly, there was no statistically significant interaction between 
de pression diagnoses and either a history of depression or physical illnesses, suggesting 
the se two potential etiological markers for primary affective disorders could not explain 
the apparent difference in the slopes of the cognitive trajectories between major and 
minor depression. While this might reflect inadequate power ofthis study sample to 
detect such an interaction, another possibility was the imprecise nature of the two proxy 
ffiI:asures, especially the history of previous depression episodes. The latter was limited to 
th~ prior two years and did not include early adulthood when the majority of cases of 
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primary major depressive disorder would have their initial onset. In addition, the 
information was partially based on interviews of patients who may have had poor recall 
of previous depression episodes. Future studies using refined measures of previous 
history of depression or an etiological approach to depression diagnoses may help clarify 
the reasons for the apparent discrepancy in the cognitive trajectories between major and 
minor depression observed. A further exploration of potential cognitive effects of 
antidepressant use will be the topic of the third manuscript. 
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CHAPTER 6 - USE OF ANTIDEPRESSANTS AND COGNITIVE 
FlNCTIONING IN OLDER MEDICAL PATIENTS WITH AND WITHOUT 
DEPRESSION (MANUSCRIPT 3) 
6.1. PREFACE TO MANUSCRIPT 3 
ln this third manuscript, 1 address the third main study aim, the role of 
amidepressant and other psychotropic medications in the relationship between depression 
and cognitive decline. The analyses build upon the findings from the first and second 
manuscripts that depression symptoms are cross-sectionally associated related to 
cognitive function, whereas depression diagnoses predict subsequent cognitive decline 
longitudinally. 1 now examine whether use ofmedications independently predicts 
cognitive decline, or whether it modifies or mediates the effects of depression diagnoses. 
ln particular, 1 examine the "net" cognitive effect of antidepressant use through the 
imerplay of the potential benefits of antidepressant medications in reducing depression 
pathology, their potential cognitive side-effects, and the detrimental effects of depression 
pathology. 
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6.2.1 ABSTRACT 
Background. The cognitive effects of antidepressant and other psychotropic medications 
in depressed older persons have important clinical implications, yet research evidence 
remains controversial, especially in those with minor depression or complex medical 
conditions. 
M«!thods. 281 medical patients aged 65 and older with a diagnosis of either major, minor 
or no depression were followed up with the Mini-Mental State Examination (MM SE) at 
3,6 and 12 months. Antidepressant exposure was ascertained using a provincial 
pn:scription database and associated with MMSE changes under alternative exposure 
time windows using a linear mixed effects mode l, while simultaneously adjusting for 
potential confounders, indications for prescriptions, and concomitant medication. 
REsuItS. Antidepressant use was not associated with cognitive decline in general, but 
interacted with depression diagnoses (p=0.038). It appeared to be associated with an 
improvement in the MMSE (2.5 to 2.2 per 100-day cumulative exposure, p=0.014 to 
0.14) in minor depression, independent of comorbid diseases, CUITent depression 
symptoms and concomitant medications. Both major and minor depression were 
independently predictive of subsequent MMSE dec1ine, especially in those not prescribed 
antidepressants (p<0.03). 
Conclusions. Antidepressants may modify the detrimental effects of depression on 
cognitive functioning over time in older medical patients towards a potential cognitive 
benefit in those with minor depression. 
K,eywords: Antidepressants, minor depression, major depression, cognitive decline, older 
persons, selective serotonin reuptake inhibitors. 
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6.2.2 BACKGROUND 
Thl~ cognitive side effects of medications bear important clinical and public health 
implications,I,2 especially in the elderly population with depression. First, the two types 
of}sychotropic medications commonly prescribed to the depressed elderly, 
antidepressants and benzodiazepines, are among the most potent drug classes that may 
compromise cognitive function. I-3 Second, the use of antidepressant and psychotropic 
medications has been suspected, but not yet proved, to play an independent role in linking 
lat,~-life depression to cognitive impairment,4-7 two common and disabling diseases in the 
elderly.4,6 And finally, research evidence regarding the benefits and harms of 
amidepressant medications is equivocal and insufficient to justify a uniform 
rec:ommendation of aggressive antidepressant treatment to the depressed elderly, 
especially those with minor depression or with complex medical conditions.8-IO 
Consistent with the cholinergic deficit hypothesis of Alzheimer's dementia, 11-14 a few 
large-scale epidemiological studies have found independent associations between poorer 
cognitive performance and exposure to antidepressant,15,16 benzodiazepines3, 15, 16 and 
antipsychotic medications, 1 5-17 many ofwhich have detectable anticholinergic effects in 
vivo. 1, 2, 13 
In depressed older persons, however, research findings appear to be conflicting. 18 
On one hand, sorne studies demonstrated that an association between antidepressant or 
other psychotropic drug use and cognitive impairment existed ev en after controlling for 
measures of depression; 16-19 on the other, a growing number of studies reported that 
successful antidepressant treatment appears to improve rather than comprise patients' 
cognitive functioning. 18,21-23 Recently, apooled study oftwo double-blind, randomized 
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12 week antidepressant (sertraline, fluoxetine and nortriptyline) trial in 444 èlderly 
people with major depression showed a significant improvement in two cognitive tasks,22 
inclependent of the observed peripheral anticholinergic side effects. 
The methodologicallimitations of randomized clinical trials included small sample 
sizes, short follow-up durations, and overrepresentations ofhealthy elderly?4 In addition, 
th~:y typically focused on a few specific antidepressant agents at fixed doses, which does 
not allow addressing confounding by other concomitant medications or the public health 
burden in the elderly due to polypharmacy or multiple medication use.25 Community-
based observational epidemiological studies often suffered from incomplete 
asœrtainment of medication exposure over time (introducing misclassification bias ),26 
and inability to control for confounding by indications and "protopathic" bias due to lack 
of clinical evaluation.27 
We decided to investigate the longitudinal relationship between antidepressant and 
other psychotropic medication use and cognitive decline in late-life depression, to 
determine whether these medications are independent risk factors, or they mediate or 
modify the effects of depression.5,6 We used data from a cohort of older medical patients 
who were followed with repeated assessments ofboth depression and cognition over 12 
months and whose medication prescriptions during the follow-up period were obtained 
through automated linkage of clinical research data with a provincial prescription 
database. 
We hypothesized that although in general antidepressants and other psychotropic 
medications are capable of causing cognitive impairments (presumably via 
anticholinergic activity), their "net" cognitive effects in depressed elderly may reflect a 
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balance or trade-off between the severity of depression pathology, the strength of the 
anti-depressant efficacy and the cognitive side-effects of the medications. As a result, we 
wculd expect that the cognitive outcome of antidepressant exposure vary across the type 
or level of depression pathology, whereas exposure to non-antidepressant psychotropics 
would lead to cognitive decline regardless of depression. 
6.2.3 METHODS 
Participants: As described in our previous publications,28, 29 the participants ofthis study 
w~:re selected from the study populations of a randomized controlled trial (RCT) of a 
geriatric psychiatric care service for major depression and an observational cohort study 
of 12-month outcomes of depression in older medical inpatients, conducted at two 
university-affiliated acute care hospitals in Montreal, Canada. In brief, eligible patients 
aged 65 years and over admitted from the emergency room to the medical services were 
screened by a research clinician using the Short Portable Mental Status Questionnaire 
(SPMSQ);3o those who scored four or less (indicative of no or mild cognitive 
impairment) were assessed using the depressive disorders section of the Diagnostic 
Interview Schedule (DIS)31 and the Hamilton Depression Rating Scale (HDRS).32 Ail 
d~:pressed and a random sample of non-depressed patients were invited to participate in 
the longitudinal component of the study. As soon as possible after recruitment, patients 
were interviewed by a trained research assistant, blind to the results of the screening 
a~,sessment. The study protocol was approved by the research ethics committees of both 
hospitals. 
In total, 1,686 eligible patients were screened for depression, ofwhom 530 
(~'l.4%) consented to participate and enrolled in the study. The main reasons for 
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exclusion included: too sick, severe cognitive impairment, admission to intensive care, 
alr,~ady discharged, transferred to long term care, not proficient in either English or 
Fnmch language, and residing outside of Montreal island. Of the 530 enrollees, 22 died 
and 94 withdrew before the baseline interview, leaving 414 (78.1 %) for baseline and 
follow-up interviews. For this longitudinal analysis, we selected 281 participants with at 
least 2 MMSE scores, representing 67.9% of the baseline cohort. There were no 
statistically significant differences (all p values above 0.07) between those included 
(N=281) and excluded (N=133) with respect to age, sex, living condition, ADL scores, 
stlldy group, hospital sites, diagnosis of depression and cognitive impairment at 
screening. However, the excluded patients were more severely ill (p<O.OI), had more 
comorbid conditions (p<0.01), higher HDRS (p=0.05) and lower MMSE (p=0.03) scores. 
Measurements: 
M,~asures of depression: A structured psychiatrie evaluation was administered, using the 
depressive disorders section of the DIS, by the research assistant at baseline and each 
subsequent follow-up. Depression symptoms were assessed using the 21-item version of 
the HDRS, the most widely used interviewer-rated scale for monitoring depressive 
symptoms in intervention studies, with higher scores indicating more pathology32. 
Patients were classified as major, minor, or no depression using an "inclusive" diagnostic 
algorithm according to the Diagnostic and Statistical Manual of Mental Disorders 4th 
Edition (DSM-IV) criteria,33 which counted current symptoms with a duration of at least 
t\\'o weeks towards a diagnosis regardless oftheir origins or aetiologies.34 The inter-rater 
reliability was checked periodically, with a kappa coefficient being 0.78 (95% CI 0.52 to 
1.00) for a diagnosis of major depression vs minor or no depression, and 0.61 (95% CI: 
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0.35 to 0.87) for a diagnosis of either major or minor vs no depression (n=28). The intra-
class correlation coefficient for HDRS scores was 0.93 (95% CI: 0.86 to 0.97, n=26). 
Ascertainment and quantification of medication exposure: 
Data on medications of the study participants during the foIlow-up period were 
obtained though linkage oftheir hospital medical records with the provincial prescription 
claims database, the Régie de l'assurance maladie du Québec (RAMQ).35 For aIl the 
pal1icipants, RAMQ provided information on the generic name, identification number, 
dosage regimen, total supply and date dispensed for each drug product during the 6 
months prior to the index hospitalization to the end of the foIlow-up period. 
For this study, we focused on two major classes ofpsychotropic medications that 
an: commonly prescribed to depressed elderly, antidepressants and benzodiazepines. 
Antidepressants included three subgroups: 1) tricyclics (TCAs), including amitriptyline, 
desipramine, doxepine, imipramine, nortriptyline, trimipramine and clomipramine; 2) 
Serotonin reuptake inhibitors (SSRIs), including fluoxetine, sertraline, fluvoxamine, 
paroxetine and citalopram; and 3) other antidepressants, including tetracyclics 
(maprotiline), monoamine oxidase inhibitors (tranylcypromine) and atypical 
antidepressants (trazodone, nefazodone, venlafaxine and bupropion). Benzodiazepines 
were divided into two subgroups based on a half-life of the parent drug and its active 
ffiI!tabolites, if applicable, of above or below 24 hourS.36 1) long-acting agents, including 
clonazepam, clobazam, chlordiazepoxide, diazepam, flurazepam and nitrazepam, and 2) 
short-acting agents, including oxazepam, lorazepam, triazolam, temazepam, bromazepam 
and alprazolam. In addition, we collectively defined a group of "other psychotropics" by 
induding non-benzodiazepine sedatives, anxiolytics, neuroleptics, lithium, anticonvulsant 
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and antiparkinson drugs. These medications have the potential to cause cognitive 
impairment,I,3, 15·17 but are used infrequently in this study population. Finally, we used a 
cli:1ician-rated anticholinergic score as a proxy measure of total anticholinergic burden 
across medications without regard to therapeutic classification.37 The anticholinergic 
score was an ordinal scale originally developed by our group to assess risk of delirium 
due to multiple medication use in older medical inpatients, with a score ranging from 0 
(no anticholinergic effect) to 3 (strongest anticholinergic effect).37 A list of medications 
evaluated in this study and assigned anticholinergic scores is available from the first 
author. 
We defined two alternative exposure time windows to examine the potential 
cognitive effects of the study medications. A long time-window was defined as the 3-
month period prior to each MMSE assessment, assuming the effects of medication 
exposure to be enduring and cumulative over time; whereas a short time window was 
confined to the one-day period immediately preceding a follow-up MMSE assessment, 
which approximated the usual mode of clinically significant acute drug events such as 
delirium. l, 2, 5, 12 To account for potential residual effects of the medications after their last 
doses and to increase the tolerance of the defined time windows to the variation of actual 
use of the medications beyond the prescribed duration, we extended each prescription by 
seven days, analogous to the minimum fixed time-window used in the 
pharmacoepidemiologic field.38 
Within each time-window, we quantified the total exposure by the number of 
exposed drug-days (EDD) across medications under each therapeutic classes, namely, 
ar,tidepressants, benzodiazepines, and other psychotropics, based on the prescribed 
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durations. Similarly, we defined a total anticholinergic burden as the sum ofproducts of 
the: assigned anticholinergic score and the number of days dispended for each individual 
me:dication across aIl the prescriptions. Since the primary objective ofthis study was to 
assess the potential cumulative effects of medication exposure over time, the EDDs based 
on the long time window assumption were used for primary analyses. 
Measure of cognitive decline: The Mini-Mental State Examination (MMSE)39 was 
administered by a trained research assistant at baseline and subsequent follow-up 
interview at 3,6, and 12 month after baseline. The MMSE is the most widely used brief 
cognitive instrument for screening cognitive impairment or monitoring its progression,40, 
41 with a range in scores from 30 (no impairment) to 0 (maximum impairment). Studies of 
its psychometrie properties show moderate to high levels of short-term test-retest 
reliability, construct and criterion validity, and adequate responsiveness to cognitive 
change over time.40,41 The inter-rater reliability of the MMSE was assessed in a 
convenience sample of patients at intervals throughout the study period, using 
independent simultaneous ratings by two or more raters, including the study psychiatrist 
(MC). The intraclass correlation coefficient was 1.00 (n=20). 
Measures of covariates: Data on covariates were collected at enrolment from either 
patient interviews or hospital charts. The demographic factors included age, sex, 
education, and living condition prior to admission. Premorbid physical function of 
activities of daily living (ADL) was assessed with the Older Americans Resources and 
Services (OARS) Center instrument,42 with a score ranging from 0 (completely 
de:pendent) to 14 (completely independent). Other covariates included those involved in 
study design or participant selection, namely, hospital (A vs B), study group (RCT 
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Intervention, RCT -Control, Not RCT), number of SPMSQ eITors at screening, and 
follow-up duration. 
We used nurse-rated clinical severity of CUITent iIInesses, scored 1 (not ill) to 9 
(moribund),43 as a marker for potential "protopathic" indications for prescribing 
m{:dications. Given the implications of cardiovascular diseases (CVD) in both dementia 
and depression etiologies,44 we defined a binary (high vs low) indicator for risk of CVD, 
based on a diagnosis of stroke, diabetes, or myocardial infarction during the previous 2 
years or a measured sitting blood pressure of at least 160/95 mm Hg from hospital charts. 
Furthermore, we collected data on histories of previous depression episodes, categorized 
as remote, recent, or neither, from patient interviews or chart reviews, which may be a 
trigger for the initial sedative or other psychotropic prescribing before study inception. 
Statistical analysis 
The baseline characteristics and longitudinal profiles of the medication exposures 
were summarized by descriptive statistics, and compared among the baseline depression 
diagnoses using one-way ANOV A for continuo us and chi-square tests for categorical 
variables, respectively. 
A mixed effects linear regression model was employed as the primary approach to 
hypothesis testing. This allowed for simultaneous accounting for both fixed and time-
varying covariates, as weil as potential inter-dependence of repeated measures on the 
same patient over time.45 Given the unequal follow-up intervals and numbers ofMMSE 
assessments across subjects, we chose the Spatial Power covariance structure to account 
for the interdependence of repeated MMSE measures.46 
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In the primary analyses, separate multivariable mixed models, designated as A to 
D, were estimated using the MMSE changes at 3,6 and 12 months as an outcome, and 
one of the four duration-based measures of medication exposures (i.e., EDDs under 
amidepressants, benzodiazepines or other psychotropics, and the total anticholinergic 
burden) as a predictor. 
We adjusted each medication exposure for potential confounding in a hierarchical 
fashion. Starting with a crude models that included only the medication exposure, we first 
adjusted for the following a priori selected covariates: age, sex, living arrangement, 
education, number of SPMSQ errors, ADL scores, hospital site, study group, duration of 
fo:low-up, and baseline MMSE score. Next, we added the protopathic indications, which 
ineluded the nurse-rated illness severity, CVD risk and history of depression. Finally, we 
expanded the models by including, first individually and thenjointly, two context-
specifie indications for antidepressant and/or benzodiazepine prescriptions, i.e. the 
baseline depression diagnoses and concurrent depression symptoms during follow-up. 
The latter was represented by a transformed HDRS score, created by subtracting the 
mean of each depression group at baseline from the raw score at each follow-up, intended 
to avoid potential multivariate collinearity between depression diagnoses and HDRS 
score. Adjustments for both indicating diseases and their severity would enhance the 
validity of an observational study addressing adverse drug effects.27 
After deriving the final models, we evaluated the specificity or uniqueness of the 
antidepressant effects controlling for concomitant benzodiazepines and other 
psychotropics, total number of medications, and total anticholinergic burden, 
respectively. Furthermore, we evaluated biologically plausible interactions between each 
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medication exposure and follow-up time, baseline depression diagnoses and transformed 
HDRS score, as weil as the interaction between follow-up time and baseline depression 
di~,gnoses. If statistically significant interactions were detected, separate models for each 
level of the effect modifiers would be fitted to obtain more accurate estimates. 
We conducted a series of sensitivity analyses to assess potential bias of the final 
mixed models. First, we refitted the models using the EDDs derived from the short time-
window as a predictor. Next, under the same long time window assumption, we refitted 
the models by: 1) using total number of (different) medications or total anticholinergic 
score as an alternative measure, ignoring the duration of use; 2) removing the seven-days 
residual period from each prescription; and 3) eliminating the prescriptions during the 
most recent 2 or 4 weeks (for antidepressant only), respectively. 
Ail the statistical analyses were conducted using SAS software version 9.1.45 
Goodness of fit was assessed using the Akaike's Information Criterion (AIC) and 
compared among nested models using the likelihood ratio chi-square tests based on -2 
restricted Log Likelihood statistics.45,46 The hypotheses were tested at a two-sided 
significance level of a =0.05. 
6.2.4 RESULTS 
The baseline characteristics of the study population are summarized in Table 1. There 
were significant differences among the three depression diagnostic groups in the 
exposure to antidepressants (p<0.05 for total and for SSRIs) and benzodiazepines (p<0.01 
für total and for long-acting agents), but not other psychotropics or total anticholinergic 
burden ( p > 0.05). In addition, the three groups differed in the HDRS and ADL sores, 
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and the history of depression (aIl p values below 0.05), but were comparable in the 
MMSE and other characteristics (p> 0.05). 
The longitudinal profiles of the medication exposures over time are presented in 
Tables 2 and 3. There were significant differences in total numbers of antidepressants, 
SSRIs (ail p<O.Ol) and benzodiazepines (p<0.05-0.01) across time. 
Table 4 summarizes a series ofmixed models estimating the effects of the four 
medication exposures. After adjusting for ail the covariates, total anticholinergic burden 
was marginally associated with MMSE improvement over time (p=0.057, model D4). 
Both major (p=0.029 to 0.017) and minor (p=0.007 to 0.005) depression were associated 
wi1:h greater MMSE decline over time (compare to no depression), regardless ofwhich 
medications were,adjusted for (models A4 -D4). Further adjustment ofmodel A4 for 
concomitant benzodiazepines and other psychotropics, total medications, or total 
anticholinergic burden had minimum impact on the effect estimates or statistical 
significance of antidepressant use or depression diagnoses (data not shown). 
The sensitivity analyses using alternative measures of medication exposures or 
exposure time window, as specified in Statistical Analyses, provided comparable results. 
There were no independent associations (data not shown), except the total anticholinergic 
bUl·den based on the short time window was associated with higher MMSE scores over 
time (0.23, p=0.004). 
A significant interaction between antidepressant use and baseline depression 
diagnoses was detected in model A4 (p=0.038, Table 4). Therefore, stratified models 
were fitted within each depression group. The antidepressant effect was statistically 
significant only in the minor depression group, with an estimated MMSE increment of 
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2.7 (95% CI: 0.6-4.7, p=0.014) per 100-day exposure, not in major (-0.20, p=0.70) or no 
depression (-0.15, p=0.84) group. The antidepressant effect in minor depression remained 
after further adjustment for concomitant benzodiazepine and other psychotropics (2.5, 
95% CI: 0.4-4.7) or total number ofmedications (2.5, 95% CI: 0.3-4.6), but became non-
significant (2.2,95% CI: -0.7-5.0, p=0.14) after adjusting for total anticholinergic burden. 
Refitting these models using antidepressant subclasses as a predictor revealed a 
sig;nificant effect for SSRIs (2.4 to 3.0, p=0.03 to 0.08) only, not for TCAs (p=0.32). 
Alternative stratification of model A4 by antidepressant use (users versus non-
uSI~rs) observed significant effects of depression diagnoses in the non-user group only, 
with an estimated MMSE decline of -0.80 (95% CI: -1.54- -0.06, p=0.035) for major 
and-l.24 (95% CI: -2.08- -0.40, p=0.004) for minor depression after adjusting for the 
covariates. In the user group, neither major (-0.16, p=0.85) nor minor (0.33, p=O.72) 
de pression were significantly associated with cognitive decline over time. 
6.2.5 DISCUSSION 
In this cohort of 281 elderly medical inpatients, we observed no overall association 
between antidepressants or other psychotropic medications and cognitive decline. 
Furthermore, the effects of both major and minor depression on cognitive decline found 
in our previous work29 remained after adjustment for risk factors and different 
m~dications, including benzodiazepines and other psychotropics for which a large body 
of literature indicates negative cognitive effects. 1,3,17,19 These findings support the 
hypothesis that depression (major or minor) may be an independent risk factor for 
cognitive decline,4, 6, 7, 29 and that its negative cognitive effect seems unlikely, at least in 
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tht: short-run, to result from or be mediated by the use of antidepressants or other 
psychotropic medications 7. 
However, the statistically significant interaction between antidepressant exposure 
and depression diagnoses suggests a possible effect modification.5, 6 Antidepressant use, 
spl!cifically SSRIs, appeared to be associated withimproved cognitive function in those 
with minor depression, independent of the physical illnesses, severity of CUITent 
de pression symptoms, and concomitant psychotropic medications. Although this apparent 
protecive effect should be interpreted with caution given the small sample size, it 
provides preliminary evidence for potential antidepressant benefits to this less severe type 
of late-life depression, for which evidence from randomized clinical trials and 
observational studies in medically ill older persons has been insufficient.6,8, 10,24 
Previous studies reporting an improved or stable cognitive functioning following 
antidepressant treatments have been restricted to major depression. 18, 20-23 Possible 
ffiI!chanisms included a "side" -effect of antidepressant efficacy secondary to the 
irnprovement in depression pathology,18,21,22 and a deprivation of the disruptive 
anticholinergic properties of the newer antidepressant agents (e.g., SSRIS).18,20,22-24 In 
addition, sorne antidepressants, such as SSRIs, may have direct pharmacological action 
on the cognitive brain through interaction with other neurotransmitter system,6,18, 47 
though the exact nature of such mechanisms has yet to be elucidated. In our study, 
although the estimated cognitive decline for major depression appeared to be reduced in 
those prescribed antidepressants (-0.16) th an those not prescribed such medications (-
0.80), no significant antidepressant benefit was detected from major depression group. 
We suspect that this might be due to an inadequate dose and/or duration of antidepressant 
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regimen, or to non-adherence by these patients after discharge from hospital. 
Altematively, their depression pathology may be too severe to be counteracted by the 
antidepressant regimens they received. 
Contrary to our hypothesis, the total anticholinergic burden did not predict 
cognitive decline; rather, it appeared to be marginally (p=0.06) associated with better 
cognitive functioning over time. One possibility is that our clinician-rated anticholinergic 
score may not accurately reflect the level of anticholinergic activities of the medications 
in vivo. As a result, the observed anticholinergic effect could not be disentangled from 
those ofmedications that were rated as anticholinergic. Consistent with this surmise, the 
anticholinergic effect became entirely non significant (p=0.08 to 0.74) after adjusting for 
antidepressant use. Altematively, in line with the postulated direct cognitive mechanism 
of antidepressants,6,47 the anticholinergic properties of antidepressants may actually 
contribute to the improvement of cognitive function in depressed elderly when the 
serotonergic system is altered, either due to the depression pathology or the treatment 
with SSRIs. 
The strengths ofthis study are several. First, we used a comprehensive 
administrative database to ascertain medication regimens throughout the follow-up 
period, reducing potential misclassification bias due to ignorance of the changes in 
medication exposure over time.26 Second, we rigorously controlled for potential 
confounding by both indicating diseases and their severity as weil as important risk 
factors, enhancing the validity of the study.27 Third, we scrutinized our study hypotheses 
using different measures of medication exposure under biologically plausible pathogenic 
assumptions, facilitating causal inference in the epidemiological context. Finally, we 
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blinded the assessors of exposure and outcome to study hypotheses and used both 
"restriction" and "adjustment" techniques to control for potential reverse causality bias 
due to baseline heterogeneity of study population in cognitive function. 
Three important limitations should be noted. First, our measure of medication 
exposure may be imprecise, because we did not take into account the dosage or actual use 
of drugs, or adherence to the prescriptions. In addition, we did not have data on non-
prescription medications or medications used during hospitalization. Second, the outcome 
measure, the MMSE, has been criticized for insensitivity to small cognitive changes and 
ceiling or floor effects,40 especially over a relatively short period of follow-up, which 
may have limited our power to detect a small yet potentially clinically important effect of 
a medication exposure. Finally, due to exclusion of the most severely ill patients and 
substantial cohort attrition during follow-up, the results may not be generalizable either to 
the most severely ill older persons or to elderly populations outside of acute care hospital 
settings. 
The clinical implications ofthis study are two fold. First, both major and minor 
depression in older medical patients may increase risk of cognitive decline, independent 
of antidepressant or other psychotropic use. Therefore, intervention on these clinically 
significant depression syndromes (either with medications or psychosocial interventions) 
is justified on their own count. Second, the detrimental cognitive effect of depression 
may be potentially reversed or prevented by antidepressant treatment among patients with 
minor depression. Although this finding should be interpreted with caution, rigorous 
investigation of potential benefits and harms of antidepressant treatment in older persons 
with minor depression, including randomized clinical trials, is warranted. 
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Table 1. Characteristics of the 5tudy Population at Baseline 
Depression Diagnoses 
Chara.:teristics* Major Minor No P Value§§ 
{N=121} {N-51} {N=109} 
Age -yr 78.7 ± 7.1 78.4 ± 6.9 79.9 ± 7.3 0.333 
Gender - n (%) Female 75 ( 62.0 ) 33 ( 64.7 ) 77 ( 70.6 ) 0.378 
Male 46 ( 38.0 ) 18 ( 35.3 ) 32 ( 29.4 ) 
EdLcation - n (%) 
<6 13 ( 11.2 ) 9 ( 18.4 ) 9 ( 8.6 ) 0.446 
6-12 43 ( 37.1 ) 18(36.7) 45 ( 42.9 ) 
> 12 60(51.7) 22 ( 44.9 ) 51 ( 48.6 ) 
Living arrangement prior to enrolment - n (%) 
Home 101 ( 83.5 ) 43 ( 84.3 ) 92 ( 84.4 ) 0.979 
Other 20 ( 16.5 ) 8 ( 15.7 ) 17 ( 15.6 ) 
SPIIIISQ scoret 1.6 ± 1.2 1.6 ± 1.4 1.6 ± 1.4 0.960 
MMSE score+ 25.8 ± 3.2 25.1 ± 3.3 26.2 ± 3.9 0.137 
HORS score§ 19.9 ± 5.8 13.5 ± 5.3 9.5 ± 5.7 <0.001 
AOL score~ 11.5±12.0 12.1 ± 11.7 12.5 ± 12.5 0.003 
Nurse-rated illness severity 3.9 ± 1.0 3.9 ± 1.0 3.7± 1.1 0.380 
Risk for cardiovascular disease - n (%) 0.584 
High 12 ( 9.9 ) 3 ( 5.9 ) 12(11.0) 
Low 109 ( 90.1 ) 48 ( 94.1 ) 97 ( 89.0 ) 
History of previous depression episode - n (%) 
Remote 16(13.2) 8(15.7) 5 ( 4.6 ) <0.001 
Recent 34 ( 28.1 ) 6 ( 11.8 ) 6 ( 5.5 ) 
Neither 71 ( 58.7 ) 37 ( 72.5 ) 98 ( 89.9 ) 
Hospital- n (%) A 91 ( 75.2 ) 43 ( 84.3 ) 94 ( 86.2 ) 0.083 
B 30 ( 24.8 ) 8(15.7) 15 ( 13.8 ) 
Study group - n (%) Il 
ReT-intervention 33 ( 27.3 ) 6 ( 11.8 ) 4 ( 3.7 <0.001 
ReT-control 26 ( 21.5 ) 8 ( 15.7 ) 1 ( 0.9 
Not ReT 62 ( 51.2 ) 37 ( 72.5 ) 104 ( 95.4 ) 
/-
Table 1 (Continued) 
Number of psychotropic medications 
A1tidepressant** TCA 
SSRI 
0.05 ± 0.22 
0.24 ± 0.50 
0.12±0.38 
0.12 ± 0.33 
0.05 ± 0.21 
0.07 ± 0.26 
Other 0.04 ± 0.20 0.02 ± 0.14 0.03 ± 0.16 ----~--~~~----~------------------
Total 0.33 ± 0.57 0.25 ± 0.52 0.15±0.36 
Benzodiazepine 
Long-acting 0.12 ± 0.36 0.12±0.33 0.02 ± 0.13 
Short-acting ____ -=~=_=..:.;;..;:~ __ ~=....=....;:..:....:..;=--__ ~:=....:::_.:.~ __ 0.36 ± 0.55 0.22 ± 0.46 0.22 ± 0.42 
Total 0.48 ± 0.67 0.33 ± 0.59 0.24 ± 0.45 
Other psychotrapic drugtt 0.26 ± 0.60 0.12 ± 0.38 0.17 ± 0.44 
Total number of medications 7.61 ± 6.06 8.08 ± 6.39 6.79 ± 5.50 
~-I score across medications++ 1.47 ± 1.78 1.69 ± 2.13 1.27 ± 1.51 
* Plus··minus signs are means ± SD. Because of missing data on sorne characteristics, 
0.204 
0.005 
0.720 
0.018 
0.012 
0.066 
0.007 
0.191 
0.372 
0.348 
the denominators that were used to determine sorne percentages differ from the total numbers of 
patients. 
t The Short Portable Mental Status Questionnaire (SPMSQ) scores range from 0 to 10, with higher 
scorell indicating more cognitive impairment. 
+ The Mini-Mental State Examination (MMSE) scores range from 0 to 30, with higher scores 
indicating better cognitive performance. 
§ The 21-item Hamilton Depression Rating Scale (HDRS) scores range fram 0 to 63, with higher 
scores indicating greater seve rit y of depression symptoms. 
11 The Activities of Daily Living (ADL) scores range fram 0 to 14, with higher scores indicating more 
indepl:!ndence. 
Il RCT denotes Randomized Clinical Trial. 
** ThE! antidepressant was divided into Tricyclic (TCA), Selective Serotonin Reuptake Inhibitor 
(SSRI), and other agents. 
tt The other psychotrapic drug included non-benzodiazepine sedatives, anxiolytics, barbiturates, 
antip~.ychotics, antiparkinson drugs, and anticonvulsants etc. 
++ The clinician-rated Anticholinergic (ACH) scores range from 0 to 3, with higher scores indicating 
greater antichilinergic level. 
§§ DE!rived fram X2 (df=2) for categorical and one-way ANOVA (df=2) for continuous variables, 
contrasting the three diagnostic groups. 
- It;,-
Table 2. Longitudinal profile of medication exposure over time 
Medication Follow-up 
Depression Diagnoses 
Major Minor No P Value+ 
exposure* time 
Mean ± SO Mean ± SO Mean ± SD 
Antidepressant 
3 month 25.7 ± 38.6 12.0 ± 28.7 6.2 ± 21.9 <0.001 § 
6 month 25.9 ± 41.4 16.5 ± 33.1 8.3 ± 26.0 0.001 Il 
12 month 26.9 ± 45.3 9.1 ± 24.9 4.4 ± 17.0 <0.001 11 
Benzodiazepine 
3 month 27.9 ± 40.5 13.9 ± 33.6 10.5 ± 25.0 <0.001 ** 
6 month 24.0 ± 37.4 17.2 ± 34.3 12.4 ± 29.5 0.035 tt 
12 month 21.5 ± 37.8 13.3 ± 31.4 11.5 ± 27.0 0.055 ;; 
Other ps~hotrapic 
3 month 13.1 ± 31.4 5.5 ± 19.4 10.7 ± 37.5 0.369 
6 month 11.3 ± 31.1 4.5 ± 16.3 12.9 ± 42.8 0.342 
12 month 12.7 ± 40.8 5.2 ± 19.0 10.7 ± 39.3 0.485 
Anticholinergic burden! 
3 month 89.3 ± 122.4 79.4 ± 122.4 55.4 ± 81.6 0.058 §§ 
6 month 87.4 ± 123.4 89.1 ± 119.6 72.1 ± 103.7 0.533 
12 month 82.4 ± 114.8 64.5 ± 99.4 59.8 ± 91.8 0.231 
* Values represent total numbers of exposed drug-days, except otherwise indicated, to each 
medication class during the 3 months prior to each follow-up outcome assessment. 
t Values represent the products of assigned ACH score and number of days exposed to each 
medication across ail prescriptions during the 3 months prior to each follow-up outcome assessment. 
+ Oerived fram one-way ANOVA, df=2 for overall comparison among the three diagnostic groups. 
§ Pairwise comparisons: major versus no depression, p<O.001; major versus minor depression, 
p<O.01. 
Il Pail"wise comparisons: major versus no depression, p<O.001. 
11 Pairwise comparisons: major versus no depression, p<O.001; major versus minor depression, 
p<O.01. 
** Pairwise comparisons: major versus no depression, p<O.001; major versus minor depression, 
p<O.05. 
tt Pairwise comparisons: major versus no depression, p<O.05. 
++ Pairwise comparisons: major versus no depression, p<O.05. 
§§ Pêlirwise comparisons: major versus no depression, p<O.05. 
-lsb..-
Table 3. Longitudinal profile of exposure to major subgroups of antidepressants and 
benzc,diazepines over time 
Medic:ation Follow-up Depression Diagnoses 
exposure* time Major Minor No P Valuet 
Mean ± SD Mean ± SD Mean ± SD 
Tricyclic antidel2ressants 
3 month 3.9 ± 15.2 4.1 ± 19.9 1.3 ± 9.7 0.330 
6 month 2.1 ± 11.0 3.8 ± 17.7 3.5 ± 15.7 0.676 
12 month 2.7 ± 14.6 0.7 ± 5.2 1.7 ± 9.7 0.576 
Selective serotonin reul2take inhibitors 
3 month 18.7 ± 32.0 6.1 ± 18.8 4.1 ± 16.7 <0.001 :t: 
6 month 18.3 ± 33.6 11.0 ± 27.8 3.5 ± 16.4 <0.001 § 
12 month 19.3 ± 34.3 7.5 ± 23.2 2.4 ± 11.5 <0.001 Il 
Long-acting benzodiazel2ines 
3 month 6.8 ± 20.8 6.7 ± 23.2 0.1 ± 0.8 0.00611 
6 month 6.0 ± 19.5 7.4 ± 23.5 1.2 ± 9.4 0.043 ** 
12 month 3.7 ± 16.3 4.3 ± 18.3 0.9 ± 6.9 0.212 
Short-acting benzodiazel2ines 
3 month 21.2 ± 35.2 7.2 ± 26.2 10.4 ± 24.8 0.004 tt 
6 month 18.0 ± 33.0 9.9 ± 26.6 11.2 ± 27.4 0.129 
12 month 17.8 ± 33.7 8.9 ± 27.0 10.5 ± 25.4 0.089 
* Values represent total numbers of exposed drug-days, except otherwise indicated, to each 
medication class during the 3 months prior to each follow-up outcome assessment. 
t Deri lied trom one-way ANOVA, df=2 for overall comparison among the three depression 
diagnostic groups. 
:t: Pair·wise comparisons: major versus no depression, p<O.001; major versus minor depression, 
p<O.O!5. 
§ Pair·wise comparisons: major versus no depression, p<O.001. 
Il Pair-wise comparisons: major versus no depression, p<O.001; minor versus no depression, 
p<O.O'I. 
,-r Pair .. wise comparisons: major versus no depression, p<O.01; minor versus no depression, p<O.05. 
**Pair-wise comparisons: major versus no depression, p<O.05; major versus minor depression, 
p<O.O!5. 
tt Pair-wise comparisons: major versus no depression, p<O.01; major versus minor depression, 
p<O.O'I. 
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Table 4. Association between medication use and MMSE changes* evaluated using mixed effects models 
Model A. Antidepressant B. Benzodiazepine C. Ôther psychotropic U. ACH burden 
No. Predictorst Est.,-r 95% CI P Est. 95% CI P Est. 95% CI P Est. 95% CI P 
value value value value 
1 Medication exposure -0.17 -0.91 -0.57 0.648 -0.60 -1.35-0.15 0.119 -0.28 -1.00-0.43 0.437 0.08 -0.15 - 0.32 0.480 
2:t: Medication exposure 0.25 -0.42 -0.92 0.462 -0.24 -0.90 - 0.42 0.476 -0.15 -0.76 - 0.46 0.631 0.21 0.01 -0.42 0.044 
3 § Medication exposure 0.23 -0.46 -0.92 0.507 -0.26 -0.92 - 0.41 0.451 -0.14 -0.74 - 0.47 0.659 0.18 -0.02 -0.39 0.083 
4 Il Medication exposure 0.29 -0.39 - 0.97 0.398 -0.16 -0.81 - 0.50 0.640 -0.15 -0.75 -0.45 0.623 0.20 -0.01 -0.40 0.057 
Depression diagnoses at baseline 
Major -0.82 -1.48 --0.15 0.017 -0.75 -1.42 - -0.08 0.029 -0.77 -1.44--0.11 0.023 -0.81 -1.47 --0.15 0.017 
Minor -1.03 -1.77 --0.29 0.007 -1.01 -1.76--0.27 0.008 -1.04 -1.79--0.29 0.007 -1.06 -1.80--0.32 0.005 
* Defined by the differences in the Mini-Mental State Examination (MMSE) scores between each follow-up and baseline, with negative 
values indicating decline; 
t Medication exposure as a predictor refers to one of four medications, represented by the total exposed drug-days (models A-C) or total 
anticholinergic (ACH) burden (model D) during the 3 months prior to each follow-up outcome assessment. 
+ Model #2 adjusted model # 1 for age, sex, education, living arrangement, activity of daily living (ADL) score, hospital, study group, Short 
Portable Mental Status Questionnaire (SPMSQ) score, baseline MMSE score, and follow-up duration. 
§ Model # 3 adjusted model # 2 for nurse-rated illness severity, risk for cardiovascular diseases and history of depression. 
Il Model # 4 expanded model # 3 with two addition al covatiates: depression diagnoses at baseline (shown in the table) and a transformed 
Hamilton Depression Rating Scale (HDRS) score during follow-up. 
,-r Represents expected MMSE change per 1 OO-day exposure to the specifie medication, with negative values indicating decline. 
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6.3 POSTSCRIPT TO MANUSCRIPT 3 
ln this section, 1 supplement the manuscript and conclude the formaI hypothesis 
testing of the thesis with the following additional data and remarks. 
6.3.1 Sensitivity Analyses of Estimated Antidepressant Effects 
Table A-lof Appendix 1 provides further details about a series of sensitivity 
analyses of the effects of antidepressant exposure on MMSE changes, based on the final 
model A4 of Table 4 in the manuscript. In brief, under the short time window assumption 
(model A), the estimated effect for antidepressant exposure remained non-significant, 
though slightly increased in magnitude, in comparison to that derived from the long time 
window. Similarly, eliminating the antidepressants prescribed during the most recent 14 
(model B) or 30 (model C) days from the long time window, or removing the 7-day 
residual period from aIl the prescriptions (model D) did not change the effect estimates for 
antidepressant use meaningfully. These results suggest that the cognitive effects of 
antidepressant medications may act through different pharmacological mechanisms from 
their therapeutic effects on reducing depression symptoms [Oxman 1996]. Results were 
consistent using number of medications to represent total antidepressant use (P>0.05, data 
not shown) and other medication exposures without considering the duration of use. 
Likewise, both major and minor depression remained independently associated 
with MMSE decline over time (p<0.05 to 0.001), and their effect estimates stayed almost 
the same as the primary analyses, no matter which alternative exposure time window was 
assumed and which medications were adjusted for (data not shown). 
Finally, although the participants whose baseline interviews were completed in 
hospital did have a lower baseline MMSE score than those interviewed at home (25.6 vs 
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26.7, p=0.029), adjustment of the final mixed models for place ofbaseline interview did 
not change the effect estimates for antidepressant use (p>0.05) or depression diagnoses 
(p<0.05 to 0.001) meaningfully. Nor was there a statistically significant "place" effect 
(p=0.81) or "place" interaction with depression diagnoses (p=0.19) or antidepressant use 
(p=0.88). 
6.3.2 The Stratified Analyses 
Table A-2 provides further details for the subgroup models described in the last 
paragraph of section 6.2.4 Results of the manuscript, including the sequential adjustments 
for concomitant medications. An additional message from these subgroup models is that in 
both major depression and no depression groups antidepressant use seemed to be 
associated, though not statistically significantly, with cognitive decline over time, 
especially when multiple medications were taken, consistent with the general belief that 
polypharmacy may increase the risk of adverse drug events due to a specifie medication 
[Colley 1993, Tune 1992]. 
6.3.3 Joint Effeet of Major Depression and Antidepressant Use 
ln a few previous cohort studies, antidepressant use at baseline has been included 
in the definition of major or persistent depression based on self-rated symptoms alone 
[Devanand 1996, Fuhrer 2003]. Therefore, 1 refit the final mixed models by adding to the 
major depression group those who were using antidepressants at baseline, but diagnosed 
as either minor (n=8) or no (n=14) depression. The effect estimates for the redefined major 
depression (N=143) remained strong and statistically significant (-0.72, p=0.03), even 
after adjusting for concomitant benzodiazepine and other psychotropic medications 
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(-0.69, p=0.04), total medications (-0.76, p=0.02), or total ACH burden (-0.80, p=0.02). 
The same was true for the redefined minor depression (N=43, effect estimates: -1.08 to -
1.13, p=0.009 to 0.007). 
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CHAPTER 7 - GENERAL DISCUSSION 
7.1 SUMMARY OF MAIN FINDINGS 
This thesis examined the relationship between depression and cognitive function in 
a sample of older medical inpatients with repeated measures ofboth over a 12-month 
follow-up period. The main findings can be briefly summarized as follow. 
1) Depression symptoms were associated with cognitive functioning cross-
sectionally but not prospectively. This cross-sectional association was independent of age, 
cardiovascular risk, illness severity, baseline physical and cognitive function and other 
potentially important risk factors of cognitive impairment, but disappeared after 
depression diagnoses were taken into account. 
2) Both major and minor depression were predictive of subsequent cognitive 
decline, independent of baseline characteristics including age, cardiovascular risk, illness 
severity, physical and cognitive function, and previous history of depression. The strength 
of the association appeared to increase with the duration offollow-up interval since the 
assessment of depression diagnoses. In addition, it remained after adjusting for the 
longitudinal variations in the severity of depressive symptoms, exposure to 
antidepressants, other psychotropic medications, and total anticholinergic burden across 
medications. Furthermore, the effect stayed statistically significant in patients who were 
not prescribed antidepressants during the follow-up. 
3) There were no overall associations between antidepressants, benzodiazepines 
or other psychotropic medications and cognitive dec\ine. However, antidepressant use 
interacted with depression diagnoses. In the minor depression group, exposure to 
antidepressants in general and to SSRIs of particular appeared to be associated with an 
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improvement in cognitive functioning over time, independent of the severity of concurrent 
depression symptoms, concomitant benzodiazepines and other psychotropic medications 
or total concomitant medications, but diminished after adjusting for total anticholinergic 
burden across medications. 
Taken together, these findings have addressed the two main research questions 
towards the three specifie aims, and partially confirmed our a priori hypotheses, as 
postulated in Chapter 3. Their unique contributions to the subject field and potential 
scientific significance will be briefly discussed in the next section. 
7.2 COMPARISON WITH THE LITERATURE 
7.2.1 The Temporal Relationship between Depression and Cognitive Functioning 
The concurrent association observed in the first manuscript seems to agree with 
previous cohort studies that reported a cross-sectional relationship between depression 
symptoms and cognitive de cline or dementia [Dufouil 1996, Henderson 1997, Chen 1999, 
Cervila 2000, Vinkers 2004, Ganguli 2006]. However, several unique methodological 
features differentiate this study from previous ones. First, depression symptoms were 
measured using a clinically validated, observer-rated depression scale, rather than patients' 
self-reports. Second, this thesis examined depression symptoms as adynamie exposure 
and "replicated" the cross-sectional relationship at multiple time points (so termed as 
"concurrent") using longitudinal analyses, rather than at a single baseline or intermittent 
time point of the follow-up. Finally, this thesis rigorously examined competing hypotheses 
about the temporality between depression and cognitive decline through operational 
statistical models, rather than relying on a lack of longitudinal relationship as sole 
evidence [Henderson 1997, Chen 1999, Cervila 2000, Vinkers 2004, Ganguli 2006]. As 
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correctly pointed out by Dufouil [Dufouil 1996], a lack of prospective association from 
studies with extended follow-up intervals may reflect the inability of the studies to capture 
such an association, which may have diminished before the outcome assessment, rather 
than render support to refuting its existence. 
On the other hand, the longitudinal prediction of cognitive decline by both major 
and minor depression stands out as a potentially important new finding. The consistency 
of this re1ationship against a variety of suspected causal risk factors and the concurrent 
variation of depression symptoms, the pattern of dose-response in terms of the "exposure" 
duration to the diagnoses, and the clinically relevant short follow-up interval within which 
the relationship was observed ail point to a potential causal mechanism. And as such, it 
provides a strong piece of evidence in support of the hypothesis that depression is an 
independent risk factor for cognitive decline in older persons [Jorm 1991, 200 1, Meyers 
1998, Steffens 2006]. To my knowledge, this is the first prospective epidemiological study 
that directly examined and empirically demonstrated a short-term temporal relationship 
between clinically significant depression syndromes and cognitive decline in the 
medically ill elderly population. 
Severa1 biological mechanisms have been speculated to explain a potential causal 
relationship between depression and cognitive impairment or dementia. According to the 
glucocorticoid cascade hypothesis, repeated and prolonged stress, a common risk factor 
for depression, may over-activate and eventually exhaust the hypothalamic-pituitary-axis 
and lead to permanent brain damage and cognitive impairment [O'Brien 1996, Jorm 
2001]. In addition, the serotonergic neurotransmitting system, whose deficiency has been 
implicated in the etiology of major depression, may play an important role in modulating 
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cognitive behavior through interactions with the cholinergie system [Steekler 1995], a 
target of neurodegenerative disease such as dementia. If such causal meehanisms do exist, 
it should not be surprising that "exposure" to clinieally signifieant depression syndromes 
be closely and quantitatively associated with cognitive decline weIl before it may develop 
into a full-blown dementia. Altematively, the relationship may be determined by a 
eommon underlying cause or shared etiology, such as vascular diseases [Alexopoulos 
1997, Lyness 1998, Patemiti 2000, Lavretsky 2004, Fuhrer 2003]. As postulated in the 
"vascular depression" hypothesis, both clinical and subclinical cerebrovascular diseases 
can cause brain damage, especially in the striatofrontal region, which in tum lead to 
depressed mood and cognitive disturbance, particularly in the executive domain. Several 
epidemiological studies observed a relationship between depression symptoms and 
cognitive impairment only in those with sorne cardiovascular pathology [Cervilla 2000] or 
in older men in whom cardiovascular diseases are disproportionately more prevalent than 
in women [Fuhrer 2003]. In this thesis, however, a measure of CVD neither had a 
significant main effect nor modified the effect of depression symptoms or diagnoses on 
cognitive function. Therefore, it seems unlikely that cardiovascular diseases could explain 
the observed relationship. 
7.2.2 Effect Modification by Antidepressant Medications 
The lack of independent associations between antidepressants or other psychotropic 
medications and cognitive decline, and the apparent interaction between antidepressant 
use and depression diagnoses suggest that the antidepressant exposure behaves mostly like 
an effect modifier, rather than an independent risk factor or mediating factor in the 
depression -cognitive de cline conundrum [Meyers 1998, Oxman 1996, Jorm 2000, 1991, 
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Steffens 2006]. While the cognitive benefit of antidepressants in minor depression should 
be interpreted with caution due to its small sample size, an improved or stable cognitive 
function following antidepressant treatments have been reported for older persons with 
major depression [Amado-Boccara 1995, Butters 2000, Doraiswamy 2003, Nebes 1999]-
Sorne authors interpreted such cognitive benefits as secondary to the alleviation of 
depression symptoms by successful antidepressant treatment, while others postulated 
possible direct effects of antidepressant, especially SSRIs and other newer generations, 
through a different pharmacological mechanism such as interactions between serotonergic 
and other neurotransmitting systems [Oxman 1996, Nebes 1999], though the exact nature 
of such mechanisms have yet to be determined. To my knowledge, this is the first 
epidemiological study that empirically demonstrated an effect-modification model in the 
longitudinal context to explain the interrelationship between late-life depression, 
medication use and cognitive decline. 
7.3 LIMITATIONS 
As an observational study, this thesis is subject to the following potential biases. 
7.3.1 Selection Bias 
Selection bias refers to the distortions of exposure-outcome association that resuIt 
from the procedure used to select participants and factors that influence study participation 
[Rothman 1998, Collet 2000]. As a resuIt, the exposure-outcome relationship observed in 
study participants does not reflect the truth in the base population. Modern epidemiology 
tends to distinguish the selection of one particular comparison group from the selection of 
the study sample. The former primarily affects the "internai validity" of a study or the 
applicability of its observed effect estimates to the source population, whereas the latter 
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mainly reduces the "external validity" or generalizability of the study results to people 
outside of the source population [Rothman 1998, Collet 2000]. 
As regard external validity, in the parent studies the majority of consecutively 
admitted patients did not reach the screening phase for depression due to application of 
eligibility/exc1usioncriteria. Second, the thesis study further excluded patients with only 
one outcome assessment. Finally, there was appreciable cohort attrition over time, as is a 
common phenomenon to older medical cohorts [Cole 1999, Morris 1999]. Although the 
excluded patients had comparable characteristics to those included in terms of major 
demographic characteristics, diagnosis of depression and cognitive impairment at 
screening, they tended to be more severely physically ill, and less emotionally and 
cognitively weIl (see Chapter 4, Manuscript 1, Methods section). Therefore, the study 
results may not be generalizable to severely ill old persons or elderly populations outside 
of acute care hospital settings. 
As regard internai validity, two types of selection bias may have particular 
implications to this thesis: reverse causality and protopathic bias [Rothman 1998, Collet 
2000]. The former may occur if a large proportion of the participants who manifested 
depression symptoms were preclinical cases of an underlying dementing disease, whose 
cognitive function would naturally deteriorate over time as the dementia progresses. As a 
result, a spurious association between depression and cognitive decline may be found. If 
depression (or other) symptoms were indeed early (or more strictly, the first) signs of 
dementia and antidepressant (or other) medications were prescribed to treat these 
symptoms, then a protopathic bias may result, whereby the antidepressant medications, 
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rather than the underlying dementia pathology, may be erroneously claimed as the 
"cause" of the observed cognitive decline. 
In this thesis, the risk for both types of selection bias has been reduced by 
restriction of the study sample to those without apparent cognitive impairment at study 
entry. In addition, the follow-up period oftwelve months in this thesis was much shorter 
than the typical time course for the development of dementia, within which it is unlikely 
that originally cognitively intact older participants would develop dementia. Furthermore, 
the three baseline groups by depression diagnoses were assembled following the same 
inclusion/exclusion criteria (except depression) and the factors used for selection of 
participants have been adjusted in the regression model. Therefore, the chance of serious 
selection bias on the effect estimates for depression diagnoses should be minimal. The 
effect estimates for medication use would be largely immune to the potential protopathic 
or other types of selection bias due to its nature ofwithin-subject sampling. This is 
especially true for antidepressant medications, which essentially demonstrated no harm or 
even protective effect on cognitive function, opposite to what can be expected from a 
dementia pathology. 
7.3.2. Information Bias 
Information bias refers to the distortion of exposure-outcome association due to 
errors in the measurement ofstudy variables [Rothman 1998]. If the measurement errors 
in one variable (exposure or disease) depend on the value of the other (so-called 
"differential"), the effect estimates can be biased either towards or away from the nul1. 
When the measurement errors do not depend on each other (nondifferential), information 
bias usually leads to an attenuation of the true effect [Rothman 1998, Collet 2000]. 
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Information bias may have specific implications for the following measurements 
of the thesis. 
1) Medication exposure: 
Use of administrative prescription database (i.e., RAMQ) for ascertaining 
medication exposure may be subject to several sources of information bias. First, the 
medication exposure was quantified based on the dispensed prescriptions rather than 
actual use of the medications, which may lead to an overestimation of the total exposure. 
Second, RAMQ does not provide information about over-the-counter medications or 
prescription during hospitalization, which may bias the effect estimates towards the null 
(if the omitted drugs have the same cognitive effects as their prescription counterparts). 
Third, for feasibility reasons (e.g., lack of data), 1 did not use dosage information or take 
into account the adherence of patients, which may bias the exposure effects either towards 
or away from the nul!. However, 1 have confined my examination of medication exposure 
within biologically plausible pathogenic time windows, and conducted a series of 
sensitivity analyses to assess potential bias using alternative measures. The results 
remainedessentially unchanged. Therefore, serious differential information bias seems 
unlikely. 
A specific case of potential information bias may be to the clinician-rated ACH 
score. The ACH score is based on clinicians' experience with observable therapeutic or 
side-effects that are typically attributable to the blockage of muscarine receptors [Bartus 
1982, Beatty 1986, Rudd 2005, Hardman 1996]. Ther.efore, the ACH score may not 
accurately reflect the level of the true ACH activities, at least not the actual ACH activities 
in vivo. However, a systematic reversion of the true ACH effects by clinicians' rating 
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seems unlikely given the reported concurrent and predictive validity ofthe ACH score in 
other studies [Carnahan 2002, Rudd 2005] and the documented ACH effect of the 
medications with a non-zero ACH score in the literature [Larson 1987, Bowen 1993, 
Hardman 1996, Oxman 1996, Tune 1992]. Therefore, the measurement errors of ACH 
score are not likely to be a reason for the observed beneficial (though not significant) 
effect of ACH burden. Future studies with refined measures of ACH properties of 
medications, preferably with external and objective validation, would be needed to clarify 
whether this is a chance finding, an artifact due to confounding by unmeasured 
medications or other factors, or it reveals an undiscovered biological mechanism. 
2) TheMMSE 
The cognitive outcome was measured by a global cognitive test, the MMSE, which 
has been criticized for insensitivity to small cognitive changes and being subject to ceiling 
or floor effects [Tombough 1992, Galasko 1991]. Furthermore, "practice" effects in 
general and "regression to the mean" in people with lower baseline MMSE scores may 
tend to "improve" cognitive performance over time [Tombough 1992, Morris 1999]. The 
overall trend of a slight increase of the MMSE scores in the study cohort from baseline to 
six months may partially reflect such measurement problems, in addition to the effect of 
place oftesting referred to above. A more specific implication of such a measurement-
related artifact may be the observed antidepressant effect in the minor depression, but not 
in the major depression group. Because patients with minor depression tended to have 
lower (but non-significant) baseline MMSE scores than those with major depression, they 
would be more likely to "improve" over time regardless of antidepressant treatment. 
However, this potential psychometric bias should have been removed by adjustment for 
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the baseline MMSE score. Similarly, place ofbaseline interview did not appear to have a 
significant impact on the cognitive functioning of the cohort (p=0.81) or the effect 
estimates for antidepressant use (p>0.05), suggesting that any bias due to place oftesting 
would be minimal [Inouye 2006]. 
On the other hand, the MMSE is a global measure of cognitive function [Tombàugh 
1992]. Its capacity is limited in measuring the specific cognitive dysfunctions that may 
characterize late-life depression, such as visual-spatial ability and complex executive 
function [Lavretsky 2004, Steffens 2006]. Future studies using instruments that are 
specifically tailored to assess such cognitive domains, such as the Trail Making Test, 
Clock Drawing Test and neuropsychological batteries [Steffens 2006], would be needed to 
answer this question. 
7.3.3 Confounding Bias 
Confounding is another major threat to the internaI validity of an epidemiological 
study, which can bias the effect estimate either towards or away from the null or reverse 
its direction [Rothman 1996]. A specific form of confounding that is particularly relevant 
to this thesis is confounding by indication [Rothman 1996, Collet 2000, Salas 1999], 
which leads to a confusion between cause and drug effects when the reason for 
prescribing, rather than prescribed drugs, is responsible for the observed effects. In 
practice, it is sometimes difficult to distinguish confounding by indication from 
protopathic bias [Collet 2000, Salas 1999]. Similarly, while reverse causation often results 
from the distortion of the population selection procedure, it can also arise from 
confounding factors related to inclusion/exclusion criteria at study entry. 
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1 controlled for confounding by indication first, by adjusting medication exposure 
for both "generic" and "context-specific" indications, and for both indicating diseases 
(depression) and its symptom severity over time. Furthermore, 1 considered and 
systematically evaluated a large array of potential confounders based on both a priori 
clinical knowledge and statistical princip les. 
Other potential confounders, such as recent life events or incidence of acute illness 
during the follow-up period, were not measured in this study and therefore not controlled. 
Although the adjustment of the depression diagnoses for the time-dependent HDRS scores 
during the follow-up may have partially eliminated the potential confounding due to such 
unmeasured situations, this adjustment does not allow for determining whether the lack of 
prospective effect of depression symptoms is due to the extraneous confounders or the 
intrinsic limitations of the instrument (i.e., HDRS). In addition, in the context of 
observational studies of adverse effects of medications, a complete elimination of 
confounding by indication is almost impossible, and the consequence of adjustment is not 
always in the desired direction [Collet 2000, Miettinen 1989]. For instance, sorne 
antidepressant medications may be prescribed to treat conditions other than depression, 
such as chronic pain syndrome, anxiety disorder and anorexia etc. Without knowing the 
concrete reasons for each prescription, an adjustment for the typical indication for 
antidepressant use, i.e., specific depression diagnosis and the severity of depressive 
symptoms, can at best rem ove sorne of the confounding. Therefore, the observed 
protective effects of antidepressant use in minor depression group also need to be verified 
by examining closely the specific indications for each antidepressant prescription. 
Ultimately, randomized clinical trials will be needed to resolve these issues. 
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7.3.4 Other limitations 
Several other methodological limitations that are related to the study design are 
also worth noting. 
1) Short follow-up interval: 
This thesis focused on a relatively short follow-up period oftwelve months -
shorter than any previous cohort studies in the subject field that ranged from one to twelve 
years (see 2.4.2 CUITent State of Epidemiological Knowledge - A Critical Literature 
Review for details). While this short follow-up had the advantage to address the effects of 
depression as a potential short-term risk factor versus a clinical concomitant of cognitive 
decline in a context close to clinical reality, it also had disadvantages. First, the 
insensitivity of the MMSE to mild cognitive decline might be exaggerated due to more 
frequent "practice" of the patients over a short time interval, as discussed in section 7.3.2. 
Information Bias. Second, a temporal relationship between depression and cognitive 
decline over a short time period is a necessary, but not a sufficient, piece of evidence for 
establishing a causal relationship between depression and dementia. Whether or not it 
persists over longer period of time or leads directly to the development of dementia needs 
to be confirmed in future. 
2) Uncertainty around the Antidepressant Effects for Minor Depression 
While the thesis had adequate statistical power to test the main hypotheses, the 
small sample size of minor depression (N=51) added uncertainty to interpretation of the 
observed beneficial effects of antidepressant use in this group. More specifically, during 
each follow-up interval, only a small portion of patients were actually using antidepressant 
medications (19.6%, 23.5%, and 13.7%, respectively). To what degree the observed 
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beneficial effects of antidepressant use may be attributed to sorne unmeasured 
confounders (such as use of over-the-counter cognitive enhancers or other psychological 
therapy, etc) needs to be investigated. In addition, evidence from randomized clinical 
trials for antidepressant benefits is, to my knowledge, mostly derived from older persons 
with major depression [Lebowitz 1997, Mittmann 1997, Mottram 2006]. Little is known 
about the therapeutic or side (cognitive or other) effects of antidepressant treatment in 
minor depression, with or without comorbid medical conditions [Williams 2000, 
McCusker 1998, Tannock 1995, Freudenstein 2001]. Therefore, whether or not the 
observed effects reflected specific characteristics of the subsets of patients, typical clinical 
features of minor depression, or the efficacy of the antidepressant treatment remains to be 
clarified. 
7.4 STRENGTHS 
The strengths and unique methodological contributions of the thesis to the subject 
field include the following aspects: 
1) Use of a clinically relevant short follow-up interval and standard psychiatric 
assessments to define depression symptoms and diagnoses, which makes the study 
findings readily translatable into the clinical management of late-life depression. 
2) Integration of a comprehensive prescription database and first-hand clinical 
information to address the effect of medication exposure, which helps reduce 
measurement errors of medication exposure and facilitates controlling for confounding by 
(clinical) indications for prescriptions; 
3) Adoption of a repeated measure cohort design and an appropriate longitudinal 
analytic approach, which enhances the validity and efficiency of the study due to 
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simultaneous control for both patient-specifie and time-varying confounders and optimal 
use of multiple observations on the same patients. 
4) Definition of exposure time windows under biologically plausible pathogenic 
hypotheses for drug-induced cognitive impairment, which facilitates the ability ofthis 
observational study to make causal inference. 
7.5 CLINICAL AND PUBLIC HEALTH IMPLICATIONS 
This thesis has the following implications for clinical and public health practice: 
1) As clinically significant syndromes, both major and minor depression in older 
medical patients are likely to be independent risk factors of cognitive de cline over the 
short-term. Therefore, intervention on late-life depression may have the potential to reduce 
the risk of future cognitive decline in this highly susceptible population. 
Due to lack of quantitative clinical criteria, it may be difficult to meaningfully 
judge the clinical significance of the observed effects for depression diagnoses. However, 
based on an estimated annual rate of decline of 3.3 MMSE points for Alzheimer' s 
dementia [Han 1999] and of 0.02 to 0.57 for community-dwelling older persons without 
dementia [Jacqmin-Gadda 1997], the estimated 0.8 (for major depression) and 1.0 (for 
minor depression) declining MMSE points per six months can be roughly translated into 
an ARC of 1.6 and 2.0 points, respectively, which falls in-between the two extremes, but 
is closer to that of de menti a patients. 
2) Antidepressant treatment, especially with SSRls, may modify the detrimental 
effects of late-life depression, and potentially preserve or improve the cognitive function 
in those with minor depression. Although this finding needs to be replicated in larger 
sample of older persons with minor depression and in randomized clinical trials, it 
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provides preliminary evidence of the potential antidepressant benefits to elderly persons 
with minor depression and complex medical conditions, in whom research evidence has 
been lac king. 
7.6 RESEARCH IMPLICATIONS 
This thesis provides the following implications for research: 
1) An effect-modification model seems to better explain the temporal 
interrelationship between depression, antidepressant medications and cognitive decline in 
the elderly population, in which depression pathology independently predicts subsequent 
cognitive decline, while antidepressant treatment may modify this relationship towards a 
potential cognitive bene fit. Therefore, future epidemiological studies aiming to elucidate 
the relationship between any two factors may need to take into account the third one in 
order to avoid bias. 
2) The disappearance of the concurrent association after adjusting for depression 
diagnoses raises a salient point that the dimensional approach to depression, even by 
objective assessment, may be inadequate to forecast future cognitive decline or address 
causation. To enhance internaI validity and facilitate causal inference, epidemiological 
studies of late-life depression may need to use clinical diagnostic criteria to define 
depression, consider biologically plausible pathogenic processes in designing follow-up 
intervals, and employ longitudinal analyses to address the natural history of depression. 
7.7 AREAS OF FUTURE INVESTIGATION 
Several remaining questions warrant further investigations: 
1) Given the study population for this thesis was drawn from acute-care hospital 
settings and the sample size is modest, the research findings should be replicated in larger 
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samples of community-dwelling elderly, preferably with longer follow-up and more 
specific and sensitive measures of cognitive functioning; 
2) To address potential bias due to the imprecise quantification ofmedication 
exposure and the limitations of administrative database, future studies should take into 
account the dosage and actual use of medication, patient adherence, and use alternative 
data sources from patient interview and hospital records when ascertaining and 
quantifying medication exposure; 
3) Two unexpected results, i.e., the beneficial antidepressant effects to minor 
depression and the apparent protective effects of anticholinergic exposure, may indicate 
scientifically important new findings, or result from residual confounding or chance. They 
de serve further investigation using larger study samples, more specific and precise 
measures of depression etiologies, medication exposure, anticholinergic and other 
alternative biological mechanisms. 
7.8 FINAL CONCLUSIONS 
1) As c1inically significant syndromes, both major and minor depression may be 
inde pendent risk factors for short-term cognitive decline in older medical patients. 
2) Antidepressant medications, especially SSRIs, may modify the detrimental 
effects of depression pathology towards a potential cognitive benefit in older persons with 
minor depression. 
3) An effect-modification model may better explain the interrelationship or 
causal pathway between depression, antidepressant use and cognitive functioning in older 
persons, in which depression is an independent risk factor and the antidepressant use is an 
effect modifier. 
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Figure A-1. Residuals Plots from the Final Mixed Model, Prospective A (supplement 
to Chapter 5, Manuscript 2) 
(1.1). Population-averaged Residuals against Predicted Values 
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(1.2). Population-averaged Residuals against Depression Diagnoses at Baseline 
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(1.3). Population-averaged Residuals against Transformed HDRS Scores 
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Table A-l. Sensitivity analysis: Evaluating effects of antidepressant exposure on MMSE changes* under alternative assumptioms 
for exposure time window (supplement to Chapter 6, Manuscript 3) 
Modelt A. Under Short Time B. Remove Most Recent C. Remove Most Recent D. Remove 7-day Window 14 days 30 days Residual Period 
Covariatet Est. Il 95% CI p Est. 95% CI P Est. 95% CI P Est.§ 95% CI p 
value value value value 
Antidepressant 033 -0.17 -0.83 0.200 032 -0.50 - 1.13 0.448 030 -0.40 -1.00 0.396 030 -0.42 -1.02 0.412 
exposure§ 
Depression diagnoses at baseline 
Major -0.83 -1.50 --0.16 0.ül5 -0.81 -1.48--0.14 0,018 -0.82 -1.48--0.15 0.017 -0.81 -1.48 --0.15 0.018 
Minor -1.04 -1.78 --0.29 0.007 -1.03 -1.77 - -0.28 0.007 -1.03 -1.77--0.29 0.007 -1.03 -1.77 --0.29 0.007 
* Defined by the differences in the MMSE scores between each follow-up and baseline, with negative values indicating dec1ine. 
t Model A assumed a short exposure time window. Models B and C assumed a long exposure time window. Model D applied to both short-
and long- time windows. 
t Other covariates inc1uded age, sex, education, living arrangement, ADL score, hospital, study group, SPMSQ errors, baseline MMSE scoré, 
follow-up duration, a nurse-rated illness severity, risk for cardiovascular diseases, previous history of depression and a transformed HDRS 
score during the follow-up. 
§ Represented by the total exposed drug-days during the 3 month period prior to each follow-up outcome assessment, exc1uding prescriptions 
dispensed in the assumed induction or residual period. 
Il Estimate (Est) denotes expected MMSE changes per IOO-day exposure to the specific medication during the 3 month period prior to each 
follow-up MMSE assessment. 
Abbreviations: MMSE, Mini-Mental State Examination; HDRS, Hamilton Depression Rating Scale; ADL, Activities ofDaily Living; 
SPMSQ, Short Portable Mental Status Questionnaire. 
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Table A-2. Stratified models by depression diagnoses: Evaluating effects of antidepressant exposure on MMSE changes* 
based on long time window, with and without adjusting for concomitant medications (supplement to Chapter 6, Manuscript 3) 
Model A. Major Depression B. Minor Depression C. No Depression 
No. Est.~ 95% CI P value Est. 95% CI P value Est. 95% CI P value 
1 t -0.20 -1.10 - 0.71 0.670 2.66 0.59 - 4.72 0.014 -0.15 -1.57 - 1.27 0.840 
2t -0.24 -1.18 - 0.70 0.616 2.54 OAO - 4.67 0.022 0.00 -1.46 - lA61 0.998 
3 § -0.15 -1.11 - 0.81 0.758 2.47 0.34 - 4.60 0.026 -0.27 -1.74 - 1.193 0.715 
4 Il -0.33 -1.50 - 0.85 0.587 2.16 0.70 - 5.02 0.142 -0.82 -2.54 -0.90 0.351 
* Defined by the differences in the MMSE scores between each follow-up and baseline, with negative values indicating decline. 
t Model 1 adjusted antidepressant exposure for age, sex, education, living arrangement, ADL score, hospital, study group, 
SPMSQ errors, baseline MMSE score, follow-up duration, a nurse-rated illness severity, risk for cardiovascular diseases, history of 
depression, and a transformed HORS score during follow-up. 
t Model 2 adjusted model # 1 for concomitant benzodiazepines and other psychotropic medications. 
§ Model 3 adjusted model 1 for total number of concomitant medications. 
Il Model4 adjusted model 1 for total anticholinergic burden. 
~ Estimate (Est) denotes expected MMSE changes per IOO-day exposure to antidepressants during the 3 month period prior to each follow-up 
MMSE assessment. 
Abbreviations: MMSE,'Mini-Mental State Examination; HORS, Hamilton Depression Rating Scale; ADL, Activities of Daily Living; 
SPMSQ, Short Portable Mental Status Questionnaire. 
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Appendix II. (A). Patient Consent Form for RCT 
St. Mary's Hospital, 
Departments of Psychiatry 
and Epidemiology 
Principal investigator: 
Dr. Martin G. Cole 
Tel: (514) 734-2684 
CONSENT FORM 
Older patients are often depressed while in hospital. We have determined that you are 
depressed and invite you to participate in a study to assess if a new way of detecting and 
managing patients with depression is effective in: 
• reducing length of hospital stay; 
• reducing symptoms of depression and improving quality of life; 
• increasing patients' abilities to manage independently; 
• increasing survival. 
Participation in this study involves the following: 
You will be assigned equally by chance either to a group which will receive usual care or 
a group which will receive the new care programme (descriptions below). 
Usual Care: this means that you will receive the care that you would normally receive 
from your doctors and nurses. Such care may include treatment of your depression if 
you and your doctor decide it is necessary. 
New care programme: this means that you will be visited by a doctor who specializes 
in caring for older patients and by a nurse who has been trained to care for patients 
who are depressed. As weIl, care ofyour depression will be arranged after you are 
discharged from hospital. 
Patients in both groups will be interviewed by a research assistant 4 times: 
1. Soon after enrolling in the study 
2. 3 months after enrolment 
3. 6 months after enrolment 
4. 12 months after enrolment 
Each interview williast not more than 1 hour, and will include questions on general 
health, emotions, and use of medical services. 
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STUDY OF A GERIATRIC 
DEPRESSION SERVICE 
St. Mary's Hospital, 
Departments of Psychiatry 
and Epidemiology 
Principal investigator: 
Dr. Martin G. Cole 
Tel: (514) 734-2684 
Your Medicare number will be used to obtain information on your use of physician 
services and medication prescriptions from the Régie de L'Assurance Maladie du 
Québec, during the past year and the next year. Information may also be requested fram 
any hospitals, CLSCs, home care providers, or other organizations from which you may 
receive health or social services during the same two-year period. 
You will be asked for the name of the family member or friend who helps you the most 
on a day-to-day basis. This person will also be asked to participate in the research. His 
or her participation will involve filling out a questionnaire about his or her health and 
raie in your care; this will take about 20-30 minutes. S/he will be asked to fill out this 
questionnaire aga in 6 and 12 months from now. 
There may be no direct benefits to you for participating in this study. There are no risks 
other than the potential risks associated with anti-depressant treatment. The study will 
not deprive you of the usual care you receive from your doctors and nurses. You will not 
stay in the hospital any longer because of your participation in the study. There are no 
experimental drugs involved in this study. The results ofthis study will help doctors and 
nurses to improve the care of patients who are depressed while in hospital. 
Participation in this study is voluntary and ifyou do not participate you will continue to 
receive care as usual from your doctors and nurses and you may discuss the options for 
treatment ofyour depression with your doctor. You may withdraw from the study at any 
time without any effect on your care. 
All research staff involved in the study will maintain confidentiality of records 
identifying the patient. All forms will be kept in a locked file cabinet. Only the study 
identification number will be entered in the computerized data base to identify the 
patients. 
If you have any questions about your rights as a participant in this research project, you 
may contact the patient representative, Monique Robitaille, at 734-2618 
You will receive a copy of the signed consent form. 
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STUDY OF A GERIATRIC 
DEPRESSION SERVICE 
St. Mary's Hospital, 
Departments of Psychiatry 
and Epidemiology. 
Principal investigator: 
Dr. Martin G. Cole 
Tel: (514) 734-2684 
1 have read the consent form for the Study of a Geriatrie Depression Service and have 
had the opportunity to ask questions. 1 agree to participate in this research project. 
Consent Date 
Witness Date 
Medicare no 
-----------------------
A-8 
Appendix II. (B). Patient Consent Form for Prognosis Study 
St. Mary's Hospital, 
Departments of Psychiatry 
and Epidemiology 
Principal investigator: 
Dr. Jane McCusker 
Tel: (514) 345-3511 ext. 5060 
CONSENT FORM 
We have determined that you do not have depression that requires treatment, although 
you may have sorne symptoms of depression. We invite you to participate in a study to 
determine whether an older patient's mental or physical cond~tion during a hospital 
admission affects their quality of life in the future. 
Ifyou participate in this study, you will be interviewed by a research assistant 4 times: 
1. Soon after enrolling in the study 
2. 3 months after enrolment 
3. 6 months after enrolment 
4. 12 months after enrolment 
Each interview will last not more than 1 hour, and will include questions on general 
health, emotions, and use of medical services. 
You will be asked for the name of the family member or friend who helps you the most 
on a day-to-day basis. This person will also be asked to participate in the research. His 
or her participation will involve filling out a questionnaire about his or her health and 
role in your care; this will take about 20-30 minutes. S/he will be asked to fill out this 
questionnaire again 6 and 12 months from now. 
Your Medicare number will be used to obtain information on your use of physician 
services and medication prescriptions from the Régie de L'Assurance Maladie du 
Québec, during the past year and the next year. Information œay also be requested from 
any hospitals, CLSCs, home care providers, or other organizations from which you may 
receive health or social services during the same two-year period 
There may be no direct benefits to you for participating in this study. The study will not 
deprive you of the usual care you receive from your doctors and nurses. The results of 
this study will help doctors and nurses to improve the care of older patients who are 
hospitalized. 
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STUDY OF PATIENT 
OUTCOMES 
St. Mary's Hospital, 
Departments of Psychiatry 
and Epidemiology 
Principal investigator: 
Dr. Jane McCusker 
Tel: (514) 345-3511 ext 5060 
Participation in this study is voluntary and ifyou do not participate you will continue to 
receive care as usual from your doctors and nurses. You may withdraw from the study at 
any time without any effect on your care. 
All research staff involved in the study will maintain confidentiality of records 
identifying the patient. All forms will be kept in a locked file cabinet. Only the study 
identification number will be entered in the computerized data base to identify the 
patients. 
If you have any questions about your rights as a participant in this research project, you 
may contact the patient representative, Monique Robitaille, at 734-2618 
You will receive a copy of the signed consent form. 
1 have read the consent form for the Study of Patient Outcomes and have had the 
opportunity to ask questions. 1 agree to participate in this research project. 
Consent Date 
Witness Date 
Medicare no 
------------------------
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Appendix IV. An Integrated Instrument: Diagnostic Interview Schedule 
(Depression) (DIS-D) /Hamilton Depression Rating Scale (HDRS) 
ID#: ___ _ Date: ________ _ 
D M y 
Rater: _______ _ Name: 
-----------Last First 
A) DIS-D 
Please score on the basis of subject's responses to the questions only. 
* These questions may be scored "No" based on responses to previous questions. 
1. Do you feel ,md or hlue or depressed? 
1. No ~ go to question # 2 2. Mild 3. Moderate 4. Severe 
1 a. How long have you felt sad or blue or depressed? 
___ days weeks 
---
months 
---
___ years 
2. Do you have trouble falling asleep or staying asleep these days? 
1. No ~ go to question # 3 2. Mild 3. Moderate 4. Severe 
2a. About how long have you had trouble falling asleep or staying asleep? 
___ days weeks months 
--- ---
___ years 
3. Do you wake up earlier than usual in the morning these days? 
1. No ~ go to question # 4 2. Mild 3. Moderate 4. Severe 
3a. About how long have you been waking up earlier than usual in the 
morning? 
___ days ___ weeks ___ months ___ years 
*4. Do you sleep more than usual these days? 
1. No -7 go to question # 5 2. 
3. Moderate (1-2 hrs longer than usual) 
Mild «lhr longer than usual) 
4. Severe (>2hrs longer than usual) 
4a. About how long have you been sleeping more than usual? 
___ days weeks months 
--- ---
___ years 
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5. Do you take medicine to help you sleep these days? 
1. No -7 go to question # 6 2. Yes 
5a. About how long have you been taking medicine to sleep? 
___ days weeks months 
--- ---
___ years 
6. Is your appetite decreased? 
1. No -7 go to question # 2. Mild 3. Moderate 4. Severe 
6a. About how long ago did your appetite decrease? 
___ days weeks months ___ years 
7. Are you losing weight? 
1. No -7 go to question # 8 2. Mild 3. Moderate 4. Severe 
7a. About how long ago did you begin to lose weight? 
___ days weeks months ___ year 
*8. l., your appetite increased? 
1. No -7 go to question # 9 2. Mild 3. Moderate 4. Severe 
8a. About how long ago did your appetite begin to increase? 
___ days ___ weeks ___ months ___ years 
*9. Are you gaining any weight? 
1. No -7 go to question # 10 2. Mild 3. Moderate 4. Severe 
9a. About how long ago did you start to gain weight? 
___ days ___ weeks ___ months ___ years 
10. Do you get tired easily or do you fil1d yourself without energy? 
1. No -7 go to question # Il 2. Mild 3. Moderate 4. Severe 
A-14 
10a. About how long have you been getting tired easily or have you been without 
energy? 
___ days ___ weeks ___ months ___ years 
11. Do you find yourself restless? Do you have trouble sitting still? Do you pace 
up anddown? 
1. No -7 go to question # 12 2. Mild 3. Moderate 4. Severe 
Il a. About how long have you been restless or have you been un able to sit still? 
___ days weeks months 
--- ---
___ years 
12. Do you talk or move more slowly than is normalfor you? 
1. No -7 go to question # 13 2. Mild 3. Moderate 4. Severe 
12a. About how long have you talked or moved more slowly than is normal for you? 
___ days ___ weeks ___ months ___ years 
13. How are you at making decisions? (Note: rate indecisiveness) 
1. No -7 go to question # 14 2. Mild 3. Moderate 4. Severe 
13a. About how long ago have you had trouble making decisions? 
___ days weeks months 
--- ---
___ years 
14. Do you have a lot more trouble concentrating than is normal for you? 
1. No -7 go to question # 15 2. Mild 3. Moderate 4. Severe 
14a. About how long ago have you had more trouble concentrating than is usual 
for you? 
___ days ___ weeks ___ months ___ years 
J 5. H(we you lost your interest and pleasure in most things that you usua/~v care 
about or en.Îoy? 
1. No -7 go to question # 16 2. Mild 3. Moderate 4. Severe 
15a. About how long have you lost interest and pleasure in things that you usual/y 
care about? 
___ days weeks months 
--- ---
___ years 
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16. Do you feel worthless or sinful or guilty? 
1. No -7 go to question # 17 2. Mild 3. Moderate 4. Severe 
16a. About how long have youfelt worthless (or sinful or guilty)? 
___ days ___ weeks ___ months ___ years 
17. Do you think about death - either your own death or death in general? 
1. No -7 go to question # 18 2. Mild 3. Moderate 4. Severe 
17a. About how long have you been thinking about death? 
___ days ___ weeks ___ months ___ years 
18. Do youfeel that life is not worth living? 
1. No -7 go to question # 19 2. Mild 3. Moderate 4. Severe 
18a. About how long have you beenfeeling that life is not worth living? 
___ days ___ weeks ___ months ___ years 
19. Do you wish to die but reject the notion oftaking your own life? 
1. No -7 go to question # 20 2. Mild 3. Moderate 4. Severe 
19a. About how long have you wished to die but rejected the notion of taking your 
own life? 
___ days ___ weeks ___ months ___ years 
*20. Do you feel so low that you think of taking your own life? 
1. No -7 go to question # 21 2. Mild 3. Moderate 4. Severe 
20a. About how long have you been thinking oftaking your own life? 
___ days ___ weeks ___ months ___ years 
*21. Have you actually attempted to take your own life? 
1. No 2. Yes 
Ifyes, when: 
___ days ago __ weeks ago ___ months ago ___ years ago 
A-16 
B)HDRS 
Please score items for the past week on the basis of ail information available. 
1. What's your mood been Iike this past DEPRESSED MOOD (Sadness, 
week? hopelessness, worthlessness): 
Have you been feeling down or depressed? 0 
Absent 
1 Indicated only on questioning 
Sad? Hopeless? 2 Spontaneously reported verbally 
ln the last week, how often have you felt 3 
Communicated non-verbaIly, i.e. 
facial expression, posture, voice, (OWN EQUIV ALENT)? Every day? AlI tendency to weep 
day? 4 VIRTUALL y ONL Y; this in 
Have you been crying at aIl? spontaneous verbal and non-verbal 
communication 
2. How have you been spending your time WORK AND ACTIVITIES: 
this past week (when not at work)? 0 No difficulty 
Have you felt interested in doing (THOSE 1 Thoughts and feelings of incapacity, fatigue or weakness related to 
THINGS), or do you feel you have to push 
activities, work or hobbies 
yourselfto do them? 2 Loss of interest in activity; hobbies or 
Have you stopped doing anything you used 
work - by direct report of the patient 
or indirect in listlessness, indecision 
to do? IF YES: Why? 
and vacillation (feels he has to push 
Is there anything you look forward to? 
self to work or activities) 
3 Decrease in actual time spent in 
(AT FOLLOW-UP: Has your interest been activities or decrease in productivity 4 Stopped work or activities because of back to normal?) present illness 
3. How has your interest in sex been this GENITAL SYMPTOMS (such as loss 
week? (l'm not asking about performance, of libido, menstrual disturbances): 
but about your interest in sex - how much 0 Absent 
you think about it.) 1 Mild 
Has there been any change in your interest in 
2 Severe 
sex (from when you were not depressed)? 
Is it something you've thought much about? 
IF NO: Is that unusual for you? 
4. How has your appetite been this past SOMATIC SYMPTOMS 
week? (What about compared to your usual GASTROINTESTINAL: 
appetite?) 0 None 
Have you had to force yourself to eat? 1 Loss of appetite but eating without 
Have other people had to urge you to eat? 
encouragement 
2 Difficulty eating without urging 
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5. Have you lost any weight since this LOSS OF WEIGHT: 
(DEPRESSION) began? IF YES: How A When rating by history: 
much? 
0 No weight loss 
IF NOT SURE: Do you think your clothes 1 Probable weight loss associated 
are any looser on you? with present illness 
2 Definite (according to patient) 
AT FOLLOW-UP: Have you gained any of weight loss 
the weight back? 3 Not assessed 
B When actual weight changes are 
measured: 
0 Less than 1 lb. loss in week 
1 More than lib. loss in one week 
2 More than 21b. loss in one week 
3 Not assessed 
6. How have you been sleeping over the last INSOMNIA EARL Y: 
week? 
Have you had any trouble faUing asleep at 0 No difficuity faUing asleep 
the beginning of the night? (Right after you 1 Complains of occasional difficulty 
go to bed, how long has it been taking you to falling asleep i.e., more than !h hour 
,,--, 
faU asleep?) 2 Complains of nightly difficulty 
How many nights this week have you had faUing asleep 
trouble faUing asleep? 
7. During the past week, have you been INSOMNIA MIDDLE: 
waking up in the middle of the night? 0 No difficulty 
IF YES: Do you get out ofbed? What do 
1 Complains ofbeing restless and 
disturbed during the night 
you do? (Only go to the bathroom?) 2 Waking during the night - any 
When you get back in bed, are you able to 
getting out of bed (except to void) 
faU right back asleep? 
Have you felt your sleeping has been restless 
or disturbed sorne nights? 
8. What time have you been waking up in INSOMNIA LA TE: 
the morning for the last time, this past 0 No difficulty 
week? 1 Waking in early hours of moming but 
IF EARL Y: Is that with an alarm clock, or goes back to sleep do youjust wake up yourself? 2 Unable to faU asleep again if he gets 
What time do you usuaUy wake up (that is, out ofbed 
before you got depressed)? 
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9. How has your energy been this past week? SOMATIC SYMPTOMS GENERAL: 
Have you been tired all the time? 
0 None 
1 Heaviness in limbs, back or head. 
This week, have you had any bac kaches, 
Backaches, headaches, muscles 
aches. Loss of energy and 
headaches, or muscle aches? fatigability 
This week, have you felt any heaviness in 
2 Any clear-cut symptom 
your limbs, back or head? 
10. Have you been especially critical of FEELINGS OF GUILT: 
yourselfthis past week, feeling you've 0 Absent 
done things wrong, or let others down? 1 Self-reproach, feels he has let people 
IF YES: What have your thoughts been? down 
Have you been feeling guilty about anything 
2 Ideas of guilt or rumination over pa st 
errors or sinful deeds 
that you've do ne or not done? 3 Present illness is a punishment. 
Have you thought that you've brought (THIS Delusions of guiIt 4 Hears accusatory or denunciatory 
DEPRESSION) on yourself in sorne way? 
voices and/or experiences threatening 
Do you feel you're being punished by being 
visual hallucinations 
sick? 
11. This past week, have you had any SUICIDE: 
thoughts that Iife is not worth living, or 0 Absent 
that you'd be better off dead? What 1 Feels life is not worth living 
about having thoughts of hurting or even 2 Wishes he were dead or any possible 
killing yourself? death to self 
3 Suicidai ideas 
IF YES: Have you actually done anything to 4 Attempts at suicide 
hurt yourself? 
12. Have you been feeling especially tense or ANXIETY PSYCHIC 
irritable this past week? 0 No difficulty 
Have you been worrying a lot about little 
1 Subjective tension and irritability 
2 W orrying about minor matters 
unimportant things, things you wouldn't 3 Apprehensive attitude apparent in 
ordinarily worry about? IF YES: Like what, face or speech 
for example? 4 Fears expressed without questioning 
13. In this past week, have you had any of ANXIETY SOMATIC (physiologic 
these physical symptoms? READ LIST, concomitants of anxiety, such as GI (dry 
PAUSING AFTER EACH SX FOR mouth, gas, indigestion, diarrhea, 
REPLY. cramps, belching); C-V (heart 
palpitations, headaches); Resp 
How much have these things been bothering (hyperventilating, sighing); Having to 
you this past week? (How bad have they urinate frequently; Sweating): 
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gotten? How much of the time, or how 0 Absent 
often, have you had them?) 1 Mild 
NOTE: DON'T RA TE IF CLEARL y DUE 2 
Moderate 
3 Severe 
TO MEDICATION (E.G., DRY MOUTH 4 Incapacitating 
AND IMIPRAMINE) 
14. In the last week, how much have your HYPOCHONDRIASIS: 
thoughts been focused on your physical 0 Not present 
health or how your body is working 1 Self-absorption (bodily) (compared to your normal thinking)? 2 Preoccupation with health 
Do you complain much about how you feel 
3 Frequent complaints, requests for 
help, etc. 
physically? 4 Hypochondriacal delusions 
Have you found yourself asking for help 
with things you could really do yourself? IF 
YES: Like what, for example? How often 
has that happened? 
15. RATING BASED ON OBSERVATION INSIGHT: 
0 Acknowledges being depressed and 
ill 
1 Acknowledges illness but attributes 
cause ta bad food, climate, overwork, 
virus, need for rest, etc 
2 Denies being ill at aIl 
16. RATING BASED ON OBSERVATION RETARDATION (slowness ofthought 
DURING INTERVIEW and speech; impaired ability to 
concentrate; decreased motor activity): 
0 Normal speech and thought 
1 Slight retardation at interview 
2 Obvious retardation at interview 
3 Interview difficult 
4 Complete stupor 
17. RATING BASED ON OBSERVATION AGITATION: 
DURING INTERVIEW 0 None 
1 Fidgetiness 
2 Playing with hands, hair etc. 
3 Moving about, can't sit still 
4 Hand wringing, nail-biting, hair 
pulling, biting of lips 
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18. 
19. 
20. 
21. 
This past week have you been feeling 
better or worse at any particular time of 
day - morning or evening? 
IF VARIATION: How much worse do you 
feel in the (MORNING OR EVENING)? 
IF UNSURE: A little bit worse or a lot 
worse? 
In the past week, have you ever suddenly 
had the feeling that everything is unreal, 
or you're in a dream or eut of from other 
people in sorne strange way? 
Any spacey feelings? 
IF YES: How bad has that been? How often 
this week has that happened? 
This past week, have you feU that anyone 
was trying to give you a hard time or hurt 
you? 
IF NO: what about talking about you behind 
your back? 
IF YES: Tell me about that. 
In the past week, have there been things 
you've had to do over and over again, like 
checking the locks on the doors several 
times? 
IF YES: Can you give me an example? 
Have you had any thoughts that don 't 
make any sense to you but that keep 
running over and over in your mind? 
IF YES: Can you give me an example? 
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DIURNAL VARIATION: 
a Note whether symptoms are worse in 
morning or evening. If NO diurnal 
variation, mark none: 
o No variation OR not currently 
depressed 
1 Worse in the A.M. 
2 Worse in the P .M. 
b When present, mark the severity of 
the variation: 
o None 
1 Mild 
2 Severe 
DEPERSONALIZATION AND 
DEREALIZATION (such as feelings of 
unreality and nihilistic ideas): 
o Absent 
1 Mild 
2 Moderate 
3 Severe 
4 Incapacitating 
P ARANOID SYMPTOMS: 
o None 
1 Suspicious 
2 Ideas of reference 
3 Delusions of reference and 
persecution 
OBSESSIONAL AND COMPULSIVE 
SYMPTOMS: 
o Absent 
1 Mild 
2 Severe 
Appendix V. Diagnostic Criteria for Major and Minor Depression Episode (DSM-
IV) and DIS-D based Algorithm 
N.B. In order to rate a symptom as present, two criteria must be met: 
1. The symptom must have been rated 2, 3, or 4. 
2. The symptom must have been present for 2 weeks or longer 
Criterion A. Symptom 1 is present: 
O-No 
1- Yes 
Criterion B. Symptom 15 is present: 
O-No 
1- Yes 
Criterion C. Among the following clusters: 
1. Symptom 2, 3, 4 or 5 is present; 
2. Symptom 6, 7, 8 or 9 is present; 
3. Symptom lOis present; 
4. Symptom Il or 12 is present; 
. 5. Symptom 13 or 14 is present; 
6. Symptom 16 is present; 
7. Symptom 17,18, 19,20,or21 ispresent. 
O-No 1 - Yes 
O-No 1 - Yes 
O-No 1 - Yes 
O-No 1 - Yes 
O-No 1 - Yes 
O-No 1 - Yes 
O-No 1- Yes 
Patient meets criteria for major depression (Criterion A or B plus 4-7 symptoms 
under Criterion C): 
O-No 
1- Yes 
Patient meets criteria for minor depression (Criterion A or B plus 1-3 symptoms 
under Criterion C): 
O-No 
1- Yes 
N.B. If symptom 20 or 21 is present or the patient has hallucinations or delusions, 
contact Dr. Cole before enrolling in the RCT. 
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Appendix VI. A Sam pie of Medication Records from RAMQ 
Patient ID DIN Date of dis~ense Generic code AHFS Code DOSE Duration 
10 2190915 10/24/1997 47146 564000 28426 30 
10 2190915 11/28/1997 47146 564000 28426 30 
10 2190915 12/26/1997 47146 564000 28426 30 
10 2190915 1/21/1998 47146 564000 28426 30 
10 2190915 2/20/1998 47146 564000 28426 30 
10 2190915 3/30/1998 47146 564000 28426 30 
10 2190915 4/24/1998 47146 564000 28426 30 
10 2190915 5/22/1998 47146 564000 28426 30 
10 2190915 6/25/1998 47146 564000 28426 30 
10 2190915 7/23/1998 47146 564000 28426 30 
10 2190915 8/20/1998 47146 564000 28426 30 
10 2190915 9/25/1998 47146 564000 28426 30 
10 2190915 10/23/1998 47146 564000 28426 30 
10 2190915 11/19/1998 47146 564000 28426 30 
10 2190915 12/23/1998 47146 564000 28426 30 
10 2190915 1/21/1999 47146 564000 28426 28 
10 2190915 2/17/1999 47146 564000 28426 28 
10 836311 2/25/1999 45586 564000 21106 30 
10 2190915 4/6/1999 47146 564000 28426 28 
10 2190915 5/6/1999 47146 564000 28426 14 
10 2190915 5/20/1999 47146 564000 28426 14 
"" " "" " "" " 
",, " 
10 1940481 4/27/2000 47061 281604 28426 30 
10 2190915 5/13/2000 47146 564000 28426 30 
10 674346 5/23/2000 1664 401200 394 30 
10 1940481 5/29/2000 47061 281604 28426 30 
10 674346 6/22/2000 1664 401200 394 30 
10 1940481 6/24/2000 47061 281604 28426 30 
10 2190915 7/17/2000 47146 564000 28426 30 
10 674346 7/22/2000 1664 401200 394 30 
10 1940481 7/27/2000 47061 281604 28426 30 
10 2230437 7/31/2000 39 280892 55924 7 
10 860751 7/31/2000 3211 81224 41602 8 
10 792667 8/11/2000 6591 81204 66856 7 
10 2236842 8/11/2000 47258 82200 54412 1 
10 2165511 8/18/2000 47140 564000 31964 30 
10 2165511 9/13/2000 47140 564000 31964 30 
10 2165511 10/13/2000 47140 564000 31964 30 
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A~~endix VII. Ps~chotro~ic medications* evaluated in the stud~ 
Generic drug na me Antide~ressant Benzodiaze~ine Other ACH Scoret 
TCA SSRI Other Long-HL Short-HL psychotropic 
amitriptyline (chlorhydrate d') 0 0 0 0 0 3 
c10mipramine (chlorhydrate de) 0 0 0 0 0 3 
desipramine (chlorhydrate de) 0 0 0 0 0 2 
doxepine (chlorhydrate de) 0 0 0 0 0 3 
imipramine (chlorhydrate d') 0 0 0 0 0 3 
nortriptyline (chlorhydrate de) 0 0 0 0 0 3 
trimipramine 1 0 0 0 0 0 2 
citalopram (bromhydrate de) 0 0 0 0 0 
fluoxetine (chlorhydrate de) 0 0 0 0 0 
fluvoxamine (maleate de) 0 0 0 0 0 
paroxetine (chlorhydrate de) 0 0 0 0 0 2 
sertraline (chlorhydrate de) 0 0 0 0 0 
bupropion (chlorhydrate de ) 0 0 0 0 0 
maprotiline (chlorhydrate de) 0 0 0 0 0 2 
nefazodone (chlorhydrate de) 0 0 0 0 0 
tranylcypromine (sulfate de) 0 0 1 0 0 0 0 
trazodone (chlorhydrate de) 0 0 1 0 0 0 
venlafaxine (chlorhydrate de) 0 0 1 0 0 0 
chlordiazepoxide (chlorhydrate de) 0 0 0 0 0 
chlordiazepoxide (chlorhydrate de) 0 0 0 0 0 1 
c10bazam 0 0 0 0 0 0 
c10nazepam 0 0 0 0 0 0 
diazepam 0 0 0 0 0 1 
flurazepam (chlorhydrate de) 0 0 0 0 0 1 
nitrazepam 0 0 0 0 0 0 
alprazolam 0 0 0 0 0 
bromazepam 0 0 0 0 0 1 
lorazepam 0 0 0 0 0 0 
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Almendix VII. Cont'd 
oxazepam 0 0 0 0 0 0 
temazepam 0 0 0 0 1 0 0 
triazolam 0 0 0 0 1 0 
buspirone (chlorhydrate de) 0 0 0 0 0 0 
carbamazepine 0 0 0 0 0 
chloral (hydrate de) 0 0 0 0 0 0 
chlorpromazine (chlorhydrate de) 0 0 0 0 0 3 
divalproex sodique 0 0 0 0 0 0 
gabapentine 0 0 0 0 0 0 
haloperidol 0 0 0 0 0 2 
lamotrigine 0 0 0 0 0 1 
lithium (carbonate de) 0 0 0 0 0 0 
l-tryptophane 0 0 0 0 0 0 
methotrimeprazine 0 0 0 0 0 2 
olanzapine 0 0 0 0 0 1 
oxcarbazepine 0 0 0 0 0 0 
phenobarbital 0 0 0 0 O· 
phenytoine 0 0 0 0 0 0 
phenytoine sodique 0 0 0 0 0 0 
phenytoine sodique 0 0 0 0 0 0 
primidone 0 0 0 0 0 0 
prochlorperazine 0 0 0 0 0 2 
quetiapine (fumarate de) 0 0 0 0 0 
risperidone 0 0 0 0 0 1 
thioridazine (chlorhydrate de) 0 0 0 0 0 3 
topiramate 0 0 0 0 0 0 
trifluoEerazine (chlorh~drate de) 0 0 0 0 0 
* List only the 58 medications that were c1assified as psychotropics among a total of 269 generic drugs. 
t Clinician-rated anticholinergic scores. 
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Appendix VIII. A Case-scenario demonstrating the strategy to define and quantify medication exposure* 
Prescription 
drug 
Flu period: day 1-15 16-30 31-45 46-60 61-75 76-91 
Therapeutic group ACH 
score 
Chlomipramine Antidepressant 3 
2 Diazepam Benzodiazepine 
3 Phenobarbital Other psychotropic 
4 Lovastatine (NOS) 0 
Medication ex~osure (analytic variable) 
# Orugs used # Antidepressants 
# Benzodiazepines 
#Other psychotropics 
Total # meds 
2 Exposed Orug EDD-Antidepressant 
Oays (EOO) EDD-Benzodiazepine 
EDD-psychotropic 
3 ACH score Cum. ACH scores 
Total ACH burden 
------
Start and en ding dates of prescriptions 
20-30 
1-15 116-30 1 31-45 
40-45 1 46-60 
76-91 
61-75 1 76-82 
1 1-15 1 16-30 1 31-45 1 46-60 1 61-75 1 76-91 1 
0 1 0 0 0 1 
1 1 1 0 1 1 
1 1 2 1 1 1 
2 3 3 1 2 3 
0 Il 0 0 0 16 
15 15 15 0 15 7 
15 15 21 15 15 7 
1 4 2 1 1 4 
15 48 21 15 15 52 
* Represents a hypothetical patient who used 4 meds and had his/her 3-month outcome (MM SE) assessment at day 92; 
t Equal the sum of each measure across relevant time periods under short- or long- time window, respectively; 
Abbreviations: ACH score, Clinician-rated anticholinergic score; STW, Short time window; L TW, Long time window. 
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Summary 
Quantityt 
STW LTW 
(091/92) (01-92) 
1 2 
0 1 
0 2 
2 3 
1 27 
0 67 
0 88 
3 5 
3 166 
" 
1 
Appendix IX. The Mini-Mental State Examination (MMSE) 
1 a) What year is this? 0 8 
b) What season is this? 0 8 
c) What month oftheyear is this? 0 8 
d) What is today's date? 0 8 
e) What day of the week is this? 0 8 
2 a) What country are we in? 0 8 
b) What province are we in? 0 8 
c) What city are we in? 0 8 
d) What is the name ofthis place? 0 8 
e) What floor of the building are we on? 0 8 
Patient is competent (score of 5 or more on items 1 & 2) 1 Yes o No 
Ifno, complete sections A, B, F, G, H only. 
3. 1 am going to say 3 words. After 1 have said ail three, 1 want you to repeat 
them. Remember what they are because 1 am going to ask you to name them 
again in afew minutes. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
shirt, brown, honesty 
Please repeat the three words for me. o 1 2 3 8 
Spell the word "world". 
Now spell it backwards please. _____ _ (30 SECONDS) 0 1 2 3 4 5 8 
What were the three words 1 asked you to remember? (10 SECONDS) 
Show a wrist watch. Ask, "what is it called?" (10 SECONDS) 
Show a pencil. Ask, "what is this called?" (10 SECONDS) 
Repeat the following phrase, "no ifs, ands or buts". (10 SECONDS) 
Take this paper in your right/left hand, fold the paper in half 
and put it on the jloor. (30 SECONDS) 
Read the words on this paper and do what it says. (10 SECONDS) 
Copy this design. (1 MINUTE) 
Write a complete sentence on this piece of paper. 
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o 1 2 3 8 
018 
o 8 
018 
o 1 238 
018 
o 8 
018 
